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Chapter 1 
1.1 Introduction  
Proteins undergo various types of modifications to orchestrate a myriad functions in a 
cell. Protein modifications occur after translation, so they are termed as post-translational 
modifications (PTMs). PTMs play a crucial role and affect diverse cellular processes.
1
 Most of 
the proteins in a cell undergo at least one type of PTM at some point to carry out a biological 
function. So far, more than 100 different PTMs have been identified occurring on the protein 
side chains and some of them are listed in Table 1.1. Most of the essential amino acid residues 
undergo PTMs, which include phosphorylation, methylation, acetylation, adenylation, acylation, 
ADP-ribosylation, glycosylation, sulfation, prenylation, etc.
1
 PTMs are carried out by a class of 
proteins called as enzymes. Dynamic regulation of these PTMs in nature is carried out by many 
enzyme families. These enzymes modify an amino acid of the protein, which triggers a sequence 
of activities, further influencing the cell function. One of the widely studied and important PTM 
in eukaryotes is protein phosphorylation, which also plays a major role in cell biology and 
disease formation.  
Table 1.1: Protein post-translational modifications of amino acid side chains.
1
                  
Residue Reaction Example 
Asp Phosphorylation 
 
Isomerization to isoAsp 
Protein tyrosine phosphatases; response 
regulators in two component systems 
Glu Methylation 
Carboxylation 
Polyglycination 
Polyglutamylation 
Chemotaxis receptor proteins 
Gla residues in blood coagulation tubulin 
Tubulin 
Ser 
 
Phosphorylation 
O-glycosylation 
Phosphopantetheinylation 
Autocleavages 
Protein serine kinases and phosphatases 
Notch O-glycosylation 
Fatty acid synthase 
Pyruvamidyl enzyme formation 
2 
 
Thr 
 
Phosphorylation 
O-glycosylation 
Protein threonine kinases/phosphatases 
 
Tyr 
 
Phosphorylation 
Sulfation 
Ortho-nitration 
TOPA quinone 
Tyrosine kinases/phosphatases 
CCR5 receptor maturation 
Inflammatory responses 
Amine oxidase maturation 
 
His Phosphorylation 
 
Aminocarboxypropylation 
N-methylation 
 
Sensor protein kinases in two 
Component regulatory systems 
Diphthamide formation 
Methyl CoM reductase 
 
Lys N-methylation 
N-acylation by acetyl, biotinyl, 
lipoyl, ubiquityl groups 
 
 
C-hydroxylation 
Histone methylation 
Histone acetylation; swinging-arm 
Prosthetic groups; ubiquitin; 
SUMO (small ubiquitin-like 
modifier) tagging of proteins 
Collagen maturation 
Cys S-hydroxylation (S-OH) 
Disulfide bond formation 
Phosphorylation 
S-acylation 
S-prenylation 
Protein splicing 
 
Sulfenate intermediates 
Protein in oxidizing environments 
PTPases 
Ras 
Ras 
Intein excisions 
Met Oxidation to sulfoxide 
 
Met sulfoxide reductase 
Arg N-methylation 
N-ADP-ribosylation 
Histones 
GSa 
Asn N-glycosylation 
N-ADP-ribosylation 
protein splicing 
 
N-glycoproteins 
eEF-2 
Intein excision step 
 
Gln Transglutamination Protein cross-linking 
 
Trp C-mannosylation Plasma-membrane proteins 
 
Pro C-hydroxylation 
 
Collagen; HIF-1a 
 
Gly C-hydroxylation C-terminal amide formation 
 
No modifications of Leu, Ile, Val, Ala, Phe side chains are known 
 
3 
 
1.1      Protein Phosphorylation 
Protein phosphorylation was first discovered by Levene and Alsberg in 1906 for the 
protein vitellin.
2
 In 1932, the PTM on vitellin was mapped to serine phosphorylation.
3
 To further 
identify the phenomenon and characterize phosphorylation as enzyme catalyzed, it took nearly 
20 years.
4
 In 1979, the Hunter group discovered tyrosine phosphorylation.
5
 These early findings 
paved the way to elucidating many signaling pathways and cellular processes.
6-8,9,10 The 
discovery of the enzyme catalyzing phosphorylation was made possible with these early 
findings.  
Protein phosphorylation is carried out by a class of enzymes called kinases. 
Phosphorylation occurs on hydroxyl containing amino acids serine, threonine and tyrosine. The 
reverse process of dephosphorylation is catalyzed by phosphatases, as shown in Scheme 1.1.
11
 In 
addition, phosphorylation can occur on histidine, arginine, and lysine residues, generally known 
as N-phosphorylation, mainly in prokaryotes.
12-14
 During phosphorylation, adenosine 5’-
triphosphate (ATP) acts as a universal cosubstrate and phosphate donor. Approximately 30% of 
cellular proteins are found to be phosphorylated at a given time
15
 and 2% of the genome is 
encoded for protein kinases.
16,17
 Because of their major role in cell biology, it is important to 
study and understand kinase function in atomic detail. Next, role of phosphorylation in signaling 
pathways, other cellular events and diseases are discussed.   
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Scheme 1.1 Protein phosphorylation and dephosphorylation on hydroxyl containing amino acids  
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2      Phosphorylation and its role in signaling pathways 
Phosphorylation plays a major role in the activity of proteins by stabilizing or triggering 
different signaling cascades, from the cell surface to the nucleus and vice versa. Signal 
transduction is a dynamic mechanism that involves a distinct set of proteins that conveys the 
signal downstream. The downstream signal can have a significant response or a harmful one in 
some instances. To illustrate the role of phosphorylation in signaling pathways, an example of 
ATM/ATR signaling pathway is discussed here (Figure 1.1). Under ionizing radiation (like UV 
or IR) causes changes in chromatin structure or DNA double strand breaks (DSBs) signaling for 
a DNA damage response. The DNA damage signal is primarily recognized by ataxia 
5 
 
telangiectasia mutated (ATM) kinase or by ataxia-telangiectasia and Rad3 (ATR) kinase related 
protein complex. The ATM and ATR kinases belong to the phosphatidylinositol-3-kinase (PI3K) 
family.
18,19
 DNA DSBs or changes in chromatin structure lead to autophosphorylation of ATM 
and its activation. Upon activation ATM is recruited at the site of DSBs along with a protein 
complex containing Rad50, meiotic-recombination-11(MRE 11), Nijmegen breakage syndrome-
1 (NBS1), and breast cancer susceptibility protein-1 (BRCA1), which signals for 
phosphorylation of checkpoint kinase (Chk2).
20,21
 Chk2 kinase activity triggers the activity of its 
effector proteins, such as p53, through phosphorylation. Chk2 kinase phosphorylates serine 15 
on p53.
22
 Phosphorylation of p53 induces stabilization by dissociating from its negative regulator 
MDM2. Phosphorylation on other residues (serine 20, or serine 37) has been implicated in the 
stabilization and accumulation of p53.
23,24
 Stabilization and accumulation of p53 leads to 
increased recruitment of transcription coactivators, such as p300 and CBP, which in turn help in 
the transactivation process and site-specific binding DNA-binding function of p53.
25
 Depending 
on the type of stress signal and cofactors involved various downstream signaling events like 
DNA repair, cell-cycle checkpoint arrest, senescence, and apoptosis take place by translocating 
p53 into the nucleus and activation of gene transcription.
26,27
 The signaling pathway discussed 
here is one of the possible pathways under IR stress. ATM was also known to directly 
phosphorylate p53 at serine 20 under stress conditions, but some reports demonstrated it as 
otherwise in vivo.
28,29
 The role of p53, its activation and functions are highlighted with relevance 
to the studies and discussion in chapter 3.  
6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Phosphorylation mediated signaling pathway of ATM/ATR under IR. The 
DNA-damage signal from DSBs is recognized by ATM kinase and is recruited at the site of 
DNA damage by phosphorylation and activation. The phosphorylated ATM is recruited 
along with a protein complex containing RAD50, MRE11, NBS1 and BRCA1 at the site of 
the DSB.
20,21
 This complex triggers the phosphorylation of chk2 kinase, which 
phosphorylates its effector proteins like p53. Phosphorylation of p53 on serine 15 signals its 
downstream effectors resulting in senescence, cell cycle arrest, apoptosis and DNA repair, 
depending on the extent of stress signal.
23-27
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1.3      Phosphorylation mediated protein-protein interactions 
Protein phosphorylation changes the electronic environment around the site of 
modification, which influences protein electrostatic interactions with other proteins. 
Phosphorylation also plays a key role in promoting protein-protein interactions. One of the 
widely studied examples is the interaction between cyclic adenosine 3’, 5’-monophosphate 
(cAMP) responsive element binding protein (CREB) and CREB binding protein (CBP). CREB 
binds to DNA through the cAMP response element (CRE) and regulates gene transcription, 
which induces cell proliferation, insulin response etc. Protein kinase A (PKA) phosphorylates 
CREB on serine 133, present in the kinase inducible domain (KID).
30,31 Phosphorylation of S133 
changes the charge state from neutral to negative and from hydrogen bond donor to hydrogen 
bond acceptor. Phosphorylated S133 of CREB interacts with Y-658 in the KID interaction (KIX) 
domain of CBP, which is important for the transcriptional activation of CREB (Figure 1.2). 
Phosphorylation induced protein-protein interactions between CREB and CBP greatly enhance 
the transcriptional activity of CREB.  
 
 
 
 
 
       Figure 1.2: Phosphorylation mediated interaction between CREB and CBP. The CREB 
and CBP proteins are shown in blue and green ribbon respectively and the pSer-133 and Tyr-658 
as ball and stick representations. The hydrogen bonding interaction between the phosphate 
(pS133) and hydroxyl group (Y658) of the two proteins regulates transcription of specific 
genes.
30, 31
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1.4      Role of phosphorylation and kinases in diseases 
Kinases and phosphorylation play a key role in signal transduction. Aberrant activity in 
the signaling process and loss of dynamic equilibrium between the activity of phosphatases and 
kinases leads to formation of diseases. There are many kinases that are linked to disease 
formation like casein kinase 2 (CK2),
32
 phosphoinositide 3-OH kinase (PI3K),
33
 epithelial 
growth factor receptor (EGFR),
34
 and protein kinase B (PKB)
35
. Kinase mediated signaling 
pathways like JAK-signal transducer and activator of transcription (STAT), PI3K-PKB etc, are 
known to have a role in cancer formation.
36,37
 
A classic example for the role of kinases in the cancer formation is the chronic 
myelogenous leukemia (CML), which is myeloproliferative disorder of blood stem cells. CML is 
caused by genetic anomaly, which is called the Philadelphia chromosome.
38
 Chromosomal 
translocation of the gene encoding Abelson kinase (Abl) on chromosome 9 and the break point 
cluster (BCR) gene on chromosome 22 results in a BCR-Abl gene. The BCR-Abl gene encodes 
for BCR-Abl fusion protein which has unusual tyrosine-kinase activity resulting in a signaling 
cascade leading to CML (Figure 1.3).
39-41
 The mechanism of CML is very well understood but 
the cause of gene translocation is still unknown.
42
 Gleevec (imatinib) is a FDA approved drug 
and widely used Abl kinase inhibitor for the treatment of CML.
43,44
 Imatinib is a rationally 
designed, selective inhibitor of tyrosine kinase activity of BCR-Abl protein. Imatinib 
competitively binds the SH1 ATP domain of BCR-Abl fusion protein blocking the 
phosphorylation-mediated signaling pathway and progression of CML (Figure 1.3). As CML 
illustrates, kinases play a role in disease formation and have become attractive drug targets. 
Recent studies have focused on developing selective kinase inhibitors because of their roles in 
various diseases.  
9 
 
 
Figure 1.3: BCR-Abl gene formation and mode of action Cartoon depicting Philadelphia 
chromosome formation associated with CML (top). Signaling pathway of BCR-Abl fusion 
protein with hyperphosphorylation activity leads to CML (bottom right). Imatinib/Gleevec 
blocks ATP binding site, preventing hyperphosphorylation activity leading to CML and controls 
the disease (bottom left). 
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1.4.1 Kinase drugs and inhibitors 
With recent advances in both in vitro and in vivo techniques, the role of phosphorylation 
in disease formation was better understood. As a result many kinases have been identified as 
potential drug targets. The challenge in the identification of selective, competitive inhibitors for 
kinases is due to their similarity in the highly conserved ATP binding site among different 
classes of kinases (kinase structure is discussed in Section 1.6).
7
 Hence it is difficult to design 
inhibitors targeting a single kinase. However some drugs have been designed despite the 
challenge. Gleevec (Imatinib) was the first selective BCR-Abl tyrosine kinase inhibitor (See 
Figure 1.3 for mechanism of action, see Figure 1.4 for chemical structure), other examples 
include 5,6-Dichloro-1-β-D-ribofuranosyl benzimidazole (DRB), and N-[2-(methylamino)ethyl]-
5-isoquinolonesulfonamide (H8), which selectively inhibit CK2 and PKA, respectively. 
Rapamycin and Everolimus are two natural products used to treat immunosupression by 
targeting mTOR. Staurosporine is also a natural product commonly used in research laboratories 
and is a non-selective kinase inhibitor (Figure 1.4). A list of FDA approved kinase inhibitors 
used to treat various diseases, mainly cancer, is shown in Table 1.2.
45,46
 
Despite their selectivity and diversity in structural features (Figure 1.4), some inhibitors 
bind to off target kinases, this leads to adverse side effects. Gleevec, one successful kinase drug 
binds to the C-Kit receptor, PDGFR, resulting in serious side effects. In addition, gleevec drug 
resistance has also developed because of mutations in the gene/ target kinase affecting the 
binding of drug in the active site.
47-49
 Hence, more selective kinase drugs are needed to treat 
diseases more effectively.  Therefore, there is a need to understand and develop new methods to 
study the role of phosphorylation and the mechanism of kinases.  
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Table 1.2: List of some of the FDA approved, commercially available kinase inhibitors.
45,46
 
 
 
 
 
 
 
Inhibitor/ 
Drug  
Disease  Targeted 
Kinase  
Company  Status  
     
Fasudil/Eril Cerebral vasospasm ROCK Eisai Japan approved (1995) 
Rapamycin/ 
Rapamune 
Immunosuppression m-TOR 
Wyeth- 
Pfizer 
FDA approved (1999) 
Gleevec/ 
Imatinib 
Cancer Bcr-Abl Novartis FDA approved (2001) 
Iressa Cancer EGFR Astra-Zeneca FDA approved (2003) 
Tarceva Cancer EGFR OSI Pharm. FDA approved (2004) 
Nexavar Cancer Raf-1 Bayer FDA approved (2005) 
Sunitinib Cancer 
VEGFR, 
PDGFR 
Pfizer FDA approved (2006) 
Crizotinib Cancer ALK, ROS-1 Pfizer FDA approved (2011) 
Vemurafenib Cancer BRAF Roche FDA approved (2011) 
Axitinib Cancer 
VEGFR, 
PDGFR 
Pfizer FDA approved (2012) 
Bosutinib Cancer Bcr-Abl, Src Pfizer FDA approved (2012) 
Tofacitinib Rheumatoid 
Arthritis 
JAKs Pfizer FDA approved (2012) 
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Figure 1.4: Chemical Structures of Some Kinase Inhibitors Staurosporine is used only for 
research purposes; all others are used for treatment of diseases (Table 1.2).
 45,46
 
 
1.5 Protein Kinases: Classification  
Protein kinases catalyze protein phosphorylation and belong to a super family of enzymes 
called transferases. Over 500 human kinases are known, representing approximately 2% of the 
human genome.
17,50
 Protein kinases are broadly classified into two classes based on their 
preferred amino acid substrates: serine/threonine protein kinases and tyrosine protein kinases. A 
third class of kinases exist that phosphorylate both serine/threonine and tyrosine residues, but 
13 
 
they are not well characterized.  Protein kinases are further grouped into eight families based on 
sequence similarities in the catalytic site (Figure 1.5).
16
  A second type of classification is based 
on the localization and activity of kinases, which are receptor (cell or nuclear membrane) and 
non-receptor (cytosolic) kinases.  
        
Figure 1.5: Classification of Human Kinases. Human kinases are mainly divided into 7 major 
groups including; aAGC: Containing PKA, PKG, PKC families; CAMK: Calcium/calmodulin-
dependent protein kinase; CK1: Casein kinase 1; CMGC: Containing CDK, MAPK, GSK3, 
CLK families; STE: Homologs of yeast Sterile 7, Sterile 11, Sterile 20 kinases; TK: Tyrosine 
kinase; TKL: Tyrosine kinase-like. Other: kinases do not belong to any of the above groups.
16
 
 
1.6 Protein Kinases: Structure, Mechanism and Specificity  
Protein kinases consist of two domains, a catalytic and a regulatory domain, which work 
cooperatively to turn on and off phosphorylation events. Some kinases, like CK2, contain two 
catalytic and two regulatory units. But CK2 can exist and function independently with catalytic 
subunit only.
51
 In the case of cSrc kinase, the catalytic domain is part of a large protein complex 
14 
 
that controls the phosphorylation activity.
52
 The catalytic subunit consists of two domains, N-
terminal and C-terminal domains, resulting in two conformations: open and closed 
conformations. The C-terminal domain, also called the larger lobe, consists of α-helices with 
substrate binding sites. The N-terminal domain, also called the smaller lobe, consists of β-sheets 
which assist in guiding the ATP to active site (Figure 1.6A). These two lobes are connected by a 
hydrophobic linker, which forms the binding site for an ATP molecule.
53
 ATP binds to the active 
site by pointing the adenine moiety inside the conserved active site, with the triphosphate group 
pointed away from the active site. ATP binding into the active site brings both the N and C-
terminal domains closer, along with the substrate and forms a ternary protein complex for 
enzymatic phosphorylation activity (Figure 1.6A). The catalytic core differs with respect to 
charge and hydrophobicity of the residues among serine/threonine and tyrosine kinases. 
Accordingly, serine/threonine kinases have a relatively shallow catalytic domain compared to 
tyrosine kinases, which have a deeper active site to accommodate the tyrosine side chain of the 
substrate.  
The catalytic active sites of kinases display similar primary structures and contain nine 
conserved amino acid residues: G52, K72, Q91, D166, N171, D184, G186, Q208, and R280 
(numbering as in PKA kinase).
54
 These residues stabilize and interact with adenine base and 
triphosphate of ATP during catalysis (Figure 1.6B). Of the known > 500 kinases, some kinases 
lack catalytic activity due to the absence of some of the key amino acids in the active site, and 
are called atypical protein kinases.
55,56
 Inactive protein kinases bind to active protein kinases 
which catalyze phosphorylation events. Inactive protein kinases also catalyze certain protein- 
protein mediated signaling in the cells.  
15 
 
 
Figure 1.6: Crystal Structure of PKA Kinase. A) Crystal structure of PKA kinase (ribbon 
structure) bound to peptide substrate inhibitor (red ribbon structure) and ATP (ball and stick 
structure) complexed with Mn
2+ 
(spheres) (PDB: 1ATP).
57
 B) Kinase-catalyzed phosphorylation 
mechanism showing major interactions of ATP with the conserved amino acids in the active site 
of PKA kinase. 
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The ATP cosubstrate is stabilized in the active site by two divalent metal ions, either 
Mg
+2
 or Mn
+2
, by chelating with phosphate groups and conserved amino acid residues in the 
active site. Aspartate (D166) acts as a base and deprotonates the hydroxyl group on the protein 
substrate, making it more nucleophilic. The ATP molecule is held tightly in the active site by the 
metal ions and amino acids (Scheme 1.2), which positions it for nucleophilic attack on its -
phosphate by the protein substrate hydroxyl group. This results in the formation of 
phosphorylated protein substrate and ADP as a byproduct (Scheme 1.2). 
Scheme 1.2: Mechanism of Protein Phosphorylation. Mechanism of protein phosphorylation 
illustrated with a serine amino acid, forming a phosphorylated serine product.  
 
The enzymatic mechanism of protein phosphorylation was long debated and two 
possibilities were proposed. An associative mechanism was proposed first, which was similar to 
a bimolecular nucleophilic substitution reaction (SN2).
58,59
 In the transition state, bonds between 
the nucleophilic substrate oxygen and -phosphate of ATP are formed simultaneously when the 
ADP molecule is still bonded to the -phosphate (Figure 1.7, Path A). More recent evidence 
supports the dissociative type or unimolecular nucleophilic substitution reaction (SN1) 
mechanism.
60-62
 In the transition state, the ADP leaving group departs from the -phosphate 
group preceding nucleophilic attack of the substrate hydroxyl (Figure 1.7, Path B). Recently, 
many kinase inhibitors are designed based on the dissociative mechanism.
60
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Figure 1.7: Proposed Transition States of Associative vs Dissociative Phosphorylation 
Mechanism. Path A: In the associative mechanism, the leaving group and incoming nucleophile 
remain attached to the reactive center. Path B: In the dissociative mechanism, the leaving group 
departs significantly before nucleophilic attack at the reactive center. 
Kinases recognize their protein or peptide substrates through a specific consensus 
sequence. Various factors affect the binding interactions of kinases and substrates, like the distal 
docking domain or the presence of other protein partners during phosphorylation. However, a 
sequence of four amino acids that are toward the N or C terminus from the site of 
phosphorylation are critical for kinase recognition and phosphorylation (Table 1.3).
50
 Consensus 
sequences for many kinases have been identified and kinases can specifically recognize acidic, 
basic, hydrophobic or proline residues in their substrates to direct phosphorylation. Abl protein 
kinase, a tyrosine kinase with a consensus sequence of I/V/L-Y-X-X-P/F (X represents any 
amino acid) phosphorylates tyrosine residues adjacent to hydrophobic residues.
63
 CK2 kinase 
phosphorylates serine/threonine residues with a consensus sequence of S/T-D/E-X-D/E, near 
acidic amino acids.
64
 c-AMP dependent protein kinase (PKA), preferentially phosphorylates 
18 
 
serine/threonine protein substrates which are flanked by basic amino acids, with R-R-X-S/T-Z 
consensus sequence.
65
 Consensus sequence scanning is routinely used to identify the protein 
substrates of known kinases. But the consensus sites and sequences of the >500 kinases are not 
known and the presence of a particular consensus site does not necessarily establish a 
substrate/kinase pair. In addition to the consensus sequences, certain docking interactions and 
binding motifs outside of the site of phosphorylation influence the affinity of substrate and 
phosphorylation activity of the kinase. The factors which govern kinase substrate interactions are 
understood and the features that are important in cosubstrate interactions and identifications are 
discussed in the next section.  
Table 1.3: Consensus Sequences of Selected Protein Kinases
50
 
 
  
                                                                                                                                                            
                                                                                                         
 
 
 
 
 
 
 
 
Kinase Consensus Sequence 
Abl  I/V/L-Y-X-X-P/F  
AKT1  R-X-R-X-X-S/T  
Aurora-A  R/K/N-R-X-S/T-B  
CaMK2 R-X-X-S/T 
CDK 1  S/T-P-X-R/K  
CHK 1  R-X-X-S/T  
CK1 pS-X-X-S/T
CK2  S/T-D/E-X-D/E  
ERK 2  P-X-S/T-P  
EGFR E-E-E-Y-F 
GRK 5  D/En-S/T-X-X-X  
GSK 3  X-S/T-X-X-X-pS  
IRK Y-M-M-M 
PKA  R-R-X-S/T-Z 
SRC  E-E-I-Y-E/G-X-F  
X – any residue, Z-hydrophobic residue, pS-
phosphorylated serine, Red/Bold-site of 
phosphorylation 
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1.7 Kinase cosubstrate Promiscuity 
 
Of the known PTM enzymes, many demonstrate cosubstrate promiscuity by accepting 
structurally similar cosubstrates.
66-72
 A few examples of enzymes demonstrating cosubstrate 
promiscuity are acetyltransferase,
73
 transglutaminase,
74
 galactosyltransferase,
75
 
methyltransferase,
76
 and farnesyltransferase.
77
 Indeed, kinases also demonstrate cosubstrate 
promiscuity with modified ATP analogs. Adenosine 5’-[γ-thio]-triphosphate (ATP-γS) was the 
first reported modified ATP analog used as a kinase cosubstrate.
78-81
 ATP-γS acts as a 
cosubstrate in kinase-catalyzed phosphorylation processes, resulting in a thiophosphorylated 
substrate (Scheme 1.3). The ATP-γS phosphorylation mechanism is similar to that of ATP, 
where the γ-phosphate group from ATP-γS is transferred onto the substrate hydroxyl group 
forming a thiophosphorylated product and ADP. The thiophosphate group can be used as a 
handle to identify and purify substrates. However, kinetic analyses with ATP-γS demonstrated 
poor catalytic efficiency compared to ATP, also known as thio effect.
82-85
 In spite of low 
catalytic turnover, ATP-γS was used to study the proteome because of the stability of 
thiophosphorylated products towards phosphatases.
86-90
 ATP-γS was also used in identification 
of novel and low abundant protein substrates.  
  
Scheme 1.3: Kinase-Catalyzed Protein Phosphorylation with ATP-γS. Serine, threonine and 
tyrosine hydroxyl groups on proteins attack the γ-thiophosphate group of ATP-γS to label 
proteins with a thiophosphoryl group.  
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In addition to the ATP-γS analog, other analogs were synthesized for selective 
phosphorylation with specific kinases by modifying both the adenine base and the γ-phosphate 
group.
91
 One analog N
6
-(benzyl) ATP-γS (Figure 1.9) was developed by the Shokat group, where 
in kinases were engineered to bind to base modified ATP analogs, which was helpful in 
purification and identification of substrates for a specific kinase by proteomic analysis.
90,86
  
Analogous to ATP-γS, the Pflum lab was interested in developing γ-phosphate modified 
ATP analogs, which can aid in labeling kinase substrates, and identifying kinase substrate pairs. 
From the crystal structures analysis of CK2 and PKA kinase, it was clear that the γ-phosphate 
group of ATP is in the solvent exposed region (Figure 1.6 and 1.8). We hypothesized that ATP 
modified with other substituents on γ-phosphate can act as cosubstrate in a kinase-catalyzed 
labeling reaction. Accordingly, the Pflum group has demonstrated that several γ-phosphate 
modified ATP analogs can act as cosubstrates and transfer the modified phosphate group onto 
the substrate as described in the following sections.
92-94
 These chemical probes will be helpful in 
understanding and characterizing signaling pathways in normal and diseased states.   
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Figure 1.8: Crystal Structure of CK2 Kinase Bound to ATP Analog. Crystal structure of 
CK2 kinase complexed with ATP analog ( Phosphoamino phosphonic acid adenylate ester) and 
Mg
+2
. Solvent exposed phosphate group is pointed out as shown with an arrow (PDB-1LP4). 
95
 
 
1.7.1 ATP-Biotin 
To initially validate cosubstrate promiscuity, kinase-catalyzed phosphorylation was 
carried out using an ATP-Biotin analog, along with a peptide substrate and recombinant kinase 
(Scheme 1.4). We found that kinases promiscuously accept ATP-Biotin and form biotinylated 
products with peptides containing serine (LRRASLG), threonine (RRREEETEEE), or tyrosine 
(EAIYAAPFAKKK) along with corresponding PKA, CK2, and Abl kinase respectively.  
Biotinylation was quantified with respect to ATP (assuming 100% complete reaction) using 
quantitative mass spectrometry (QMS) analysis (Table 1.4).
96,97
 Next, we tested the compatibility 
of ATP-Biotin with full length protein substrate (β-casein) and CK2 kinase. Biotinylation of the 
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substrates was analyzed using gel electrophoresis, followed by visualizing the biotin tag using 
streptavidin-horseradish peroxidase (SA-HRP) conjugate.  In addition, when HeLa cell lysates 
were incubated with ATP-Biotin, we found that cellular kinases utilized ATP-Biotin to 
biotinylate cellular substrates.
96,97
 These results demonstrate that kinase-catalyzed biotinylation 
can be generally applied to probe endogenous kinases and substrates.   
Scheme 1.4: Kinase-Catalyzed Biotinylation using ATP-Biotin. Hydroxyl containing amino 
acids on peptides or proteins are biotinylated with ATP-biotin in the presence of kinases. See 
Table 1.4 for the structure of ATP-biotin. 
 
Table 1.4: Kinase-Catalyzed Labeling of Peptide Substrates using Previously Reported 
ATP analogs.
94,98,99
 
 
23 
 
1.7.2 ATP-Dansyl 
After successful demonstration of kinase catalyzed biotinylation, we were interested in 
examining the compatibility of kinases with other γ-phosphate modified ATP analogs. 
Commercially available ATP-dansyl (Scheme 1.5) was used to test the compatibility in a kinase 
reaction. Similar to ATP-biotin, ATP-dansyl was incubated with peptides in the presence of their 
corresponding kinases and the efficiency of dansylation was analyzed using QMS (Table 1.4).
93
 
This data indicated that ATP-dansyl was successfully used as a cosubstrate in kinase-catalyzed 
phosphorylation.  
To further characterize the kinase cosubstrate promiscuity of ATP-dansyl, kinetic studies 
were carried out. An absorbance assay was used to study the kinetics of ATP and ATP-dansyl 
with PKA kinase and a peptide substrate.
100,101
 ATP-dansyl and ATP maintained similar KM 
values (23 μM and 24 μM respectively), indicating that the γ-phosphate modification did not 
alter the binding of ATP in the active site. In contrast the kcat of ATP-dansyl was 9-fold less 
compared to ATP, demonstrating that the kinase reaction with ATP-dansyl is slower than ATP.
93
 
Overall, this data demonstrates that γ-phosphate modified ATP analogs act as cosubstrate in 
kinase-catalyzed labeling reactions, and can be used for studying kinase substrates and kinase 
mediated signaling pathways. 
Scheme 1.5: Kinase-Catalyzed Dansylation using ATP-Dansyl. Hydroxyl containing amino 
acids on peptides or proteins are dansylated with ATP-Dansyl in the presence of kinases. See 
Table 1.4 for the structure of ATP-Dansyl. 
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1.7.3 γ-phosphate Modified ATP analogs 
In addition to the γ-phosphate modified analogs synthesized by the Pflum lab, other 
research groups have synthesized and studied the applications of the analogs. The Carlson group 
synthesized ATP-BODIPY, where the BODIPY fluorophore was attached to γ-phosphate of ATP 
using sulfur (Figure 1.9). ATP-BODIPY showed competitive binding with ATP and was used to 
study the autophosphorylation activity of histidine kinases.
102,103
  
The Kraatz group synthesized an ATP-ferrocene analog, where the γ-phosphate is 
attached to a ferrocene moiety with a hydrocarbon linker (Figure 1.9). This ferrocene 
modification was used as a handle to detect kinase activity electrochemically and with anti-
ferrocene antibodies. In addition, ATP-ferrocene was shown to compete with ATP for kinase 
binding and was used to profile kinase activity in complex mixtures and for kinase inhibitor 
profiling.
104-107
   
Apart from profiling substrates, γ-phosphate modified ATP analogs were also used to 
label and identify kinases in complex mixtures. ATP-acyl-biotin analogs developed by Active X 
Biosciences were used to biotinylate kinases (Figure 1.9).
108,109
 These analogs were designed 
based on ATP binding to the active site of kinases. The ATP binding site is highly conserved 
(with only a few exceptions) and contains two lysine residues. One of the lysine is found in the 
ATP binding region and the other one near the C-terminus closer to the - and β- phosphates of 
ATP. Once ATP-acyl-biotin was bound in the active site, the conserved lysine residue forms a 
covalent linkage with the acyl biotin group, displacing ATP. Formation of a stable covalent 
linkage with a biotin tag helps in the purification and identification of kinases selectively.
108,109
 
This method was applied to identify active kinases and kinase inhibitors. 
108,109 
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Figure 1.9: Structural Diversity of -Phosphate Modified ATP Analogs. -Phosphate 
modified ATP analogs synthesized and applied to study phosphorylation by various groups. 
Applications were briefly discussed in the text. 
 
 
1.8 Photocrosslinking analog- ATP-ArN3 
Many ATP analogs were developed to characterize kinases and its substrates using 
proteomics. But identifying the genuine upstream kinase of a protein substrate in the normal and 
disease states is still challenging. Signaling pathways have multiple complimentary pathways 
and inhibition of a particular cascade can be compensated by others. In addition, one particular 
substrate can have multiple kinases depending on the cellular environment and vice versa.   
Besides, the interaction between kinase and its substrate is transient. Designing a γ-phosphate 
modified ATP analog that can identify kinase substrate pairs will be helpful in studying 
phosphorylation dependent signaling pathways. Such a chemical probe will allow us to map 
phosphorylation mediated signaling pathways in normal and diseased states of cells. 
Accordingly, the Pflum lab wanted to develop an ATP analog modified at the γ-
phosphate position with a photocrosslinking group. When the photocrosslinking ATP analog was 
incubated with a kinase and its substrate, kinases will promiscuously transfer the modified 
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phosphate group onto the substrate. With concurrent UV irradiation, the photocrosslinker is 
activated and covalently links kinase and its substrate in a phosphorylation dependent manner, as 
depicted in Figure 1.10. Previously Dr. Sujit Suwal from our lab synthesized ATP-arylazide 
(ATP-ArN3), an ATP analog modified at the -phosphate with an aryl azide photolabel, to 
covalently link kinase and substrate upon phosphorylation and UV irradiation. Initial studies 
showed that ATP-ArN3 acted as a kinase cosubstrate and modified the corresponding peptide 
substrates with high conversion efficiency (Table 1.4). Next, to test phosphorylation mediated 
kinase substrate crosslinking, we used CK2 kinase phosphorylation of casein protein substrate as 
a model system. CK2 kinase, ATP-ArN3, and casein substrate were incubated under UV 
irradiation for 2 hours, followed by SDS-PAGE separation and western blot analysis with anti-
CK2 to identify the kinase-substrate complex. Crosslinking was observed in an ATP-ArN3 and 
UV dependent manner (Figure 1.11, lane 4), wherein a higher molecular weight complex 
corresponding to CK2 and casein was observed.
98
 In contrast, no higher molecular weight bands 
were observed with ATP under similar conditions or with TFA treatment (Figure 1.11, lanes 3 
and 5). These observations support the formation of kinase substrate complexes through 
phosphorylation-dependent kinase-substrate crosslinking. 
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Figure 1.11: Kinase-Catalyzed Photocrosslinking with ATP-ArN3. CK2 kinase was 
incubated with full length α-casein in the presence of ATP or ATP-ArN3 before separation by 
SDS-PAGE and visualization with a CK2 antibody. Reactions were incubated either with or 
without exposure to 365 nm light (UV). Trifluoroacetic acid was added to a final 
concentration of 50% after crosslinking to cleave the phosphoramidate bond of the crosslink. 
The expected 68 kDa crosslinked complex is indicated as CK2-casein.
98
  
CK2-casein 
CK2 
 1 2 3 4 5 
CK2 + + + + + 
α-casein + + + + + 
ATP + - + - - 
ATP-ArN3 - + - + + 
UV - - + + + 
acid - - - - + 
 
 
Figure 1.10: Phosphorylation-Dependent Kinase-substrate Crosslinking approach. Cartoon 
depicting phosphorylation-dependent kinase substrate crosslinking upon UV irradiation. 
    
 
 
 
28 
 
 
1.9 Current methods to identify kinase-substrate pairs 
Phosphorylation is an important PTM in cell signaling and affects various cellular 
functions, which emphasizes the need to develop new techniques to monitor phosphorylation as 
well as to identify the signaling partners. Techniques used to understand and monitor 
phosphorylation include radiolabel 
32
P,
110
 phospho specific antibodies,
111
 immobilizing metal 
affinity chromatography,
112
 Pro-Q diamond phosphate stain,
113
 and covalent modifications of the 
phosphate, including the Pflum lab’s γ-phosphate modified ATP analogs.93,97,114,115 A variety of 
methods have been used to identify kinase-substrate pairs. The consensus sequences for many 
protein kinases have been determined using combinatorial peptide libraries.
116,117
  Based on 
sequence preferences, kinase-substrate pairs are routinely revealed by consensus site 
searching.
116,117
 Unfortunately, the consensus sequences of all 500 human protein kinases are not 
yet available. Techniques to identify protein-protein interactions are also used, including yeast 
two-hybrid and pull-down assays.
118,119
 While these classical methods have shown success, the 
transient kinase-substrate interaction can be lost or overlooked during purification or gene 
expression. As alternatives, several chemical methods have been developed to convert the 
unstable kinase-substrate interaction into a covalent linkage, which facilitates purification and 
identification.  The Shokat lab developed analog-sensitive kinase mutants
86
 and a mechanism-
based cross-linker
120
; the Cole group created a photocrosslinking ATP analog
121
 to  identify 
kinase substrate pairs. Some of these methods are further discussed in Chapter 2 and 3. 
1.10     Thesis Projects 
The Pflum lab has developed ATP-ArN3, a phosphorylation-dependent kinase-substrate 
photocrosslinker, which crosslinks kinase and substrate in a phosphorylation dependent manner 
(Figure 1.10). To expand the scope and utility of other photolables in our approach, we wanted to 
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synthesize ATP analogs modified with different photocrosslinkers. Because of the difference in 
the properties of different photoprobes, comparative studies were performed and analyzed the 
crosslinking of kinase substrate pairs with ATP-ArN3 (chapter 2).  As a further application of 
these chemical probes, experiments were done to obtain optimum conditions for crosslinking in 
the presence of cell lysates. Next, to demonstrate the applicability of the analogs, p53 protein 
substrate was chosen as a model system. Experiments were carried out to identify kinases of p53 
protein using cell lysates in vitro. Mass spectrometry analysis of the observed crosslinked bands 
revealed some novel and known kinases of p53 (chapter 3). This work highlights the utility of 
these chemical probes in identifying kinase substrate pairs using natural kinases and substrates. 
These probes are novel and will be useful in understanding the role of kinases in signaling 
pathways and biological processes. 
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Chapter 2 
 
2. Comparative Study of Phosphorylation-Dependent Kinase-Substrate Photocrosslinkers  
 
In this chapter, various aspects of photocrosslinking and photocrosslinking groups are 
discussed, with brief historical preview. Different types of photocrosslinking analogs were 
synthesized and tested with recombinant kinases. These analogs were successfully used to 
crosslink CK2 kinase and casein protein substrate. Autodock computational program was used 
for docking analysis and to analyze the factors governing crosslinking.  
 
2.1       Introduction to photocrosslinking   
 
In nature, living organisms contain various biomolecules like proteins, carbohydrates, 
nucleic acids, lipids, and metabolites. These biomolecules undergo various modifications like 
phosphorylation, acetylation, methylation etc to perform different functions. It is critical to 
understand the mechanism and nature of interactions between biomolecules involved, to promote 
a biological event. To study the complex network of protein interactions, many methods have 
been developed like affinity-based experiments, tandem affinity purifications (TAP) and mass 
spectrometry.
122,123
 These methods have been powerful in studying protein-protein interactions 
using cell lysates, but there is a possibility of identifying false positives as well as loss of some 
weak interactions during the purification process. Alternatively, photoaffinity labeling (PAL) is 
used to identify interacting proteins by forming a covalent bond. In PAL a natural substrate is 
tagged with a photolabel and introduced into a system under investigation, upon irradiation the 
photolabel crosslinks interacting biomolecules (Figure 2.1). 
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Figure 2.1: Scheme Depicting Protein-Protein Photocrosslinking. 
 
PAL was first proposed by Prof. Westheimer in 1962 using a diazoacetyl group.
124
 In the 
past few decades, many photoprobes have been developed and applied to study various 
biological systems, as shown in Table 2.1.
124-135
 These photoprobes are broadly classified based 
on the reactive intermediate formed upon photolysis. They are divided into carbene-generating, 
nitrene-generating, radical-generating, and electrophilic carbon-generating photolabels.  For 
successful PAL, the photoprobe needs to meet certain basic criteria.
136
  
1. The photoprobe should be chemically inert towards other biological functionalities and in 
the absence of actinic light. 
2. The photoprobe should be activated under mild conditions without causing damage to the 
biological system under study. 
3. In order to capture the interacting biomolecules, the lifetime of the excited photolabel 
should be shorter than the lifetime of the interacting protein complex. 
4. Upon irradiation the photoprobes should be able to form a covalent bond with any -CH,  -
NH, -OH, polar, non-polar or saturated groups present in proximity. 
Depending on the biological system under study some other additional criteria can be considered. 
So far there are no ideal photoprobes that fit all criteria, but the compounds generating nitrenes, 
carbenes, diradicals and aryl cations upon photolysis meet most of these requirements.  
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Table 2.1: Chronology of Photoprobes Used to Study Biomolecules 
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2.1.1    Azides 
Phenyl azides are widely used and studied compared to alkyl azides due to their stability. 
Aryl azides can be irradiated over a broad range (254-400 nm) depending on the 
substitution
137,138
 and loss of a molecule of nitrogen produces a nitrene. The nitrene intermediate 
inserts into C-H and hetero atom (X)-H bonds (X = O, N, S) or it can undergo ring expansion to 
form a long lived intermediate ketenimine, which reacts with nucleophiles as shown in Figure 
2.2.
139
 The broad reactivity of nitrenes allows them to crosslink with a variety of biomolecules, 
but this high reactivity also leads to non-specific labeling especially, when the nitrene undergoes 
ring expansion.   
 
Figure 2.2: Reactivity of Aryl Azides under Photolysis 
2.1.2   Diazirines 
Diazirines require 350 nm light to form highly reactive carbene, which broadly reacts 
with biomolecules by C-H and X-H (X = O, N, S) insertions
140,141
 as shown in Figure 2.3. 
Similar to aryl azides, carbenes can undergo Wolf type rearrangement to form a ketene, which 
reacts with nucleophiles like water to form carboxylic acids, reducing crosslinking efficiency.
142
 
The reactivity of the carbene is similar to that of a nitrene, but relatively smaller size of the 
diazirine doesn’t perturb the biomolecules complex under study, which is advantageous. 
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Formation of a long lived ketene intermediate can react with nucleophiles producing nonspecific 
crosslinking. Despite these drawbacks, diazirine and aryl azides have been widely studied in 
various biological applications with different substitutions (Table 2.1). 
 
 
Figure 2.3: Reactivity of Diazirines under Photolysis 
 
2.1.3   Benzophenones 
Benzophenone upon photolysis at 350-360 nm produces a diradical species, which 
participates in crosslinking reactions by inserting in C-H and X-H (X = O, N, S). An advantage 
with benzophenone is that the diradical can crosslink with biomolecules in proximity or it can 
relax back to its ground state, which can be excited again as shown in Figure 2.4.
143
  This results 
in high efficiency with benzophenone compared to others photolabels, but it also requires longer 
irradiation times.
144
 Benzophenone was found to have a preference for methionine residues when 
they are in close proximity. Absence of methionine residue at the site of crosslinking might 
offset its use in some biological PAL studies.
145
 Some other features of benzophenone like its 
bulky size and lipophilicity may also complicate its use in some studies.  
 
 
35 
 
 
 
Figure 2.4: Reactivity of Benzophenone under Photolysis 
 
To explore the nature and scope of these photoprobes in phosphorylation-dependent kinase-
substrate crosslinking, we synthesized ATP analogs containing an aryl azide and a 
benzophenone. A summary of the current methods for identifying kinase-substrate pairs is 
discussed before the synthesis of ATP analogs and its application. 
2.2       Existing methods for the identification of kinase-substrate pairs 
The crystal structures of different kinases have provided significant input about the 
structure and mechanism of kinases (chapter 1). Similarly, techniques like in vitro 
phosphorylation, yeast two-hybrid systems, pull down assays, and chemical approaches like 
mechanism based crosslinkers, bifunctional photocrosslinkers were employed to identify kinase 
substrate pairs. Despite of these techniques mapping the entire kinome, determining the kinase 
activities, its effectors in the signaling pathways is still challenging. With increasing evidence 
from recent literature about the involvement of kinases in many diseases, there is a strong need 
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to develop new techniques that identify genuine kinase-substrate pairs. Therefore, tools that can 
identify kinase-substrate pairs in a phosphorylation dependent manner will be helpful in cell 
signaling studies.  In the following section a few existing methods for identifying kinase-
substrate pairs are discussed, emphasizing the chemical approaches due to their relevance to this 
work. In general, the techniques available to study kinase substrate pairs are broadly classified 
into four major groups. 
1. In vitro phosphorylation 
2. Physical association 
3. Genetic approach 
4. Chemical approach 
2.2.1   In Vitro Phosphorylation 
Of these methods, in vitro phosphorylation is the most traditionally used method. The 
substrate of a particular kinase can be identified by incubating a kinase of interest with 
radiolabeled [γ-32P] ATP, with a purified substrate or cell lysates. The sites of phosphorylation 
are identified by resolution of the reaction mixture by SDS-PAGE analysis and Mass 
spectrometry.  An alternative to the in vitro phosphorylation approach and using whole cell 
lysates mimicking cellular environment, was developed by the Shokat group.
146,147
 In this 
method, ATP analog (N
6
-benzyl-ATP-γS) was modified with a sterically bulky group on the 
adenine base, which prohibits binding to the kinase active site. A kinase of interest was mutated 
(as-Kinase: analog sensitive kinase) to accommodate the bulky group of N
6
-benzyl-ATP-γS 
selectively. When an enzymatic reaction was carried out with as-kinase and N
6
-benzyl-ATP-γS 
in the presence of cell lysates, the as-kinase selectively phosphorylated its substrates and the γ-
thiophosphate group was transferred to its substrate (Figure 2.5). After phosphorylation, the sites 
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of phosphorylation and substrates can be characterized unambiguously, using 2D gel analysis, 
and phospho-specific antibodies, coupled with mass spectrometry. This As-kinase approach was 
used to label and identify substrates for JNK,
148
 CDK7,
149
 ERK2,
150
 CDK1-Cyclin B
86
 and 
CDK2-Cyclin A
151
 kinases in human cells; c-Src,
152
 v-Src,
153
 PKA,
154
 Abl related-gene (Arg),
155
 
and Erk2
90
 kinases in murine cells; and Cdc28 (CDK1),
156
 Hog1,
157
 and Pho85-Pcl1
158
 kinases in 
yeast cells.     
 
 
Figure 2.5: Schematic Representation of Phosphorylation by an Analog Sensitive Kinase 
(as-kinase). Cell lysates were incubated with mutant kinases, ATP and modified N
6
-Benzyl-
ATP-γS. Substrates for the mutant kinase were labeled as thiophosphorylated products. 
Thiophosphorylated products were purified and identified by MS analysis.  
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2.2.2.   Physical Association 
Another important method that is used to identify kinase substrate pairs is yeast two 
hybrid (Y2H) assay. Y2H is a physical interaction screen, which is mainly used to identify 
protein-protein interactions.
118
 In Y2H approach, a fusion protein containing the catalytic site of 
a kinase and the DNA-binding domain of a transcription factor (for example, in yeast Gal4 or in 
bacteria LexA) is used as “bait”. A set of substrates fused to an activation domain is used as 
“prey” to screen for interactions that turn on the transcription and promote growth and/or a color 
change or production of galactosidase (Figure 2.6). Y2H screens of kinase and substrate do not 
require primary information on the sequence specificity of the kinase and allows for 
identification from a cDNA library of the interacting proteins. In Y2H, the interacting kinase and 
substrate are likely to be in their native conformation since their entire screen is performed in 
vivo. For example, Y2H was successfully used in the identification of PICK1 as a substrate of 
PKC kinase,
159
 and many others.
160,161
 Y2H system is robust, rapid and sensitive, but due to 
some limitations, like over-expression of proteins and abnormal protein activities it is not widely 
used in kinase substrate pair identification. 
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Figure 2.6: Yeast two-hybrid System Showing the Prey and Bait Interaction. When the bait 
containing DNA binding domain (BD) binds to the promoter, the prey is reunited with its 
activation domain (AD), as a result the expression will be turned ON. Transcription is turned 
OFF when there is no interaction between the bait and prey. Bait contains the kinase catalytic 
domain and prey contains the substrate sequence.
118
 
 
2.2.3   Chemical approaches 
A variety of chemical approaches have been developed to identify and confirm kinase 
substrate pairs. These chemical methods have commonly used a crosslinking strategy to 
transform the transient interaction of kinase and substrate into a covalent linkage, forming a 
kinase-substrate complex.  The crosslinked kinase substrate protein complex can be identified 
using SDS-PAGE analysis, western blot and mass spectrometry. Covalent crosslinking can be 
achieved by modifying one of the interacting partners with a chemically reactive group or a 
photoreactive probe at the site of interaction. Chemically reactive probes like aldehydes or other 
electrophilic groups and photoreactive probes like azides, diazirine and benzophenone have been 
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extensively used in the crosslinking studies. Next some of the currently used chemical 
approaches for kinase substrate crosslinking are briefly explained. 
2.2.3.1     Mechanism-based crosslinking approach 
The mechanism-based crosslinking approach was reported by the Shokat group. In this 
approach a bi-functional crosslinker containing an o-phthaldialdehyde group attached to the 5’-
hydroxyl of adenosine moiety was used. When this modified analog is bound in the ATP binding 
pocket of the kinase, the o-phthaldialdehyde substituent is positioned near a lysine residue in the 
active site (Figure 2.7). When in close proximity, the amino group of the lysine reacts with one 
of the aldehydes of ATP analog to form an imine. Incubation with a pseudo-substrate containing 
a cysteine in place of the reactive hydroxyl group initiates a cascade reaction with the imine and 
the remaining aldehyde of the ATP analog to form a covalent complex. This mechanism-based 
crosslinker approach was demonstrated with a few kinases and their corresponding biotinylated 
substrate peptides.
162
 When crosslinking was performed between fluorophore-labeled peptide 
substrates and kinases in the presence of lysate, numerous non-specific fluorophore labeled 
products were observed because of the reactivity of the aldehyde ATP analog. To overcome 
these challenges, the Yao group has developed a second generation mechanism based crosslinker 
replacing o-phthaldialdehyde group with naphthalene-2, 3-dicarboxaldehyde (NDA, Figure 
2.8).
163
 The NDA modification was better accommodated in the kinase active site and 
compatible with serine/threonine and tyrosine kinases. This second generation analog was 
successfully used with various kinases and fluorophore labeled peptides in the presence and 
absence of cell lysates.  
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Figure 3.3: Schematic Representation of the Mechanism Based Crosslinking Approach.  
Reaction of lysine side chain and the mercapto group of the pseudo-substrate with the modified 
ATP analog in a three component reaction results in a crosslinked kinase-substrate complex.
162
 
 
 
Recently, a third generation mechanism-based crosslinker was developed by the Shokat 
group (Figure 2.8).
164
 In this crosslinker, adenosine moiety was replaced by a potent kinase 
inhibitor scaffold, 3-aminopyrazole, and the reactive o-phthaldialdehyde was replaced with the 
less reactive thiophene-2, 3-dialdehyde to reduce non-specific labeling in the presence of cell 
lysate. This new crosslinker was successfully used to crosslink Akt1 kinase selectively with 
fluorescein-labeled peptide substrate in the presence and absence of cell lysates. Some of the 
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drawbacks of this method are the requirement for mutation of serine to cysteine in the substrate, 
validation with other types of kinases, and possible side reactions between the mercapto group in 
the pseudo-substrate with peripheral residues of kinase and substrate. 
 
 
Figure 2.8: Chemical Structures of Mechanism Based Crosslinkers. The NDA-ATP analog 
was developed by the Yao group. The inhibitor based third generation crosslinkers were 
developed by the Shokat group.   
 
2.2.3.2     Bifunctional photocrosslinking ATP analog 
The Cole group developed a crosslinking ATP analog to identify kinase substrate pairs 
using an azide photoprobe.
165
 ATP was modified with azide photoprobes on its phosphate and 
base portions. An azide moiety at the C-8 position of adenine could be easily accommodated into 
the kinase hydrophobic hinge region and upon photoactivation, covalently locked the ternary 
complex (Figure 2.9). This bi-functional photocrosslinker was successfully used to crosslink, Src 
kinase, with the protein substrate Csk. However, no further application of the bifunctional 
photocrosslinker ATP-analog has been reported. These methods have undoubtedly contributed to 
the study of kinases, but still there is a need to unambiguously identify genuine kinase-substrate 
pairs and the sites of phosphorylation. Novel chemical tools should be developed which are 
compatible with natural kinases and substrates in their native environment, maintaining the 
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activity of proteins during identification, and afford efficient covalent complex formation from 
transient proteins interaction. 
 
 
Figure 2.9: A Schematic Representation of a Bi-functional ATP Analog.  The ATP analog is 
bound in the kinase active site and forms a ternary complex. Upon UV irradiation, both the azide 
groups are activated and one crosslinks to the kinase and the other with substrate.  
 
 
2.3      Phosphorylation-Dependent Kinase-Substrate Crosslinking 
 
           Various methods have been developed to identify kinase substrate pairs as explained 
previously. Alternatively, the Pflum lab has developed phosphorylation-dependent kinase-
substrate crosslinking using modified ATP analogs. This concept was based on the kinase 
cosubstrate promiscuity discussed earlier (Chapter 1). Briefly the kinase and substrate were 
incubated with an ATP analog attached to a photoprobe, the modified phosphate group was 
transferred onto the substrate. Then with simultaneous UV irradiation, the photolabel crosslinks 
to the kinase (Figure 2.10B). When the reaction mixtures are separated by SDS-PAGE followed 
by western blot analysis with an antibody, a higher molecular weight band corresponding to the 
kinase-substrate complex should be observed (Figure 2.10B). This crosslinking method employs 
the natural kinase and substrate without any modifications and serves as a powerful tool in 
profiling the phosphoproteome.  
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Figure 2.10: Scheme of Phosphorylation-Dependent Kinase-Substrate Photocrosslinking 
A) Chemical structures of ATP (1) and  phosphate modified ATP analogs, ATP-arylazide 
(ATP-ArN3, 2), ATP-diazirine (ATP-DAz, 3) and ATP-benzophenone (ATP-BP, 4).  B) 
Cartoon depicting kinase-catalyzed protein phosphorylation along with UV-mediated 
crosslinking of kinase and substrate.  
 
 
 
  
   
 
 To compare and contrast the applicability of various photoprobes in phosphorylation-
dependent crosslinking, ATP-benzophenone (ATP-BP, 4) was synthesized and compared to 
ATP-ArN3. Because of the similarities in the reactivity of aryl azide and diazirine, ATP-diazirine 
(ATP-DAz, 3) was used only for computational studies.  
Substrate Substrate
Kinase-Substrate complex
Kinase
Substrate 
SDS-PAGE
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2.4       Synthesis of ATP-benzophenone (ATP-BP, 4) analog 
The ATP-BP 4 was synthesized in two steps starting from 4-benzoyl benzoic acid 5 as 
shown in Scheme 2.1. Benzophenone amine linker 7 was prepared by activating 4-benzoyl 
benzoic acid 5 with EDCI, followed by reaction with the diamine linker 6. Finally, ATP was 
coupled to benzophenone photolabel containing amine 7 using a reported procedure involving 
EDCI under controlled pH of 5.6-5.8 in aqueous medium. ATP-BP was obtained by purification 
of the reaction mixture by ion exchange chromatography.
166,167
  
Scheme 2.1: Synthesis of ATP-Benzophenone (ATP-BP, 4) 
 
 
2.5       Kinase cosubstrate compatibility of ATP-BP analog using QMS analysis 
We next investigated the compatibility of the ATP-BP analog in kinase-catalyzed 
labeling using quantitative mass spectrometric (QMS) analysis with peptide substrates.
96
 QMS is 
isotopic differential labeling of peptide substrate and quantified using MALDI-TOF MS analysis. 
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Briefly, kinase catalysed labeling reaction was carried out with peptide substrate, 
recombinant kinase and ATP, followed by esterification with deuterated methanol, acetyl 
chloride (Figure 2.11). Similarly, in a separate eppendorf tube, kinase catalysed reaction was 
performed with ATP-BP and esterification with methanol, acetyl chloride (Figure 2.11). 
Methanol was evaporated and the residue is dissolved in a small volume of water (10µL). Equal 
volumes of sample from both ATP and ATP-BP reaction tubes were mixed and analyzed using a 
MALDI-TOF. Assuming 100% conversion in the kinase reaction with ATP, the relative percent 
conversion in the ATP-BP kinase reaction can be calculated from the peak areas obtained from 
the MALDI MS spectrum (Figure 2.12). 
 
 
 
 
 
 
 
 
 
 
Figure 2.11: Scheme of Quantitative Mass Spectrometric (QMS) Analysis. A 
schematic representation of QMS analysis carried out with peptide substrate, recombinant 
kinase, ATP and ATP analog.   
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CK2 kinase was tested due to its variable conversions observed with several ATP analogs 
in our previous studies,
167
 which make it an ideal model kinase. QMS data showed that both 
analogs were accepted by CK2.  The CK2 peptide was modified with ATP-BP and CK2 kinase 
with 71% conversion. In earlier studies, ATP-ArN3 demonstrated a labeling efficiency of 51% 
(Table 2).
166
  Therefore, ATP-BP analog demonstrated enhanced labeling efficiency compared to 
ATP-ArN3. Overall, QMS data suggest that the ATP-BP analog is compatible with kinase 
catalyzed labeling. Next we wanted to test whether the ATP-BP analog is capable of kinase-
substrate crosslinking.  
Table 2.2: MALDI-TOF MS analysis of CK2 peptide after incubation with ATP-BP and 
CK2 kinase.
a  
 
Analog % Conversion 
  
ATP-BP 71% 
ATP-ArN3 51% 
 
a
Percentage conversions were determined using quantitative MS by comparing to ATP 
phosphorylation (100%), as previously described.
96
  Data reported previously with ATP-
ArN3 are shown for comparison. 
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  m/z     SN     Res.                 Intens.     Area 
1540.968 115.0   4094  813.42   317 
       1562.199     129.6     3420         916.66      431 
 
Figure 2.12: QMS MADLI-TOF Spectrum of ATP-BP Analog Quantitative MALDI-TOF 
MS of peptide substrate (RRREEETEEE) with CK2 kinase and either ATP 1 or ATP-BP 4. The 
peak at m/z ~1541 corresponds to heptamethylated phosphopeptide after reaction with ATP-
benzophenone and acidic cleavage of phosphoramide bond, while the peak at m/z ~1562 
corresponds to the deuterated heptamethylated phosphopeptide after phosphorylation with ATP. 
Percent conversion of this single trial was 74% (Trial 1); Additional trials are shown in 
Appendix A, Figures A2.2. 
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2.6 Phosphorylation-dependent kinase-substrate photocrosslinking with ATP-BP 
analog 
Phosphorylation-dependent kinase-substrate photocrosslinking studies were performed 
similar to the ATP-ArN3 analog and purified protein substrate and recombinant CK2 kinase was 
used. α-casein was chosen as a model substrate because it is widely used as a substrate for CK2 
kinase.
168
 Crosslinking experiments were carried out by incubating CK2 kinase and α-casein 
with the ATP analog under UV light for 2 hours. The reaction mixtures were separated on SDS-
PAGE and visualized by western blot analysis with CK2 antibody.  
In the case of ATP-BP, CK2 kinase was incubated with α-casein protein and ATP-BP 
analog under UV irradiation. With separation of the reaction mixture on SDS-PAGE and western 
blot analysis with CK2 antibody, we found a CK2-reactive crosslinked band at ~68 kDa, 
corresponding to the catalytic α subunit of CK2 (45 kDa)169,170 and β-casein (23 kDa) (Figure 
2.13, lane 7). In addition to the expected 68 kDa crosslinked band, higher molecular weight 
complexes were also observed (Figure 2.13, lane 7). The crosslinked complex was not present in 
the absence of UV light (Figure 2.13, lane 4), in the presence of competitor ATP (Figure 2.13, 
lane 6) or when treated with TFA (Figure 2.13, lane 8). Prior work showed that genetically 
incorporated benzophenone was capable of producing multiply crosslinked protein complexes, 
suggesting that the higher molecular weight complexes are multimers.
171-173
 These experiments 
show that ATP-BP is capable of phosphorylation-dependent crosslinking, although with 
formation of higher molecular weight complexes that were not observed with the ATP-ArN3 
analog (Chapter 1, Figure 1.11). To identify the factors causing differences in QMS studies and 
crosslinking efficiency of these analogs we sought to computational studies.   
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2.7 AutoDock studies of ATP-ArN3, ATP-DAz, and ATP-BP 
   2.7.1     AutoDock analysis using CK2 kinase crystal structure 
To understand the differences in the QMS and crosslinking efficiency data, we docked 
ATP-ArN3, ATP-DAz, and ATP-BP into the active site of CK2 kinase (GenBank ID: 7766821, 
pdb:1DAW) using the Autodock Vina program (http://vina.scripps.edu/).
174
  ATP-DAz analog 
was previously synthesized by Dr. Sujit Suwal, but complete analysis was not yet finished. ATP-
DAz analog was used in computational studies for comparison. ATP-ArN3 demonstrated the 
lowest binding energy amongst the three analogs (-8.1 kcal/mol, Appendix A, Table A2.1). 
Figure 2.13: Kinase-Catalyzed Photocrosslinking with ATP-BP. CK2 kinase was 
incubated with α-casein in the presence of ATP or ATP-BP under UV for 2 hrs at 30 °C, 
the resulting mixtures were separated by SDS-PAGE and visualized by coomassie blue 
staining (top) and western blotting with anti-CK2 (bottom). The gels are representative 
of three independent trials (Appendix A, Figure A2.1). Refer to Chapter 1, Figure 1.11 
for ATP-ArN3 crosslinking experiment. 
 
 
CK2-casein 
      CK2  
 casein 
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 CK2-casein 
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The most favorable binding mode positioned the phosphate group within 3.5-4.0 Å of 
G46 and G48 of CK2, while the linker of ATP-ArN3 was located near K158 and H160 (Figure 
2.14A). In the case of ATP-DAz, the docking study resulted in a higher binding energy of -6.5 
kcal/mol (Appendix A, Table A2.2), perhaps due to fewer interactions observed compared to the 
other two analogs (Figure 2.14).  The most favorable mode of ATP-BP maintained interactions 
similar to that of ATP-ArN3 (Figure 2.14C), although with a reduced binding energy of -7.3 
kcal/mol (Appendix A, Table A2.3). The docking data poorly mimic the observed kinase 
conversion (Table 2.2) or crosslinking efficiencies (Figure 2.13 and 1.11) of the ATP analogs.  
One possible cause for the discrepancy is the lack of a bound peptide substrate in the CK2 kinase 
structure, which could skew the analysis. 
 
 
 
A. B. C. 
Figure 2.14: Docking of ATP-analogs into the Active Site of CK2 Kinase. The crosslinkers of the 
ATP-analogs (ball and stick structures) protrudes from the active site of CK2 kinase (green ribbon), but 
within close proximity to G46, G48, K158 and H160 (red). A) ATP-ArN3, B) ATP-DAz, C) ATP-BP.   
 
G46 
G48 
H160 
K158 
G48 
G46 
G48 
H160 
K158 
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2.7.2    AutoDock analysis using PKA kinase crystal structure 
To understand the influence of a peptide substrate on ATP analog binding, we also 
performed docking studies with PKA kinase.  The PKA crystal structure contains a bound 
peptide inhibitor in the active site, in addition to an ATP mimic (Genbank ID 6755076, pdb: 
1ATP).  ATP-BP demonstrated the lowest binding energy of -9.7 kcal/mol among the three 
analogs (Appendix A, Table A2.6). The most favorable binding mode positioned the phosphate 
groups within 3.5-4.0 Å of G52 and T51 and the ethylene glycol linker 3.0-3.5 Å away from R18 
and N20 in the peptide inhibitor (Figure 2.15C). Similar types of interactions were observed with 
ATP-ArN3 and ATP-DAz, but with higher energy binding (-7.2 kcal/mol for both analogs, 
Figures 2.15A, 2.15B, and Appendix A, Table A2.4, A2.5).  
  In this case with PKA and its bound peptide inhibitor, the ATP analog binding energies 
are consistent with labeling efficiency data, where ATP-BP demonstrates the highest kinase 
conversions (71%, Table 2.2) and the lowest binding energy (-9.7 kcal/mol).  Likewise, the ATP-
Figure 2.15:  Docking of ATP-analogs into the Active Site of PKA Kinase. ATP-analogs 
(ball and stick structures), PKA kinase crystal structure consists of PKA kinase (green ribbon), 
and peptide substrate inhibitor (cyan). The modified group protrudes from the active site 
but within close proximity to G52, T51, R18, and N20 (red). A) ATP-ArN3, B) ATP-
DAz, C) ATP-BP.  
A.  B.  C.  
T51 G52 
R18 
N20 
G52 
N20 
T51 
G52 
R18 N20 
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ArN3 demonstrates kinase conversions (51%, Table 2.2) similar to binding energies (-7.2 
kcal/mol) observed.  These data strongly suggest that docking studies should utilize a kinase with 
a bound peptide to best reflect experimental results. In addition to binding energies, another key 
difference observed in the docking analysis was the positioning of the photocrosslinkers relative 
to the kinase structure. In the case of ATP-ArN3, the aryl azide group was located within 3.2-4.4 
Å of the protein complex in both the CK2 and PKA studies (Figure 2.16).   
 3.2 
 K122 
 E230 
 4.4 
 3.5 
 E230 
 3.6 
 4.4 
 6.7  
4.3 
 R18 
 R19 
 R15 
 
Figure 2.16: Distance Measurements between Representative Amino Acid Residues in the 
Kinase and ATP-ArN3 analog from the Autodock Analysis. A) The distances shown are from 
the azide nitrogen of ATP-ArN3 to the nearest atoms of K122 and E230 on CK2 kinase. B) The 
distances shown are from the azide nitrogen of ATP-ArN3 to the nearest atoms of R15, R18, 
R19, and E203 on PKA kinase complex.  
 
Similarly, with ATP-DAz, the diazirine group was located within 3.5-4.5 Å of either 
protein complex. In contrast, the benzophenone group of ATP-BP was positioned within 3.7-5.0 
Å of the CK2 kinase, but 5.2-6.5 Å away from the PKA complex (Figure 2.17).  This distance 
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analysis suggests that the large benzophenone group is positioned away from the kinase-substrate 
complex, which could result in reduced crosslinking efficiency. However, the smaller aryl azide 
or diazirine groups are located near the kinase active site for efficient crosslinking.  Therefore, 
the docking studies point towards the size of the photocrosslinking group as a factor influencing 
the efficiency of kinase-mediated crosslinking. 
 
 G52 
 Y330 
 E331 
 5.2 
 5.8 
 6.5 
 H160 
      K122 
 3.9 
 5.0 
 3.7 
 
Figure 2.17: Distance Measurements between Representative Amino Acid Residues in the 
Kinase and ATP-BP analog from the Autodock Analysis. A) The distances shown are from 
the benzophenone carbonyl of ATP-BP to the nearest atoms of K122 and H160 on CK2 kinase 
B) The distances shown are from the benzophenone carbonyl of ATP-BP to the nearest atom of 
G52, Y330, and E331on PKA kinase complex. 
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2.8       Conclusions 
            In this chapter, we performed a comparative study of photocrosslinking ATP analogs for 
use in phosphorylation-dependent kinase-substrate crosslinking. These analogs were compatible 
with kinase-catalyzed labeling and appropriate for crosslinking CK2 with casein substrates.  
Interestingly, while the ATP-BP analog was the most efficient kinase cosubstrate, the ATP-ArN3 
analog produced the most distinct crosslinked complex.  Docking studies indicated that the size 
of the crosslinking group could influence its position in the active site, and consequently 
crosslinking efficiency. Combined, this study revealed that ATP-ArN3 and ATP-DAz (docking 
studies only) are excellent reagents for kinase-catalyzed photocrosslinking due to their small size 
and reasonable kinase compatibility.  While ATP-BP was the best cosubstrate, it produced higher 
order crosslinked complexes with CK2 and casein. Photocrosslinking ATP analogs will serve as 
useful tools in dissecting kinase substrate specificity due to their phosphorylation-dependent 
mechanism and can play a role in studying signaling pathways. 
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2.9 Experimental 
   2.9.1    Materials 
ATP, sodium azide and sodium nitrite were purchased from Fisher. CK2 was bought from New 
England Biolabs. CK2 peptide substrate (RRREEETEEE) was purchased from Promega. 4-
aminobenzoic acid, 2, 2’-ethylenedioxy bis-(ethylamine), 4-hydroxy- -cyanocinnamic acid 
(4HCCA) and 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) were 
purchased from Acros. 4-benzoyl benzoic acid, N-hydroxy succinimide (NHS), N-methyl 
morpholine (NMM), 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES) were 
bought from SigmaAldrich. Tris-base, ethylenediamine tetra acetic acid (EDTA) and sodium 
chloride were obtained from JT Baker. D4-MeOH, D2O, CDCl3 was purchased from Cambridge 
Isotope Lab. Inc. Flash chromatography was performed on silica gel, 200-400 mesh (Merck). A-
25 sephadex was purchased from Aldrich. The anti-CK2 antibody was bought from Millipore 
and Sigma-Aldrich. Goat anti-Mouse IgG H&L (HRP) secondary antibody was purchased from 
Abcam. SuperSignal West Dura Chemiluminescent Substrate was purchased from Thermo 
Scientific. Sypro® Ruby protein stain was purchased from Invitrogen, and Coomassie blue stain 
was purchased from NuSep.  
   2.9.2    Instruments 
 
1
H NMR, 
13
C NMR, 
31
P NMR (Varian Mercury-400) and ESI MS (Waters ZQ2000) were used 
to authenticate the synthesized compounds. The triethylamine counterion in ATP-BP 4 was 
observed at δ 1.18 and 2.8 in the 1H NMR and δ 8.7 and 46.0 in 13C NMR.  The peaks around δ 
4.95 and 3.31 in the 
1H NMR and δ 58.0 in 13C NMR were due to CD3OD solvent. Likewise, the 
peaks at δ 4.80 and 7.24 in the 1H NMR were due to D2O and CDCl3, respectively. The peak at δ 
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77.0 in 
13
C NMR was due to CDCl3.  IR spectra were recorded on an FT/IR-460 plus (JASCO 
DCo. Ltd.) spectrometer. Absorbance of intermediate compounds and the ATP-analog were 
measured on an HP 8452A Diode array UV-Vis spectrophotometer. High resolution mass spectra 
were obtained using LCT Premier XT (Waters). The concentration of the ATP analog was 
calculated using the UV-Vis spectrophotometer. Quantitative mass spectrometric analyses of 
phosphopeptides resulting from the kinase reactions were performed using a MALDI-TOF MS 
(Bruker Ultraflex) with 4-hydroxy-α-cyanocinnamic acid (4HCCA) matrix. A Thermo 
Scientific-Pierce UVP 3UV Ultraviolet lamp was used for crosslinking.  
   2.9.3    Synthesis of the ATP-ArN3 (2) analog 
ATP-ArN3 was synthesized as reported earlier.
92
 This analog was used for experiments discussed 
in chapter 3. 
   2.9.4    Synthesis of the ATP-BP (4) analog 
(a) Synthesis of N-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-4-benzoylbenzamide 7: 
To a stirred solution of 4-benzoyl benzoic acid 5 (620 mg, 2.13 mmol) in dry DCM (10 mL) was 
added EDCI (713 mg, 3.73 mmol) and NMM (322 mg, 3.13 mmol) at room temperature.  After 
stirring for 30 min, this solution was added drop wise to an ice cooled DCM solution (200 mL) 
of 2,2’-ethylenedioxy bis-(ethylamine) 6 (638 mg, 4.3 mmol) over a period of 30 min, followed 
by stirring for 2 hrs at room temperature. The solvent was evaporated to dryness and the residue 
was purified by flash chromatography using a stepwise solvent system, initially with DCM: 
EtOH (3:1) followed by DCM:EtOH:NH4OH (3:1:0.05) to yield benzophenone linker 7 (43%, 
420 mg, 1.2 mmol). 
1
H NMR (400 MHz, CDCl3): δ 3.15 (b, 2H), 3.62- 3.74 (m, 12H), 7.47 (t, 
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2H), 7.59 (t, 1H), 7.74 (m, 4H), 7.89 (b, 1H), 8.05 (d, 2H) 
13
C NMR (100 MHz, CDCl3): δ 40.1, 
69.9, 70.1, 70.2, 127.5, 128.5, 129.9, 130.0, 132.9, 136.9, 137.5, 139.9, 167.0, 196.3. IR (neat, 
cm
-1
): 658, 716, 768, 864, 926, 1117, 1277, 1541, 1649, 2872. HRMS [M+H
+
] C20H25N2O4; cal: 
357.1814 found: 357.1812.  Spectra are in Appendix A,  Figures A2.3 to A2.6. 
(b) Synthesis of ATP-[γ] -N-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-4-benzoylbenzamide 4: 
ATP-2Na (30 mg, 0.05 mmol) was dissolved in water (5 mL) and the pH was adjusted to 7.0 
with 1N aqueous HCl. EDCI (380 mg, 2 mmol) was added and the pH was adjusted to 5.6-5.8 
with 1N aqueous HCl followed by addition of water (1 mL). Benzophenone amine linker 7 (400 
mg, 1.1 mmol) was dissolved in water (1 mL), added to the reaction  mixture, and  incubated for 
2 hours at room temperature while controlling the pH at 5.6-5.8.  The reaction mixture was 
brought to pH 8.5 using 1 M triethylamine bicarbonate (TEAB) buffer and purified using an A-
25 sephadex anion exchange column with a gradient of 0.1 M to 1.0 M TEAB buffer solution 
(pH=8.5) as the eluent. The purified product was lyophilized to dryness to obtain the TEA salt of 
ATP-BP 4 (28%, 11.83 mg, 0.014 mmol). The product was dissolved in 25 mM HEPES buffer, 
pH 7.2-7.5, aliquoted into single use fractions and stored at -80
 
°C until use (for up to several 
months). With the aid of UV absorbance, the concentration of the final product was calculated. λ 
= 261 nm,  ε = 21000. 1H NMR (400 MHz, D2O): δ 3.54-3.74 (m, 12H), 4.15 (m, 1H), 4.21 (m, 
1H), 4.28 (m, 1H), 4.50 (m, 1H), 4.67 (m, 1H), 5.98 (d, 1H), 7.50 (t, 2H), 7.67 (m, 3H), 7.75 (d, 
2H), 7.83 (d, 2H), 8.10 (s, 1H), 8.43 (s, 1H). 
31
P NMR (162 MHz, CD3OD): δ -1.53 (d, γ-P), -
11.69 (d, α-P), -23.08 (t, β-P). IR (cm-1): 655, 715, 914, 991, 1060, 1222, 1647, 1707, 2366, 
2981, 3275. HRMS: [M-H
+
] C30H31N7O16P3; cal: 844.1510; found: 844.1505. Spectra are in 
Appendix A, Figures A2.7 to A2.11. 
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   2.9.5    Quantitative mass spectrometric (QMS) analysis: 
Quantitative MALDI-TOF MS was performed using a previously described protocol.
96
 Briefly, 
each reaction mixture contained ATP or a synthetic ATP-analog (1.0 mM final concentration), 
CK2 substrate peptide (40 μM), and CK2 kinase (10 units/μL) in the manufacturer-supplied 
buffer (1X). The final volume of the reaction was 10 μL. The reaction mixtures were incubated 
for 2 hours at 30 °C. The products formed after the enzymatic reaction was esterified at all 
carboxylic acids using acetyl chloride (50 μL) and either d4-methanol (200 μL, for the ATP 
reaction) or d0-methanol (200 μL, for the ATP-ArN3 reaction). Reaction mixtures were incubated 
at room temperature for 2 hours. Under these conditions, the phosphoramidate bond of the ATP-
BP product was cleaved to yield a phosphopeptide. The solvent in the resulting reaction mixtures 
was evaporated in vacuo.  Phosphopeptide mixtures were separately dissolved in a minimum 
amount of water (5 μL). For MS analysis, the two phosphopeptide samples were mixed (2 μL of 
each) with 10 μL of a matrix solution (saturated solution of alpha-cyano-4-hydroxy cinnamic 
acid in 70 % acetonitrile, 30 % water and 0.1% TFA). The mixture (1 μL) was spotted on a 
MALDI plate (Standard 384 MTP, Bruker) and isotopically differentiated phosphopeptides were 
analyzed on MALDI-TOF MS instrument. MALDI-TOF MS spectra of three independent trials 
with ATP-BP 4 are shown in Appendix A, Figures A2.2.  The mean of these three independent 
trials is reported in Table 2.2 
   2.9.6    Crosslinking experiment protocol 
Crosslinking experiments were performed as reported previously.
92
 Briefly, CK2 kinase (5 
units/µL) was incubated with ATP-BP (2.5 mM) or ATP (2.5 mM) in CK2 buffer (20 mM 
HEPES, 50 mM KCl, 10 mM MgCl2) for 5 minutes on ice, followed by the addition of α-casein 
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(100 μM). The final reaction volume was 20 μL. Equal concentrations (2.5 mM) of ATP-BP and 
ATP were added for competitive reaction control. The reaction mixtures were incubated for 2 hrs 
at 30 °C. Crosslinked protein was obtained by simultaneously irradiating the appropriate reaction 
tubes with a handheld UV lamp (365 nm). The presence of the phosphoramidate bond in the 
crosslinked product was confirmed by acid-mediated cleavage of the complex by adding 20 μL 
of trifluoroacetic acid (TFA) to the reaction mixture (final concentration of 50% TFA) and 
incubating at 30 °C for 1 hour. The sample tube containing TFA was neutralized using 100 mM 
Tris base (50 μL) and the volume was reduced in vacuo. The reaction products were separated by 
SDS-PAGE and the proteins were visualized with Coomassie blue stain or SyproRuby stain, or 
western blotting with an anti-CK2 antibody after electrotransfer onto PVDF membrane 
(Immobilon-P
SQ
).  
2.9.7. Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE)  
The SDS-PAGE gels were prepared with a stacking layer and a separating layer (as described in 
Molecular Cloning, Appendix 8.40-8.45)
119
. The lower layer contained approximately 4 mL of 
solution resulting in a 10% separating layer. The separating layer consisted of 1 mL of 4X 
Tris/SDS separating buffer (0.4% w/v SDS, 1.5 M Tris, brought to pH 8.8 with HCl), 1 mL 40% 
w/v 37:1 acrylamide:bisacrylamide, 1.96 mL filtered water, and 40 μL of freshly prepared 10% 
ammonium persulfate (APS) (Fisher). Polymerization was initiated by the addition of 4 μL of 
tetramethylethylenediamine (TEMED) (Acros Organics) and poured into the sandwiched glass 
gel plates. Methanol was added on top of the separating layer, gently removing any air bubbles 
without disturbing the acrylamide layer. The upper stacking layer was prepared by mixing 0.5 
mL 4X Tris/SDS stacking buffer (0.4% w/v SDS, 1.5% Tris, brought to pH 6.8 with HCl), 0.25 
mL 40% w/v 37:1 acrylamide: bisacrylamide, 1.24 mL distilled water. The methanol was drained 
61 
 
and dried carefully. APS (10%, 10 μL) and TEMED (2 μL) were added, initiating polymerization 
and the solution was poured on top of the separating layer. A ten well comb was placed to create 
wells for loading proteins. The SDS-PAGE gel running chamber was filled with a 1X SDS 
running buffer, which was composed of 0.1% SDS, 0.025 M Tris, and 0.25 M glycine. A protein 
molecular weight marker (5 µL, EZ-RUN Pre-Stained Protein Marker, Fisher) was loaded onto 
the gel as a standard, using gel loading tips (Fisher). The gel was run using a mini-protean basic 
power pack unit at constant 200 Volt, 400 amps for 60-90 mins depending on the resolution of 
gel according to the protein of interest. 
 
2.9.8. Western Blotting 
 
Proteins separated by SDS-PAGE were transferred to a polyvinylidene difluoride (PVDF) 
membrane (Immobilon P, Millipore). The PVDF membrane was pre-wet with methanol and 
proteins were transferred using the Mini-Transblot Electrophoretic Transfer Cell apparatus from 
BioRad, with 0.01 M CAPS (N-cyclohexyl-3-aminopropanesulfonic acid) at pH 10.5, 
supplemented with 10% methanol as the buffer. The transfer process was done at constant 90 V 
for 90 mins. After the transfer was complete, the membrane was air dried for firm attachment of 
proteins. The membrane was re-wetted with methanol and incubated overnight in a blocking 
solution of 5% (w/v) non-fat dry milk powder in PBST ( 1X buffer contains 137 mM NaCl, 2.7 
mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4 and 0.1% Tween-20). The membrane was 
washed with PBST and then incubated in recommended dilution of primary antibody (1: 500 to 
1:1000) for one to two hours (longer incubation time can lead to non-specific labeling). The 
membrane was rinsed with PBST for 5 minutes, twice, to remove excess antibody. Secondary 
antibody (1: 1500 to 1:3000) was added and incubated for 1 to 2hr, and then washed with PBST 
(5 minutes two times). The PVDF membrane was developed using HRP substrate, in case of 
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HRP antibodies and visualized using the Typhoon 9400 scanner in chemiluminescence mode at 
600 PTM. In case of fluorophore labeled antibodies the manufacturer instructions were followed 
using the Typhoon 9400 scanner in fluorescence mode. 
2.9.9 Coomassie Blue Staining  
The SDS-PAGE gel was gently placed into a clean container and 50 mL of commercially 
available Coomassie Brilliant Blue stain (NuSep) was added. The gel was incubated in the 
staining solution at room temperature overnight, with gentle rocking. The stain was removed and 
50 mL of destaining solution (6% acetic acid) was added and incubated at room temperature for 
1-2 hours. The Coomassie stained gel was imaged using a document scanner (HP Scanjet 
G4010). 
   2.9.10  Autodock analysis 
The Autodock Vina program was designed by Dr. Oleg Trott of Molecular Graphics Lab at The 
Scripps Research Institute.
174
 It was downloaded free from the website- 
http://vina.scripps.edu/index.html. The Autodock Vina program was executed as per the tutorial 
instructions found on the website. The crystal structures were downloaded from the RCSB 
Protein Data Bank (1ATP for PKA and 1DAW for CK2).  The PyMOL program (Schrödinger 
Inc.) was used to delete ATP in the active site. The ATP analog structure was drawn in Chem 3D 
Pro (CambridgeSoft) and MM2 from Chem 3D pro was used for energy minimization. The 
output file of the different binding modes is shown in Appendix A, Tables A2.1 to A2.6. The 
lowest binding energy mode that conforms to the kinase-catalyzed phosphorylation mechanism 
is in bold for each docking experiment. The grid box dimensions used in all the analyses were 
the same or similar. 
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Chapter 3 
 
 Previous studies have demonstrated the utility of ATP-ArN3 and ATP-BP 
photocrosslinking analogs for kinase-catalyzed labeling and crosslinking studies. In addition, we 
explored the important features of photolabels for photocrosslinking with AutoDock studies. In 
this chapter, experiments were done to find the optimum conditions for phosphorylation-
dependent kinase-substrate photocrosslinking in the absence and presence of cell lysates. ATP-
ArN3 and ATP-BP photocrosslinking analogs were successfully used to identify novel kinases of 
p53 using natural kinase and substrate. A brief description of p53 and its importance is included 
at the beginning of the chapter. 
3.1       Introduction  
 In order to demonstrate the novelty and applicability of the photocrosslinking ATP 
analogs in identifying known or novel kinases of a substrate, or vice-versa, we need to validate 
the chemical tool with a well studied protein. For this purpose p53, was chosen as the protein of 
interest because of its implication in various cancers and diseases. 
3.1.1    p53 –“Guardian of the Genome” 
p53 was discovered in 1979, independently reported by six groups
175-180
 and 
characterized as tumor suppressor protein later in 1989.
181,182
 Because of its central role in many 
cellular processes, p53 was dubbed the “cellular gatekeeper” 183 or “guardian of the genome”.184 
p53, also known as tumor suppressor protein (TP53) is a 44 kDa protein containing 393 amino 
acids that is encoded by the TP53 gene on the short arm of chromosome 17 (17p13). Even 
though p53 is a 44 kDa protein, it migrates as a  53 kDa protein on SDS-PAGE due to high 
number of proline residues and it gained the name p53 (protein at 53 kDa).  
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The p53 protein is a tetramer, tied together with flexible side arms (Figure 3.1A).  P53 
consists of four functional domains: an N-terminal transactivation domain (TAD) also called the 
proline rich domain; a central DNA-binding domain (DBD), which binds to DNA and where 
most of the mutations observed in many cancers are found; a tetramerization domain (TD), 
where all the domains are attached; and a C-terminal domain (CD) that regulates p53 activity. 
Upon activation of p53 with stress signal, DNA is bound to the p53 DBD in a sequence specific 
manner where flexible residues are ready to act on DNA and assemble specific proteins for 
transcription (Figure 3.1B).
185
  
 
Figure 3.1: Illustration of p53 from crystal structures (a) Cartoon depicting p53 tetramer (b) 
Cartoon depicting DNA interacting with p53. These illustrations are rendered from the crystal 
structures of p53 domains (PDB ID- 1OLG,
186
 1YCQ,
187
 1TUP
188
). This figure was obtained 
from July 2002, RSC-PDB, molecule of the month by David S. Goodsell, 
(http://dx.doi.org/10.2210/rcsb_pdb/mom_2002_7). Copyright permission received from RSC-
PDB to use the images. 
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P53 undergoes various PTMs, such as phosphorylation, acetylation, ubiquitination, 
glycosylation, sumoylation, ADP-ribosylation, neddylation and methylation, under various stress 
signals, leading to different cellular processes (Figure 3.2). PTM of p53 leads to various 
biological processes through stabilization, increased DNA binding of p53, and activation of 
transcription. An example of signaling pathway involving p53 was discussed in chapter 1 
(Section 1.2). p53 plays a central role in mediating signaling processes critical for cell fate. 
Abnormalities in the function or mutations at the DNA binding domain of p53 can lead to 
diseases. In many types of cancers, mutations are commonly identified in the p53 DNA binding 
domain. Multiple phosphorylation sites have been identified on p53 and phosphorylation of each 
of these sites have further downstream effects in cell growth, proliferation and are also linked to 
diseases (Figure 3.2). Many in vitro kinases are known for p53 and some in vivo kinases have 
also been validated (Table 3.1).
189,190
 Our goal was to use ATP-ArN3 to identify kinases and 
proteins that interact with P53 by crosslinking after phosphorylation upon UV irradiation. By 
focusing on p53, we sought to uncover novel kinases of p53 and their functions and roles in 
disease formation. This approach allows us to establish a method for identification of true 
kinase-substrate pairs and also phosphorylation dependent protein-protein interactions.  
One of the interesting phosphorylation sites on p53 is serine 392, which is 
phosphorylated by CK2 under stress conditions like UV irradiation (Table 3.1). There is a 
conflict regarding whether CK2 is both an in vitro as well as an in vivo kinase of p53.
191-193
 ATP-
ArN3 crosslinker will be a good chemical tool to demonstrate and identify the true cellular kinase 
for Serine 392. 
 
 
66 
 
Table 3.1: List of some of the kinases known  to phosphorylate p53.
194
 
195
 
 
 
Kinase Activated by Phosphorylation  
site on p53 
Molecular or cellular 
outcome 
 
ATM DNA damage Ser15 Apoptosis 
ATR γ-radiation  
UV light 
Ser15, Ser37 Apoptosis 
CDK (CDC2/CDK2) UV light Ser315 Increased p53 
transcription 
AURKA  Overexpression of 
AURKA   
Ser315 Ubiquitylation and 
degradation of p53 
CHK1/CHK2 Ionizing radiation Ser20 Disruption of the 
MDM2–p53 complex 
 CK2 UV light Ser392 Increased p53 activity 
CK1 Topoisomerase-
directed drugs and 
DNA damage 
Ser6, Ser9, 
Thr18(requires 
Stabilization of p53 
through 
phosphorylation of 
Ser15) 
 
Stabilization of p53 by 
inhibition of MDM2  
 
DNAPK DNA damage Ser15, Ser37 Disruption of the 
MDM2–p53 
PKR Interferon Ser392 Not determined 
CSN-associated  
kinase complex 
Unstressed Thr 150, Thr155, 
Ser149 
Degradation 
ERKs UV light Ser15 Apoptosis 
ERK2 Doxorubicin Thr55 Activation of p53 
GSK3β ER stress Ser315, Ser376 Inhibition of p53 
mediated apoptosis 
HIPK2 UV light Ser46 Facilitates CBP 
mediated acetylation 
of p53 (at Lys382); 
arrest and apoptosis 
JNK UV light Ser20 Apoptosis 
p38 kinase UV light Ser20 Apoptosis 
p38 UV light Ser 15 Apoptosis 
p38 kinase UV light 
DNA damage 
Ser 392 Increased DNA-
binding activity of p53 
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Figure 3.2: Overview of p53 Post-translational Modifications. p53 undergoes different PTMs 
like methylation (Me), acetylation (Ac), ubiquitination (Ub), glycosylation (o-Glc), sumoylation 
(S), phosphorylation (P), ADP-ribosylation (ADP) and neddylation (N8), of which 
phosphorylation is the major PTM. PTMs occur under different conditions and are carried out by 
different enzymes depending on the stress conditions as shown above, leading to a biological 
function. This figure was obtained with permission from Kruse, J.-P.; Gu, W., Cell 2009, 137 
(4), 609-622.
189
 License Number: 3186091178308 
 
3.2 Results and Discussion 
 Experiments were carried out to identify optimal conditions for crosslinking such as order 
of addition, UV irradiation time and concentration of ATP analog. Further explore the conditions 
for crosslinking in the presence of cell lysates and apply those conditions to identify novel 
kinases of p53 protein.  
3.2.1 Optimization of CK2 kinase and casein photocrosslinking conditions 
During phosphorylation-dependent kinase-substrate photocrosslinking studies of the CK2 kinase 
and casein protein substrate, a few important observations were made. First, the ATP-ArN3 or 
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ATP-BP analogs obtained after lyophilization were resuspended in 25 mM HEPES buffer (pH 
7.5) instead of Tris buffer because amine-containing buffers can quench the reactive intermediate 
formed during UV irradiation, inhibiting crosslinking. Second, the order of addition in the kinase 
reaction is critical.  The optimal order is: water, CK2 kinase buffer, CK2 kinase, followed by 
addition of ATP-analog and incubation on ice for 5 minutes. Subsequently, α-casein substrate 
was added and incubated under UV for 2 hrs at 30 °C for crosslinking. Experiments were next 
performed to examine the optimal concentration of ATP analog and irradiation time needed for 
high levels of crosslinking. 
To investigate the effect of UV irradiation time, as well as concentration of aryl azide on 
crosslinking efficiency, reactions were carried out with UV irradiation times of 30 minutes, 1 
hour, and 2 hours using 1 mM, 2.5 mM and 5 mM concentrations of ATP-ArN3 in the presence 
of CK2 kinase and casein substrate. SDS-PAGE separation and western blot analysis of the 
photocrosslinking reactions with CK2 antibody found that UV irradiation for 30 mins at any 
concentration of ATP-ArN3 (Figure 3.3, lanes 3-5) produced only a faint band. With 1 hour UV 
irradiation, visible crosslink bands were observed at 1 mM and 2.5 mM concentration of ATP-
ArN3 (Figure 3.3, lane 6, 7) compared to 5 mM concentration of ATP-ArN3 (Figure 3.3, lane 8).  
In the case of 2 hour UV irradiation, a significant crosslink band was observed at all 
concentrations of ATP-ArN3 (Figure 3.3, lane 9-11). In conclusion, consistent crosslinked bands 
were observed with 1 mM and 2.5 mM concentration of ATP-ArN3 and UV irradiation for 2 
hours. Next, experiments were performed to identify conditions for phosphorylation-dependent 
kinase-substrate crosslinking in the presence of cell lysate. 
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Figure 3.3: Photocrosslinking of CK2 and α-casein with Various Concentrations of ATP-
ArN3 and UV Irradiation times. Photocrosslinking reactions were performed with CK2 kinase 
and casein substrate in the presence of ATP-ArN3 and UV at 30 °C, followed by SDS-PAGE 
separation and visualization with a CK2 antibody. ATP-ArN3 concentrations and UV irradiation 
times are as indicated below each reaction lane. The expected ~68 kDa crosslinked band is 
indicated as CK2-Casein, and 45 kDa band of CK2 kinase as CK2.  
 
3.2.2 Photocrosslinking kinase and full length protein substrate in the presence of cell 
lysates using ATP-ArN3 
   To identify conditions for crosslinking in the presence of cell lysates, experiments were 
performed with ATP-ArN3, CK2 kinase, α-casein substrate and Jurkat cell lysates similar to 
photocrosslinking with full length protein (Section 2.9.6). Briefly, CK2 kinase was incubated 
with α-casein and lysates in the presence of ATP or ATP-ArN3 under UV for 2 hrs at 30 °C. The 
 1 2 3 4 5 6 7 8 9 10 11 
CK2 + - + + + + + + + + + 
Casein - + + + + + + + + + + 
ATP-ArN3 
(mM) 
- - 1.0 2.5 5.0 1.0 2.5 5.0 1.0 2.5 5.0 
UV - - + + + + + + + + + 
30 mins 2 hours 1 hour 
CK2-Casein 
CK2 
 
  MW (KDa) 
130 
95 
72 
55 
43 
34 
26 
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resulting mixtures were separated by SDS-PAGE and visualized by western blotting with anti-
CK2. In these photocrosslinking experiments, 10 μg of Jurkat cell lysate and 10 mM, 15 mM 
(final) concentration of ATP-ArN3 were used to overcome the cellular ATP concentration and 
observe the crosslink between CK2 and casein. SDS-PAGE separation and western blot analysis 
of crosslinking between CK2 kinase and α-casein substrate in the presence of cell lysates is 
shown in Figure 3.4. A crosslinked band corresponding to the molecular weight of CK2 and α-
casein was observed in the presence (Figure 3.4, lane 6) and absence (Figure 3.4, lane 4) of cell 
lysates. But the crosslinked band was not observed when the reaction was carried out with ATP 
(Figure 3.4, lane 5) or with CK2 only (Figure 3.4, lane 1), or lysate only (Figure 3.4, lane 2), or 
α-casein only (Figure 3.4, lane 3). Crosslinked complex was also not observed in the absence of 
exogenous CK2 kinase at 10 mM or 15 mM concentrations of ATP-ArN3 (Figure 3.4, lane 8, 9 
respectively). In addition, crosslinked complex was not significant when 15 mM concentration of 
ATP-ArN3 was used in the presence of exogenous CK2 (Figure 3.4, lane 7). The optimum 
conditions were 10 mM of ATP-ArN3 and 10 µg of total protein for crosslinking CK2 kinase and 
α-casein protein substrate. With the optimum conditions obtained for crosslinking kinase and 
substrate in the presence of cell lysate using ATP-ArN3 in our model system, we wanted to 
demonstrate phosphorylation-dependent kinase-substrate crosslinking with other known kinase 
substrates using cell lysates. 
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Figure 3.4: Photocrosslinking of CK2 and α-casein in the Presence of Jurkat Cell Lysates. 
Photocrosslinking reactions were performed with CK2 kinase, casein substrate, and ATP-ArN3 in 
the presence of Jurkat cell lysates and UV at 30 °C, followed by SDS-PAGE separation and 
visualization with a CK2 antibody (top), SyproRuby protein staining (bottom). ATP-ArN3 
concentration and components of each reaction lane are as indicated.10 µg (total protein) of 
Jurkat cell lysates were used in each reaction. The expected ~68 kDa crosslinked band is 
indicated as CK2-Casein, and the 45 kDa band of CK2 kinase as CK2. Additional trials are 
shown in Appendix B, Figure A3.1. 
 
 
 
 1 2 3 4 5 6 7 8 9 
CK2 + - - + + + + - - 
Lysates - + - - + + + + + 
Casein - - + + + + + + + 
ATP-ArN3  (mM) - - - 2.5 - 10 15 10 15 
ATP (mM) - - - - 10 - - - - 
UV - - - + + + + + + 
A. Westernblot with  
anti-CK2 
B. SyproRuby Staining  
CK2 
CK2-Casein 
CK2 
CK2-Casein 
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3.3  Phosphorylation-dependent photocrosslinking of natural kinase and substrate using     
ATP-ArN3 analog 
After successful demonstration of kinase-substrate crosslinking in the presence of cell 
lysates using ATP-ArN3, we wanted to demonstrate crosslinking with natural kinases and 
substrates. As described in the beginning of this chapter, p53 was chosen for this study, because 
of its role in signaling processes and diseases.  
   3.3.1    Photocrosslinking experiments with RKO cell lysate and ATP-ArN3  
Crosslinking experiments were carried out using RKO cell lysates. RKO cells are 
adherent colon cancer cells that have relatively high levels of wild type p53 protein. RKO cell 
lysates (30 µg of total protein) were incubated with ATP-ArN3 (10 mM final concentration) and 
photocrosslinking was performed by incubating under UV for 2 hours at 30 °C. Initial 
crosslinking experiments were performed with RKO cell lysates in the presence of ATP-ArN3 
with and without exogenous CK2 kinase, to validate p53 as a substrate of CK2 kinase. 
Unfortunately, we did not observe any obvious higher molecular weight bands corresponding to 
crosslink between CK2 and p53 or with any other protein when probed with anti-p53 and anti-
CK2 (Figure 3.5, lanes 6, 7, 8, and 9).  High molecular weight protein complexes were also not 
observed in the presence and absence of exogenous CK2 kinase (Figure 3.5, lane 6, 8 vs. 7, 9). 
But the photocrosslinking reaction with CK2 kinase, ATP-ArN3 (2.5 mM), and casein substrate 
formed the CK2 crosslinked complex both in the presence and absence of cell lysates (Figure 
3.5A, lane 4 and 5), signifying that the phosphorylation-dependent kinase-substrate crosslinking 
reaction controls were successful. Importantly, p53 protein band at ~53 kDa was also not 
observed in the p53 western blot (Figure 3.5B, lane 1). Western blot analysis of various 
concentrations of RKO cell lysates with anti-p53 indicated that the presence of p53 in the lysate 
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sample was not noticeable. Therefore an insufficient level of p53 protein in the RKO cell lysates 
was prohibiting visualization of the crosslinking. The next goal was to identify conditions for 
increasing p53 protein levels in the RKO cell lysates or to find alternative model proteins for  
crosslinking studies. 
 
       
 
 
 
 
 
 
Figure 3.5: Photocrosslinking Reaction using ATP-ArN3 and RKO cell lysates. 
Photocrosslinking reaction was performed by incubating the reaction components under UV as indicated 
for each lane, at 30 °C for 2 hrs, followed by SDS-PAGE separation and visualization with a CK2 
antibody (top), and p53 antibody (bottom). The ATP-ArN3 concentration was 10 mM except for lane 4 
which contained 2.5 mM. RKO cell lysates (30 µg) were used in each reaction. The expected ~68 kDa 
crosslinked band for control reactions lane 4 and 5 was indicated as CK2-Casein, ~45 kDa band of CK2 
kinase was labeled CK2 and the expected p53 protein at ~53 kDa was labeled p53. 
 1 2 3 4 5 6 7 8 9 
Lysates + - - - + + + + + 
CK2 - + - + + + - + - 
Casein - - + + + - - - - 
ATP-ArN3  - - - + + + + + + 
UV - - - + + + + + + 
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B) Westernblot with anti-p53 
A) Westernblot with anti-CK2 
CK2-Casein 
CK2 
p53 
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   3.3.2    MDM2 regulation of p53 
To explore conditions for increasing p53 expression, we needed to understand the p53 
regulation and activation pathways. Under normal conditions, p53 has a high turnover rate and 
its availability is low. Stress conditions like UV or IR radiation triggers a signaling event through 
ATM/ATR and CHK1/2 kinases, which phosphorylate MDM2 to disrupt the MDM2/p53 
interaction.  MDM2 is a negative regulator of p53. As a result, disruption of MDM2 and p53 
interactions stabilizes p53 (Figure 3.6).
196
 Once p53 is stabilized, it accumulates and carries out 
important functions, such as DNA repair and cell cycle arrest check points.
185,197
  Because 
negative regulator MDM2 degrades p53, we treated RKO cells with the MDM2 inhibitor, (±)-
Nutlin-3 (Figure 3.7A).
198,199
 (±)-Nutlin-3 inhibits the MDM2 and p53 interaction by blocking 
the p53, MDM2 binding site. Although we use the racemic mixture, it was shown that only one 
enantiomer ((-)-Nutlin-3) (Figure 3.7B) is active and the stereochemical assignment for the 
enantiomers is arbitrary.
198
  
Figure 3.6: Cartoon Depicting the Regulation and Stabilization of p53 by MDM2 complex. 
In normal conditions p53 undergoes proteolysis by MDM2 (left), but during stress conditions 
p53 is stabilized through phosphorylation to decide cell fate (right).
196
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Figure 3.7: Treatment of RKO cells with (±)-Nutlin (A) Chemical structure of (±)-Nutlin-3 
(B) Chemical structure of (-)-Nutlin-3, the active enantiomer (C) SDS-PAGE separation and 
western blot analysis with anti-p53, of lysates obtained after RKO cells were treated with (±)-
Nutlin-3. The contents of each lane are molecular weight marker (M), DMSO treated control cell 
lysates (lane 1), 10 μM of (±)-Nutlin-3 treated cell lysates (lane 2), and 20 μM of (±)-Nutlin-3 
treated cell lysates (lane 3). The expected 53 kDa p53 protein band is indicated as p53. 
(±) Nutlin-3 was dissolved in DMSO solvent and supplemented to the growth media at 
either 10 or 20 μM concentrations overnight. Control cells were similarly treated but with DMSO 
alone. When RKO cells were treated with 10 μM or 20 μM of (±)-Nutlin-3, p53 expression was 
observed (Figure 3.7C, lane 2 and 3) incontrast to DMSO treated cells (Figure 3.7 C, lane 1). 
Because a racemic mixture of Nutlin was used for treatment, the effective concentration of the 
drug is only half of the concentrations (5 μM and 10 μM respectively). Lysates obtained from 
cells treated with 20 μM (±)-Nutlin-3 were used for the crosslink experiments; higher 
concentrations of Nutlin were not used because they can induce apoptosis.
198,199
 Other drugs like 
Doxorubicin or Etoposide have also been used to increase the p53 levels in cells, but were found 
to phosphorylate some of the key amino acids on p53 to signal stress conditions.
199
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3.3.3   Photocrosslinking experiments with ATP-ArN3 and (±)-Nutlin-3 treated RKO cells 
lysates  
Crosslinking studies were carried out with RKO lysates obtained after Nutlin treatment. 
ATP-ArN3 was incubated with Nutlin treated RKO lysates under UV for 2 hrs at 30 °C. Reaction 
mixtures were separated on SDS-PAGE and western blot analysis with anti-p53 was used to 
identify p53-specific higher molecular weight crosslink bands. In the presence of ATP-ArN3 and 
UV, crosslinked bands specific to P53 were observed (Figure 3.8, lane 7), but not without UV 
(Figure 3.8, lane 3). As a control, when treated with acid the crosslinked bands were not 
observed due to cleavage of the phosphoramidate bond (Figure 3.8, lane 8). The crosslinked 
bands observed were also not present in other controls like lysates only (Figure 3.8, lane 1), 
lysates only in the presence of UV (Figure 3.8, lane 5), lysates treated with ATP in the presence 
(Figure 3.8, lane 6) and absence (Figure 3.8, lane 2) of UV. When heat denatured lysates were 
incubated with ATP-ArN3 in the presence of UV (Figure 3.8, lane 4), no crosslinked bands were 
observed due to loss of protein activity. When the crosslinked experiment was carried out and 
probed with anti-CK2, unfortunately none of the higher molecular weight bands contained CK2 
(Figure 3.8, lane 7), indicating that the higher molecular weight crosslinked bands do not contain 
CK2. After successful demonstration of phosphorylation-dependent kinase-substrate crosslinking 
with the ATP-ArN3 analog using cellular proteins in vitro, our next goal was to identify the 
kinases or phosphorylation-dependent interacting proteins of p53.  
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Figure 3.8: Photocrosslinking Experiment with ATP-ArN3 and Nutlin Treated Cell Lysate. 
Photocrosslinking reactions were performed by incubating the reaction components under UV as 
indicated for each reaction, at 30 °C for 2 hrs, followed by SDS-PAGE separation and 
visualization with a p53 antibody (top), and CK2 antibody (bottom). An ATP-ArN3 
concentration of 10 mM (final) and 30 µg total protein from Nutlin treated RKO cell lysates 
were used in each reaction. As a control in lane 2, lysates were heated denatured for 5 minutes at 
95 °C before the addition of ATP-ArN3. As a control in lane 8, TFA was added to a final 
concentration of 50% after crosslinking to cleave the phosphoramidate band of crosslink. The 
high molecular weight crosslinked complex is indicated as p53 crosslinked bands, the 45 kDa 
band of CK2 kinase as CK2 and the 53 kDa band of p53 protein as p53. Additional trials are 
shown in Appendix B, Figure A3.2. 
              1  2  3  4  5  6  7  8  
Lysates +  +  +  -  +  +  +  +  
Heat denatured lysate -  -  -  +  -  -  -  -  
ATP -  +  -  -  -  +  -  -  
ATP-ArN3 -  -  +  +  -  -  +  +  
UV -  -  -  +  +  +  +  +  
TFA -  -  -  -  -  -  -  +  
B) Westernblot with anti-CK2 
A) Westernblot with anti-p53 
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3.4 Experiments to validate phosphorylation of p53 by DNA-PK kinase 
DNA-protein kinase (DNA-PK) belongs to a family of phosphatidylinositol 3-kinase-like 
(PI3K) protein kinases. DNA-PK’s are well known for their role in V(D)J recombination for 
antibody diversity and normal immune development.
200,201
 Recent studies show that DNA-PK is 
involved in p53 posttranslational modification in the ATM/ATR mediated pathway, controlling 
the cell fate in response to severe DNA damage.
202-204
 A more recent study indicates that DNA-
PK forms a complex with p53 and is recruited to the p21 promoter. This complex formation 
abrogates p21 transcription, inhibiting the cell cycle arrest pathway and triggering an apoptotic 
response to DNA damage.
205
 
To identify if DNA-PK is one of the kinases of p53 in the crosslinked complex, 
crosslinking experiments were carried out as above, but with western blot analysis using p53 and 
DNA-PK antibodies (Figure 3.9). A higher molecular weight crosslinked band recognized by the 
p53 antibody was observed only in the presence of UV (Figure 3.9A, lane 7).  The p53 
crosslinked complex was not observed with ATP-ArN3 in the absence of UV (Figure 3.10A, lane 
3); or with ATP in the presence (Figure 3.10A, lane 6), or in the absence (Figure 3.10A, lane 2) 
of UV; or with ATP-ArN3 and heat denatured lysates, in presence of UV (Figure 3.10A, lane 4). 
Absence of crosslinked bands in these controls implies that the crosslink is p53 specific in a UV 
and ATP-ArN3-dependent manner.  
When probed for the presence of DNA-PK in the p53 crosslink complex (Figure 3.9B), a 
higher molecular weight band reactive to the DNA-PK antibody was observed (Figure 3.9B, lane 
7), but not observed in the absence of UV (Figure 3.9B, lane 3) or other controls (Figure 3.9B, 
lanes 1, 2, 5, 6, and 8). Heat denatured lysates with UV and ATP-ArN3 also showed a higher 
molecular weight band (Figure 3.9B, lane 4) similar to the reaction lane (Figure 3.9B, lane 7). 
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Perhaps this can be attributed to ineffective heat inactivation of DNA-PK kinase activity. To 
overcome this challenge, lysates can be treated with kinase inhibitor Staurosporine, followed by 
incubating with ATP-ArN3 under UV, which might result in loss of undesired crosslinking.  
Further studies with kinase inhibitor treatment will validate DNA-PK as one of the kinases in the 
crosslinked complex.  In fact, when crosslinking was carried out with Staurosporine treated 
lysates, we observed a loss in higher molecular weight band (Appendix B, Figure A3.3, lane 4). 
Our, next goal was to validate some of the known kinases of p53 from the literature and the 
novel kinases identified in our MS analysis.  
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            Protein staining  
 
 
                        
    
 
 
 
 
Figure 3.9: Photocrosslinking Experiments to validate Phosphorylation of p53 by DNA-PK 
kinase. The photocrosslinking reaction was performed by incubating the reaction components 
under UV as indicated for each reaction at 30 °C for 2 hrs, followed by SDS-PAGE separation 
and visualization with a p53 antibody (A), DNA-PK antibody (B), and Commassie blue staining 
(C). ATP-ArN3 (10 mM) and 30 µg total proteins from Nutlin treated RKO cell lysates were used 
in each reaction. Lysates were heat denatured before the addition of ATP-ArN3 for 5 minutes at 
95 °C. TFA added to a final concentration of 50% after crosslinking to cleave the 
phosphoramidate band of crosslink. The high molecular weight crosslinked complex is indicated 
as p53 crosslinked bands, 53 kDa band of p53 protein as p53, DNA-PK protein band as DNA-
PK, and the DNA-PK complex as DNA-PK crosslinked bands. Additional trials are in Appendix 
B, Figure A3.3.  
              1  2  3  4  5  6  7  8  
Lysates +  +  +  -  +  +  +  +  
Heat denatured lysate -  -  -  +  -  -  -  -  
ATP -  +  -  -  -  +  -  -  
ATP-ArN3 -  -  +  +  -  -  +  +  
UV -  -  -  +  +  +  +  +  
TFA -  -  -  -  -  -  -  +  
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3.5 Experiments to validate phosphorylation of p53 by FNK kinase  
  FNK kinase is a serine/threonine protein kinase and is a member of the polo-like kinase 3 
(PLK3) family. PLK3 kinases are involved in cell cycle regulation and FNK is involved during 
the  entry of cells into the cell cycle and during mitosis of cycling cells.
206
 PLK3/FNK is known 
to phosphorylate p53 at serine 20 under oxidative stress conditions.
207,208
 Since, FNK/PLK3 
kinase is known to phosphorylate p53 experiments were carried out to investigate the presence of 
FNK kinase in the observed crosslinked bands.  
Crosslinking experiments were carried out using optimized conditions as above, but using 
a western blot analysis with p53 and FNK antibody (Figure 3.10). Higher molecular weight 
complexes containing p53 were observed only in the presence of ATP-ArN3 and UV (Figure 
3.10A, lane 4) and not in the presence of ATP and UV (Figure 3.10A, lane 3). Crosslinked bands 
were not observed in the presence of UV with lysates (Figure 3.10A, lane 2), or with lysates in 
the absence of UV (Figure 3.10A, lane 1). 
When probed for the presence of FNK in the p53 crosslinked complex, no FNK antibody 
reactive bands were observed (Figure 3.10B, lane 4). But in the crosslink reaction lane 4, there 
was a slight shift observed in the FNK band and with less intensity compared to controls (Figure 
3.10B, lane 1, 2, and 3). Few possibilities for the lack of presence of FNK reactive band in the 
crosslinked complex are phosphorylation status of FNK
206
 or the FNK-p53 crosslink was so 
minimal that could not be observed in the western blot or FNK is not a kinase of p53 under the 
reaction conditions. Therefore, these data clearly demonstrated the utility of ATP-ArN3 analog as 
well as pointing towards the use of analytical techniques to unambiguously identify the protein 
partners. As a result, MS based crosslinking approach was used in identifying novel kinases or 
substrates of p53 protein, which is discussed next in this study. 
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Figure 3.10: Photocrosslinking Experiments to Validate Phosphorylation of p53 by FNK 
Kinase. A Photocrosslinking reaction was performed by incubating the reaction components 
under UV as indicated for each reaction at 30 °C for 2 hrs, followed by SDS-PAGE separation 
and visualization with a p53 antibody (A) and an FNK antibody (B). ATP-ArN3 (10 mM) and 30 
µg total protein from Nutlin treated RKO cell lysates were used in each reaction. The high 
molecular weight crosslinked complex is indicated as p53 crosslinked bands, 53 kDa band of p53 
protein as p53, FNK protein band as FNK.  
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3.6       Mass Spectrometry (MS) Coupled with Crosslinking Approach    
   3.6.1    Immunoprecipitation of p53 crosslinked complex 
To identify the kinases in the p53 crosslinked complex in the earlier experiments, 
antibodies of some of the known kinases were used. However it is tedious and expensive to 
check the elaborate list of known kinases of p53 in the crosslinked complex using antibodies. To 
overcome this challenge, we sought to MS based crosslinking approach. Wherein the crosslinked 
complex has to be purified from the complex mixture of proteins, separated by SDS-PAGE, and   
processed to identify the proteins through mass spectrometry analysis. In general, an affinity 
purification method like immunoprecipitation (IP) is used to purify protein complexes of interest 
from complex cellular mixture. IP of p53 crosslinked complex was performed using mouse 
monoclonal and rabbit polyclonal antibodies because each of the antibodies recognizes different 
epitopes on the antigen. These epitopes on the antigen (p53) can be forbidden due to changes in 
structure or conformation on crosslinking or they could be blocked by the interacting protein. In 
order to identify all the possible crosslinked and interacting proteins of p53, IP was performed 
with two antibodies. Photocrosslinking was carried out with ATP-ArN3, and Nutlin treated RKO 
cell lysates under UV for 2 hours at 30 °C. This reaction mixture, containing p53-crosslinked 
complexes was immunoprecipitated using A/G agarose beads and the p53 full length antibody 
from either rabbit or mouse. p53 immunoprecipitates from both crosslinked and uncrosslinked 
lysates were separated by SDS-PAGE before visualization by SyproRuby staining and western 
blot analysis with anti-p53 (Figure 3.11). As seen in figure 3.11A, several new bands were 
observed with crosslinking (lanes 4 and 8) compared to the IP of lysates incubated with ATP 
(lanes 3 and 7) and IP of lysates (lanes 2 and 6). In the western blot analysis, (Figure 3.11B) 
there were also a few specific bands present in the crosslinked lanes (Figure 3.11B, lanes 4, and 
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8) compared to the ATP control (Figure 3.11B, lanes 3, 7). Gradient SDS-PAGE (4-12%) gels
209
 
were made and used in this experiment for better resolution and migration of the crosslinked 
complexes.  The next goal was to identify the p53 protein partners in the crosslinked complex 
using mass spectrometry.  
 
 
 
 
 
 
 
 
 
Figure 3.11: Immunoprecipitation (IP) of p53-Crosslinked Complexes  
Photocrosslinking reactions were performed by incubating the reaction components under UV as 
indicated for each reaction, at 30 °C for 2 hrs, followed by immunoprecipitation with p53 
antibody (rabbit polyclonal (r) or mouse monoclonal (m)) and SDS-PAGE separation and 
visualization with SyproRuby protein staining (top), and p53 antibody (1
0
-rabbit polyclonal and 
2
0
 anti-rabbit HRP, bottom). ATP-ArN3 (10 mM) and 30 µg total protein from Nutlin treated 
RKO cell lysates were used in each reaction. The high molecular weight crosslinked complex is 
indicated as p53 crosslinked bands, the 53 kDa band of p53 protein as p53.  
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   3.6.2.   Mass Spectrometry Analysis of p53 crosslinked complexes  
 
Mass spectrometric studies were done in collaboration with my colleague Todd Faner. 
The SyproRuby stained gel (Figure 3.11A) was used for mass spectrometry studies where each 
lane (lanes 3 and 4; 7 and 8, Figure 3.11A) was cut into 1mm slices above the 50 kDa band, with 
equal and precise markings in all lanes. In-gel digestion and trypsinization was performed to 
extract peptide fragments of the proteins from the gel slices. The peptide mixture was separated 
on a nanoflow HPLC instrument and analyzed by MS analysis. The 12 most abundant ions from 
each injection were further fragmented using high energy collisional dissociation (HCD). The 
raw data was analyzed using the Proteome Discoverer and Mascot search algorithm programs. 
The peptide fragments identified were mapped to human protein sequence databases with strict 
parameters. The proteins identified from mass spectrometric analysis from both crosslinked and 
uncrosslinked lysates were tabulated. After removing proteins found in uncrosslinked lysates 
from crosslinked lysates, 5 kinases and more than 200 associated proteins unique to the 
crosslinked lysates were found from Q Exactive mass spectrometric analysis (Table 3.2 and 
Appendix B, Tables A3.1, A3.2).  
The kinases and proteins were identified with high confidence and probability (Table 
3.2). In addition, the kinases identified were observed in the high molecular weight gel slices 
unique to the crosslinked lanes (Appendix B, Table A3.2). Of the identified kinases in MS 
analysis, DNA-dependent protein kinase (DNA-PK),
202-204
 Interferon-induced double-stranded 
RNA-activated protein kinase (EIF2AK2)
210
 are known to phosphorylate p53. Interestingly, 
Serine/threonine-protein kinase MRCK beta (MRCKβ), SRSF protein kinase 1 (SRSF1), and 
Cyclin-dependent kinase 12 (CDK12) are novel kinases of p53 newly identified with this 
crosslinking approach. These experiments provide conditions for characterizing p53 associated 
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proteins as well as identification of endogenous kinases and substrates of interest. Previously, 
DNA-PK was identified as one of the kinase in the p53-crosslinked complex (Section 3.5) with 
westernblot analysis, the same was true from MS analysis. In addition, FNK kinase was not 
identified as the kinase in the p53-crosslinked complex (Section 3.6) either with westernblot 
analysis or with MS analysis. These two kinases highlight the consistent results observed both 
with westernblot and MS analysis. Therefore these photocrosslinking analogs can be successfully 
used to identify novel kinases of a substrate or vice versa and can play a role in elucidating 
signaling pathways. Next step was to validate few of the kinases and interacting proteins of p53 
identified in this study. 
Table 3.2: List of kinases identified with Q Exactive mass spectrometry analysis 
No Identified Proteins  
Accession 
Number/ 
Gel 
Slice  
No. of peptides identified (Probability)  
  Mol. Wt Mol. 
Wt. 
Range 
Crosslinked 
lysates 
 
R-AB           M-AB 
Uncrosslinked 
lysates 
 
R-AB          M-AB 
1 DNA-dependent 
protein kinase 
catalytic subunit  
PRKDC_
HUMAN/
469 kDa 
>170 
kDa 
6 (100%) 
 
47(100%) 
 
- 
 
- 
 
2 Serine/threonine-
protein kinase 
MRCK beta  
MRCKB_
HUMAN/
194 kDa 
>170 
kDa 
3 (100%) 
 
1 (98%) 
 
- 
 
- 
 
3 Interferon-induced, 
double-stranded 
RNA-activated 
protein kinase  
E2AK2_ 
HUMAN/
62  kDa 
>95 
kDa 
1 (99%) 
 
3 (100%) 
 
- - 
4 SRSF protein kinase 
1  
SRPK1_ 
HUMAN/
74 kDa 
~130 
kDa 
- 2 (100%) 
 
- - 
5 Cyclin-dependent 
kinase 12  
CDK12_
HUMAN/
164 kDa 
>170 
kDa 
- 2 (100%) 
 
- - 
Crosslinked and uncrosslinked lysates were immunoprecipitated using Rabbit polyclonal 
antibody (R-AB) and Mouse monoclonal antibody (M-AB)  
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3.7 Photocrosslinking experiments with ATP-BP analog and (±)-Nutlin-3 treated RKO 
cells lysates  
 ATP-ArN3 was successfully used as a phosphorylation-dependent kinase-substrate 
photocrosslinker to identify the novel kinases of p53 using Nutlin treated RKO cell lysates. 
Previously (chapter 2), an ATP-Benzophenone (ATP-BP) photocrosslinker was successfully 
used in phosphorylation-dependent kinase-substrate crosslinking of CK2 kinase and casein 
protein.  Now we want to test the applicability of this ATP-BP analog in identifying novel 
kinases of p53.  
To test the feasibility of the ATP-BP analog, crosslinking reactions were performed 
similar to that of ATP-ArN3 and along with westernblot analysis using anti-DNA-PK, anti-GAK 
and anti-p53.  DNA-PK was chosen because it was identified in the MS analysis with ATP-ArN3 
and was also validated by westernblot.  Cyclin G-associated kinase (GAK), also known as 
auxilin II was also chosen, because it is one of the known kinase of p53.
211,212
 GAK has a 
molecular weight of 160 kDa. GAK plays an important role in stabilization and transcription of 
p53, by forming a complex with other cofactors involved in the DNA repair process.
211,212
   
Western blot analysis of crosslinking experiments with p53 antibody (Figure 3.12A, C) 
revealed high molecular weight complexes in the presence of UV and ATP-ArN3 (Figure 3.12A, 
lane 7) and ATP-BP (Figure 3.12A, lane 8). Crosslinked bands were not observed in the absence 
of UV with ATP (Figure 3.12A, lane 3) or ATP-ArN3 (Figure 3.12A, lane 4), or in lysates 
(Figure 3.12A, lane 1, 2). ATP-BP formed higher molecular weight crosslinked bands in an 
ATP-BP and UV dependent approach (Figure 3.12A, lane 8).  
When probed with anti-GAK for the presence of GAK kinase in the p53-crosslinked 
complexes, no higher molecular weight bands were observed in the case of ATP-ArN3 
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photoprobe (Figure 3.12B, lane 7). When the ATP-BP photocrosslinker was used, a high 
molecular weight crosslinked band was observed corresponding to the p53-GAK complex 
(Figure 3.12B, lane 8). The high molecular weight crosslinked complex was absent in lysates 
control (Figure 3.12B, lane 1, 2) and in the absence of UV (Figure 3.12B, lane 3, 4, 5). Another 
important observation made during these experiments was that washing the PVDF membrane 
with PBST after overnight blocking with 5% milk resulted in non specific signals and high 
background. To overcome this non-specific labeling, after overnight blocking, primary antibody 
was added without washing the membrane.   
DNA-PK reactive band was observed in the higher molecular weight p53-crosslinked 
complex in the case of either ATP-ArN3 photoprobe (Figure 3.12C, lane 7) or ATP-BP photo 
crosslinker (Figure 3.12C, lane 8) when probed with anti-DNA-PK. But the DNA-PK band 
intensity was reduced with ATP-BP compared to ATP-ArN3 photocrosslinker. The higher 
molecular weight complex was absent in lysates (Figure 3.12C, lane 1, 2) and in the absence of 
UV (Figure 3.12C, lane 3, 4, 5). Therefore the ATP-BP analog was successfully used to 
demonstrate phosphorylation-dependent kinase-substrate photocrosslinking using cellular 
proteins in vitro. In addition, we validated GAK kinase as one of the protein found in the p53 
crosslinked complex. Future studies would include performing MS analysis of p53-crosslinked 
complex to identify novel kinases or phosphorylation dependent interacting proteins of p53 
similarly identified using ATP-ArN3 photocrosslinker.  
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Figure 3.12: Photocrosslinking Experiments with ATP-BP and Nutlin treated RKO Cell 
lysates. Photocrosslinking reactions were performed by incubating the reaction components under UV as 
indicated for each reaction at 30 °C for 2 hrs, followed by SDS-PAGE separation and visualization with a 
p53 antibody (A), a GAK antibody (B), and a DNA-PK antibody (C). ATP-ArN3, or ATP-BP analog (10 
mM) and 30 µg of Nutlin treated RKO cell lysates were used in each reaction. The high molecular weight 
crosslinked complex is indicated as p53 crosslinked bands, 53 kDa band of p53 protein as p53, DNA-PK 
protein band as DNA-PK ; DNA-PK  and p53 crosslinked complex as DNA-PK+P53; GAK  protein band 
as GAK; GAK and p53 crosslinked complex as GAK+P53.    
              1  2  3  4  5  6  7  8  
HeLa lysates +  - - - - - - - 
Nutlin treated RKO lysate -  +  +  + +  +  +  +  
ATP -  - + -  - +  -  -  
ATP-ArN3 -  -  -  +  -  -  +  - 
ATP-BP -  -  -  -  +  - -  +  
UV -  -  -  -  -  + + +  
C)   Westernblot with 
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B)   Westernblot with 
anti-GAK 
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3.8 Conclusions and Future directions 
In conclusion, ATP-ArN3 was successfully used in photocrosslinking CK2 kinase and 
casein substrate in the presence of cell lysates. Further studies demonstrated that 
photocrosslinking with low concentration of ATP-ArN3 for 2 hours yielded comparable 
crosslinking.  With optimized crosslinking conditions in the presence of cell lysates, ATP-ArN3 
was successfully used to identify novel and known kinases of p53. Some of the interacting 
proteins of p53 were also identified using MS analysis. DNA-PK and GAK were validated as the 
kinases of p53 using ATP-ArN3 and ATP-BP photocrosslinkers. The novel kinases identified in 
this study were MRCKβ, SRSF1 and CDK12. MRCKβ kinase plays a role in cytoskeleton 
organization and during mitosis.
213,214
 p53 is known to be involved in the mitosis process,
215,216
 
but there is no known mechanism through which p53 and MRCKβ interact. In future, 
experiments will be performed on establishing the role of p53 and MRCKβ in the cellular 
function and cytoskeleton organization. Performing in vitro phosphorylation studies and 
establishing kinase-substrate relationship will be the first step in validating MRCKβ, CDK12, 
and SRSF1 as kinases of p53, further studies will be carried out to establish their role in cellular 
processes (Figure 3.13). 
 
Figure 3.13: Cartoon Depicting the Possible Cellular Roles of Kinases (Identified in MS 
analysis) and p53 
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Developing next generation of ATP analogs such as affinity based crosslinking reagents 
and acid stable ATP analogs, will be helpful in the identification of kinase-substrate pairs as well 
as the site of crosslink.  Specifically, these modified -phosphate ATP analogs require 
phosphorylation for crosslinking, in contrast to other kinase-substrate crosslinking approaches. 
Because these modified ATP analogs participate in phosphorylation, the crosslink will contain 
both kinase and substrate. One powerful feature of this methodology is that we can obtain an 
atomic level snapshot of the interactions between proteins, when coupled with analytical 
techniques like Mass Spectrometry (MS). These tools will help us in validating our 
understanding of protein-protein interactions, their role in signaling pathways and functioning of 
the cell.  
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3.9 Experimental 
3.9.1 Materials  
Cell culture grade dimethylsulfoxide (DMSO) was purchased from ATCC. The disodium salt of 
Adenosine 5’-triphosphate (ATP.2Na), glycerol, sodium hydroxide (NaOH), potassium chloride 
(KCl), magnesium chloride (MgCl2), sodium chloride (NaCl), sodium dodecyl sulfate (SDS), 
and glacial acetic acid were purchased from Fisher. Ammonium bicarbonate, α-casein, tris(2-
carboxyethyl) phosphine HCl (TCEP), iodoacetamide, and proteomics grade trypsin were bought 
from Sigma. CK2 was purchased from New England Biolabs. Triton X-100 was purchased from 
Fluka. Coomassie Brilliant Blue was obtained from NuSep. Trifluoroacetic acid (TFA) and 
Immobilion-P PVDF membrane were purchased from Millipore. SyproRuby stain was obtained 
from Invitrogen. Eagle’s minimum essential medium (EMEM) (30-2003) and RKO cell culture 
sample (CRL-2577) were purchased from ATCC. Acrylamide/Bis acrylamide solution (40%, 
37.5:1) was purchased from Bio-Rad. Proteomics grade formic acid was purchased from 
Proteochem. Anti-p53 (Rabbit) polyclonal antibody (SC-6243), anti-p53 (Mouse) monoclonal 
antibody (SC-55476), and protein A/G-PLUS agarose beads (SC-2003) were purchased from 
Santa Cruz Biotechnology Inc. Anti-DNA-PK antibody (4602P) and Anti-rabbit IgG HRP-linked 
secondary antibody (7074) were purchased from Cell Signaling Technology. Fetal bovine serum 
(FBS), antibiotic-antimycotic (100X), TrypLE™ Express (1X) with Phenol Red and Alexa 
Fluor® 647 Goat Anti-Rabbit IgG (H+L) (A-21244) were purchased from Life Technologies. 
Goat anti-mouse IgG (H+L) (HRP) (ab97040) secondary antibody was purchased from Abcam. 
Goat anti-mouse HiLyte Fluor™ 647-labeled secondary antibody was purchased from Anaspec. 
A free sample of anti-FNK antibody (GTX111495) was obtained from Genetex Inc. A free 
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sample of Anti-GAK antibody (H00002580-B01P) was obtained from Abnova. (±) Nutlin-3 was 
purchased from Cayman Chemicals.  
3.9.2 Instrumentation  
A SPD131 DDA ThermoSavant speedvac was used to evaporate solvents in vacuo. SDS-PAGE 
apparatus was purchased from BioRad (Protean III) and a mini-gel setup was used. Western 
blotting was carried out using the mini-transblot electrophoretic transfer Cell apparatus from 
Bio-Rad. Western blot and SDS-PAGE gel images were visualized using a Typhoon 9210 
scanner (Amersham Biosciences).  
3.9.3 Procedure for crosslinking of CK2 kinase and casein in the presence of cell               
lysates   
The order of addition is important in crosslinking. The order used was water, CK2 buffer, CK2 
kinase, ATP analog or ATP, followed by cell lysates or casein. Briefly, CK2 kinase (5 units/µL) 
was incubated with ATP-BP (10 mM) or ATP (10 mM) or ATP-ArN3 (10 mM) in CK2 buffer 
(20 mM HEPES, 50 mM KCl, 10 mM MgCl2, pH 7.2-7.5) for 5 minutes on ice, followed by the 
addition of α-casein (100 μM) and Jurkat cell lysates (10 µg total protein). The final reaction 
volume was 20 μL. Equal concentrations of ATP-analog and ATP were added for a competitive 
reaction control. The reaction mixtures were incubated for 2 hrs at 30 °C. Crosslinked protein 
was obtained by simultaneously irradiating the appropriate reaction tubes with a handheld UV 
lamp (365 nm). The presence of the phosphoramidate bond in the crosslinked product was 
confirmed by acid-mediated cleavage of the complex by adding 20 μL trifluoroacetic acid (TFA) 
to the reaction mixture (final concentration of 50% TFA) and incubating at 30 °C for 1 hour. The 
sample tube containing TFA was neutralized using 100 mM Tris base (50 μL) and the volume 
was reduced in vacuo. The reaction products were separated by SDS-PAGE and the proteins 
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were visualized with coomassie blue stain (Section 3.9.7) or SyproRuby stain (Section 3.9.8) or 
western blotting with an anti-CK2 antibody after electrotransfer onto PVDF membrane 
(Immobilon-P
SQ
).  
3.9.4   Procedure for crosslinking using ATP-Analog and RKO cell lysates  
To an eppendorf tube containing the required amount of water, was added 2 µL CK2 
buffer (20 mM HEPES, 50 mM KCl, 10 mM MgCl2), 1 µL JLB buffer without protease inhibitor 
(50 mM HEPES, pH 8.0, 150 mM NaCl, 10% glycerol, 0.5% Triton X-100), 1 µL HEPES buffer 
(0.1 M), followed by addition of RKO cell lysates or Nutlin treated RKO cell lysates (30 µg total 
protein). Next, ATP-ArN3 (10 mM), ATP-BP (10 mM) or ATP (10 mM) was added and the 
reaction mixture was incubated on ice for 3-5 minutes covered with aluminum foil. The reaction 
mixtures were incubated for 2 hrs at 30 °C. Crosslinked protein was obtained by simultaneously 
irradiating the appropriate reaction tubes with a handheld UV lamp (365 nm). The presence of 
the phosphoramidate bond in the crosslinked product was confirmed by acid-mediated cleavage 
of the complex by adding 20 μL trifluoroacetic acid (TFA) to the reaction mixture (final 
concentration: 50% TFA) and incubating at 30 °C for 1 hour. The sample tube containing TFA 
was neutralized using 100 mM Tris base (50 μL) and the volume was reduced in vacuo. The 
reaction products were separated by SDS-PAGE and the proteins were visualized with coomassie 
blue stain (Section 3.9.7) or SyproRuby stain (Section 3.9.8) or western blotting with an antibody 
after electrotransfer onto PVDF membrane (Immobilon-P
SQ
).  
3.9.5 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE)  
Refer to chapter 2, section 2.9.7. 
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3.9.6 Western Blotting   
Refer to chapter 2, section 2.9.8. 
3.9.7 Coomassie Blue Staining  
Refer to chapter 2, section 2.9.9. 
3.9.8 SyproRuby Staining  
The SDS-PAGE gel was gently placed into a clean container containing 50 mL fixing solution 
(50% methanol and 7% acetic acid in water) and incubated with gentle rocking at room 
temperature for 30 minutes. Fixing solution was removed and the process was repeated for 
another 30 min, for a total of one hour. The fixing solution was poured off and 25 to 30 mL of 
SyproRuby protein stain (Invitrogen) was added in the absence of light. The container was 
covered in aluminum foil to protect from light and incubated with gentle shaking overnight at 
room temperature. Sypro Ruby stain was carefully decanted and saved for later use. The saved 
stain can be used up to ten times. The gel was then destained to remove excess stain and reduce 
background. Destaining solution (10% methanol and 7% acetic acid in water) was added and the 
gel was incubated at room temperature for 30 minutes. The destaining solution was discarded 
and the gel was rinsed with distilled water for 5 minutes to remove any excess acid and to 
prevent corrosive damage to the instrument used for visualization. The stained gel was imaged 
using the Typhoon 9400 scanner at an excitation wavelength of 450 nm and an emission of 610 
nm. 
3.9.9 Starting a New RKO Cell Culture  
 
RKO cells obtained from ATCC (1.0 mL, 5 × 10
6
 cells, ATCC CRL-2577) in cryogenic vials on 
dry ice and were stored in a liquid nitrogen storage tank (Thermolyne) upon receipt. EMEM 
media was supplemented with 10% FBS, 1% antibiotic-antimycotic and filtered through 0.22 μm 
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pore size sterile filters. When starting a new cell culture, a frozen aliquot was removed from the 
liquid nitrogen tank and thawed quickly in a 37 °C water bath. The contents of the vial were then 
transferred to a 15 mL centrifuge tube containing 5 ml of warm EMEM media (containing FBS 
and antibiotic). The cryogenic vial was rinsed with 5 mL of EMEM media to recover the 
contents and all the solution was mixed gently in the centrifuge tube. The tube was centrifuged at 
1000 rpm for 5 minutes at 25 °C. The supernatant was carefully discarded without disturbing the 
cell pellet and the cell pellet was resuspended in 5 mL of EMEM media (containing FBS and 
antibiotic) and transferred to a tissue culture flask (25 cm
2
 size). The cells were cultured in a 37 
°C incubator under a 5% CO2 environment with 95% relative humidity. Cell growth was checked 
periodically using microscopy or by counting the cells with a hemocytometer and the cell count 
was maintained between 0.5-1.0 × 10
6 
cells per mL.   
 
3.9.10  Banking of RKO cells for long term use  
 
Confluent cells (1 × 10
6
 cells per mL) were trypsinized off the flask and collected by 
centrifugation at 1000 rpm for 5 minutes at 4 °C. Trypsinization was done using TrypLE™ 
Express (1X) containing trypsin-like enzyme with phenol red indicator.  TrypLE™ Express (1X) 
(5-10 mL) was added to the flask to cover the surface and incubated at 37 °C for 10 minutes. The 
presence of any growth media inhibits the action of the TrypLE™ Express, so it’s essential to 
rinse with 1XPBS prior to trypsinization. After 10 minutes, when adherent RKO cells appeared 
to dissociate from the flask, EMEM media (5 to 10 mL) was added to stop the action of 
TrypLE™ Express. The media was carefully mixed and the flask was rinsed with an additional 5 
to 10 mL of media to collect all the cells. The cell pellet obtained by centrifuging 50 mL of cell 
culture media (50 X 10
6
 cells) was washed with 1XPBS (cell culture grade, phosphate buffered 
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saline consisting of 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4).   
Cel pellet obtained after washing with PBS was resuspended in 10 mL of fresh EMEM media 
with a final concentration of 10% v/v DMSO (cell culture grade) and aliquoted into cryogenic 
vials (Corning, 5 X 10
6
 to 10 X 10
6
 cells in each vial). The cells were slowly cooled in a stepwise 
fashion starting at -20 °C overnight and then -80 °C overnight followed by storing in a liquid 
nitrogen storage tank (Thermolyne).  
 
3.9.11  Treatment of cells with (±)-Nutlin-3 and collection of cells  
 
For (±)-Nutlin-3 treatment, 1.5 X 10
6
 cells were seeded in a 75 cm
2
 tissue culture flasks in 10 mL 
of EMEM growth medium 24 hours prior to treatment. (±)-Nutlin-3 (Cayman Chemicals, 10 mM 
stock solution in DMSO) was added to the media at various concentrations (10 µM, 20 µM) and 
incubated for 24 hours. Control cells were treated with an equivalent amount of DMSO. After 24 
hours, the growth media was carefully removed and the flask was rinsed with 1X PBS and 
trypsinized (see section 3.10.10). The media was transferred to a conical tube and centrifuged at 
1000 rpm for 5 minutes at 4 °C. The supernatant was discarded and cells were gently washed 
with 10 mL of cold 1X PBS.  The cell pellet can be used immediately or stored at -80 °C until 
needed. 
 
3.9.12  Cell lysis procedure  
 
Frozen control or (±)-Nutlin-3-treated RKO cell pellets were thawed and kept on ice, or fresh 
cell pellets were used directly. Cells were resuspended in lysis buffer (200 µL; 50 mM HEPES, 
pH 8.0, 150 mM NaCl, 10% glycerol, 0.5% Triton X-100 and freshly added 1X protease 
inhibitor cocktail V). Cells were mixed in lysis buffer by pipetting several times and lysis was 
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achieved    by mixing with rotation at 4 °C for 10 minutes. The soluble fraction was separated 
from the cell debris by spinning at 15,000 rpm at 4 °C for 25 minutes. The supernatant was 
collected without any debris into a clean epitube.  The concentration of total protein in the lysate 
was determined using a Bradford assay
217
 and the lysate was distributed into single use aliquots, 
which were stored at -80 °C. To preserve the activity of proteins, the entire lysis process was 
carried out at 4 °C on ice and as quickly as possible. 
 
3.9.13  In-Gel Protein Digestion  
 
For MS analysis, proteins were excised from gels and digested with trypsin. The in-gel protein 
digestion method was adapted from Shevchenko, A et al.
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 Benchtop surfaces, gloves, and tools 
used during in-gel digestion were washed with 70% ethanol (Decon Laboratories) prior to use to 
avoid contamination with keratin. The gel from SDS-PAGE (Section 3.4.4) was stained with 
SYPRO
® 
Ruby (Invitrogen) and scanned on a Typhoon 9210 variable mode imager (Amersham 
Biosciences). The gel was stored until processing (one week) in destaining solution (7% acetic 
acid (Mallinckrodt Chemicals), 10% methanol (EMD) in ultrapure H2O). Prior to band excision, 
the gel was washed with 10% methanol in ultrapure water twice for a minimum of 2 hours. The 
proteins in the gel were visualized on an FBTIV-88 ultraviolet trans-illuminator briefly to aid in 
the excision of the lanes-of-interest. Gel lanes were excised and cut into 8 equal slices (0.7 cm x 
0.4 cm) from the 55 kDa molecular weight marker to the top of gel, using a 1.5 inch straight 
razor (Stanley). Slices were then cut into approximately 1 mm
3
 pieces which were placed into 
1.5 mL Protein LoBind tubes (Eppendorf) after rinsing the tubes with HPLC grade acetonitrile 
(EMD). Gel slices were washed with 1:1 (v/v) solution of 50 mM ammonium bicarbonate (Fluka 
Analytical) and acetonitrile for 10 minutes (100 μL of total volume). The liquid was removed 
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and replaced with an equal volume of acetonitrile. After 5 minutes with manual agitation as 
needed, gel particles turned white and stuck together. Acetonitrile was removed and replaced 
with 100 μL 50 mM ammonium bicarbonate for 5 minutes. Acetonitrile (100 μL) was then added 
and incubated for 10 minutes. All liquid was removed and replaced with neat acetonitrile (100 
μL) for 5 minutes. After gel pieces shrunk and turned opaque white, acetonitrile was removed 
and samples were dried in a speedvac concentrator (SDP131DDA, Thermo Scientific Savant) for 
10 minutes. Dried gel pieces were rehydrated and cysteine’s were reduced in 100 μL reducing 
buffer (50 mM TCEP and 25 mM ammonium bicarbonate) at 37 °C for 20 minutes. Samples 
were allowed to cool on the bench for 10 minutes before removing excess reducing buffer. 
Alkylation was performed by adding 100 μL 100 mM iodoacetamide (Sigma) in 25 mM 
ammonium bicarbonate buffer to samples and incubating at room temperature in the dark for 30 
minutes.  Alkylation buffer was removed and gel particles were washed with 100 μL solution of 
50 mM ammonium bicarbonate and acetonitrile (1:1), twice for 15 minutes each on a rocking 
platform. All liquid was then removed and 100 μL of acetonitrile was added and incubated for 5 
minutes. After gel particles shrank and became white, the liquid was removed and particles were 
dried in speedvac for 10 minutes. Activated proteomics grade trypsin (Sigma) in digestion buffer 
(40 mM ammonium bicarbonate, 9% acetonitrile) was added to each sample in sufficient volume 
(75 μL) to cover the particles. Samples were kept on ice for 1 hour and additional digestion 
buffer was added (50 μL) to keep particles covered. Tubes were transferred to 37 °C incubator 
for digestion overnight. Peptide solutions were removed with gel-loading tips and transferred to 
new, pre-rinsed 0.5 mL Protein LoBind tubes. Peptides were further extracted from gel particles 
with 75 μL 0.1% (v/v) formic acid (Proteochem) in water:acetonitrile (65:35) with bath 
sonication for 5 minutes. After sonication, extracted peptide solutions were combined with 
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overnight peptide solutions and frozen at -80°C. Samples were then dried in the speedvac for 2 
hours and stored at -20 °C before analysis. Dry peptides were reconstituted by solubilizing in an 
aqueous solution containing 5% acetonitrile, 0.1% formic acid and 0.05% trifluoroacetic acid by 
sonicating for 1 minute in a total volume of 20 μL.   
 
3.9.14 Mass Spectrometric Analysis  
 
(Analysis was performed by Todd Faner at the Proteomics core facility) 
 Peptides were desalted in-line and separated by reverse phase chromatography (Acclaim 
PepMap100 C18 pre-column, Acclaim PepMapRSLC C18 analytical column, Thermo Scientific) 
on a nanoflow HPLC instrument (Easy-nLC 1000, Thermo Scientific), followed by ionization 
with a Nanospray Flex Ion Source (Proxeon Biosystems A/S) and introduced into a Q Exactive 
mass spectrometer (Thermo Scientific). A linear gradient of 95% buffer A (water, 0.1% formic 
acid) with 5% buffer B (acetonitrile) to 90% buffer A, with 10% buffer B over 2 minutes, 
followed by 68% buffer A, with 32% buffer B over 30 minutes at a flow rate of 300 nL/min, was 
used for separation. Pumps and instrument methods were controlled with Thermo Xcalibur 2.2 
SP1.48 software (Thermo).  
The instrument was operated in positive mode and data was acquired using a data-dependent top 
12 method. The 12 most abundant  ions from the full MS scan (375-1600 m/z) were selected for 
fragmentation by high energy collisional dissocation (HCD). Dynamic exclusion was enabled 
with 12.0 s duration and precursor isolation width set to 3.0 m/z. Resolution of full MS and HCD 
scans was 70,000 at 375 m/z and 17,500 at 200 m/z, respectively. Normalized collision energy 
for HCD spectra was 30 eV and data were acquired in profile mode. Isotope exclusion, singly 
charged and unrecognized charged ion exclusion was enabled.  
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3.9.15. Peptide Spectrum Matching and Data Analysis 
Analysis of raw data was performed with Proteome Discoverer 1.4.0.288 (Thermo) using the 
Mascot search algorithm (Matrix Science). The SwissProt_2013_04 database was used against 
human protein sequences and the reverse decoy protein database used to calculate false 
discovery rates (FDR). Secondary analysis was performed using Scaffold 4.0.5 (Proteome 
Software) with X! Tandem software (The Global Proteome Machine Organization) for subset 
database searching. Minimum protein identification probability was set to ≥99% with 2 unique 
peptides per protein and ≥80% minimum peptide identification probability.  
Mascot and X! Tandem algorithms were searched with a precursor mass tolerance of 10 ppm and 
fragment mass tolerance of 0.02 Da. Target FDR was set to 0.01 (strict) and 0.05 (relaxed). 
Carbamidomethylation of cysteine (+57) was set as a fixed modification. Variable modifications 
included oxidation of methionine (+16), protein n-terminal acetylation (+42), phosphorylation on 
serine, threonine, and tyrosine (+80). Enzyme specificity was defined for trypsin as c-terminal to 
lysine and arginine with 1 missed cleavage site allowed. The parameters for the data analysis of 
each set of proteins obtained were mentioned in the tables, if different. 
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Figure A2.1: Kinase-catalyzed Photocrosslinking with ATP-BP. CK2 kinase was 
incubated with α-casein in the presence of ATP or ATP-BP under UV for 2 hrs at 30 °C. 
The resulting mixtures were separated by SDS-PAGE and visualized by coomassie blue 
staining (2A) or SyproRuby staining (1A) and western blotting with anti-CK2 (1B, 2B).  
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 1  2  3  4  5  6  7  8  
CK2  +  -  +  +  +  +  +  +  
α-casein  -  +  +  +  +  +  +  +  
ATP  -  -  +  -  +  + -  -  
ATP-BP -  -  -  +  -  +  +  +  
UV  -  -  -  -  +  +  +  +  
TFA  -  -  -  -  -  -  -  + 
1A. 
1B. 
2A. 
2B. 
CK2-casein 
CK2 
CK2-casein 
CK2 
CK2 
CK2-casein 
CK2-casein 
CK2 
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Trial 3 Trial 2 
74% 65% 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
m/z SN Res. Intens. Area Conv% 
Trial 2 1540.840 21.2 5016 55.36 18 65% 
 1562.074 39.0 5803 101.99 28  
       
Trial 3 1540.906 42.7 5160 161.56 50 74% 
 1561.909 52.3 4335 197.63 72  
 
 
Figure A2.2: Quantitative MALDI-TOF MS of peptide substrate (RRREEETEEE) with CK2 
kinase and either ATP 1 or ATP-BP 4. The peak at m/z ~1541 corresponds to heptamethylated 
phosphopeptide after reaction with ATP-benzophenone and acidic cleavage of phosphoramide 
bond, while the peak at m/z ~1562 corresponds to the deuterated heptamethylated 
phosphopeptide after phosphorylation with ATP. 
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Compound Characterization: 
 
 
 
   
             
    
 
 
 
 
 Figure A2.3: 
1
H-NMR of compound 7 recorded in CDCl3 solvent. 
 
 
 
 
 
Figure A2.4: 
13
C-NMR of compound 7 recorded in CDCl3 solvent. 
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Figure A2.5:  HR-MS of compound 7 recorded with methanol solvent. 
 
Figure A2.6: IR spectrum of compound 7. 
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Figure A2.7: 
1
H-NMR of ATP-BP 4 recorded in D2O solvent. 
 
 
 Figure A2.8: UV absorbance of ATP-BP 4.  
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Figure A2.9: 
31
P-NMR of ATP-benzophenone 4 recorded in D2O solvent. 
 
 
 
Figure A2.10: HR-MS of ATP-BP 4 recorded with methanol solvent. 
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Figure A2.11: IR spectrum of compound ATP-BP 4. 
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Autodock analysis: 
The lowest binding energy mode that conforms to the kinase-catalyzed phosphorylation 
mechanism is in bold for each docking experiment. The grid box dimensions used in all the 
analysis were same or similar. 
A) CK2 kinase docking  
Table A2.1. The grid dimensions and output file with all the different binding modes obtained 
from docking of ATP-ArN3 (2) and CK2 kinase.  
center_x = 21.579  size_x = 22 
center_y = 5.811  size_y = 30 
center_z = 19.517 size_z = 18   exhaustiveness = 8. 
 
mode |   affinity | dist from best mode 
     | (kcal/mol) | rmsd l.b.| rmsd u.b. 
-----+------------+----------+---------- 
   1         -8.1      0.000      0.000 
   2         -7.2      3.685      5.354 
   3         -7.2      8.785     10.991 
   4         -7.1      3.032      5.129 
   5         -7.1      4.889      7.208 
   6         -6.9      2.469      3.659 
   7         -6.9      3.559      5.621 
   8         -6.8      5.732      8.818 
   9         -6.7     10.940     13.509 
Table A2.2. The grid dimensions and output file with all the different binding modes obtained 
from docking of ATP-DAz (3) and CK2 kinase.  
center_x = 21.579   size_x = 22 
center_y = 5.811   size_y = 30 
center_z = 19.517  size_z = 18   exhaustiveness = 8 
mode |   affinity | dist from best mode 
     | (kcal/mol) | rmsd l.b.| rmsd u.b. 
-----+------------+----------+---------- 
   1         -6.5      0.000      0.000 
   2         -6.5      3.228     11.654 
   3         -6.1      2.106      3.128 
   4         -5.8      4.891     12.286 
   5         -5.8      2.521      4.035 
   6         -5.7      3.274     11.896 
   7         -5.5      1.740      2.940 
   8         -5.4      2.944      5.893 
   9         -5.3      1.727      2.881 
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Table A2.3. The grid dimensions and output file with all the different binding modes obtained 
from docking of ATP-BP (4) and CK2 kinase. 
center_x = 21.579  size_x = 22 
center_y = 5.811   size_y = 30 
center_z = 19.517  size_z = 18   exhaustiveness = 8 
mode |   affinity | dist from best mode 
     | (kcal/mol) | rmsd l.b.| rmsd u.b. 
-----+------------+----------+---------- 
   1         -7.3      0.000      0.000 
   2         -7.3      4.706     11.056 
   3         -6.7      1.462      2.275 
   4         -5.3      3.205      8.800 
   5         -5.2      4.051      8.731 
   6         -5.1      4.015      8.548 
   7         -5.0      4.001      8.547 
   8         -4.9      3.656      4.845 
   9         -4.8      3.301      9.279 
 
B) PKA kinase docking 
Table A2.4. The grid dimensions and output file with all the different binding modes obtained 
from docking of ATP-ArN3 (2) and PKA kinase. 
 center_x = 12.723    size_x = 28 
 center_y = 8.552    size_y = 20 
 center_z = 2.82    size_z = 16   exhaustiveness = 8 
 
mode |   affinity | dist from best mode 
     | (kcal/mol) | rmsd l.b.| rmsd u.b. 
-----+------------+----------+---------- 
   1         -7.6      0.000      0.000 
   2         -7.6      2.552      4.617 
   3         -7.2      3.196     15.716 
   4         -7.2      2.061      3.817 
   5         -7.2      2.418      4.028 
   6         -7.2      2.202     14.849 
   7         -7.1      3.220      5.859 
   8         -7.0      2.486      4.993 
   9         -7.0      2.848      5.832 
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Table A2.5. The grid dimensions and output file with all the different binding modes obtained 
from docking of ATP-DAz (3) and PKA kinase. 
center_x = 12.723    size_x = 28 
center_y = 8.552     size_y = 20 
center_z = 2.82    size_z = 16   exhaustiveness = 8 
 
mode |   affinity | dist from best mode 
     | (kcal/mol) | rmsd l.b.| rmsd u.b. 
-----+------------+----------+---------- 
   1         -7.5      0.000      0.000 
   2         -7.3      1.233      2.256 
   3         -7.2      2.663     14.449 
   4         -7.2      1.440      2.310 
   5         -7.1      2.304     14.531 
   6         -6.9      2.774      4.834 
   7         -6.8      4.594      6.423 
   8         -6.8      2.376     14.876 
   9         -6.8      2.321      3.800 
 
Table A2.6. The grid dimensions and output file with all the different binding modes obtained 
from docking of ATP-BP (4) and PKA kinase. 
center_x = 12.886    size_x = 28 
center_y = 8.549    size_y = 20 
center_z = 2.924    size_z = 18   exhaustiveness = 8 
 
mode |   affinity | dist from best mode 
     | (kcal/mol) | rmsd l.b.| rmsd u.b. 
-----+------------+----------+---------- 
   1        -10.2      0.000      0.000 
   2        -10.0      1.646      2.884 
   3         -9.7      4.611     13.432 
   4         -9.6      3.385     14.637 
   5         -9.6      4.480     14.024 
   6         -9.6      3.417      5.212 
   7         -9.6      3.992      6.090 
   8         -9.4      1.918      3.723 
9      -9.2      2.214      4.154 
 
 
 
112 
 
APPENDIX B  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 2 3 4 5 6 7 8 9 
CK2 + - - + + + + - - 
Lysates - + - - + + + + + 
Casein - - + + + + + + + 
ATP-ArN3  (mM) - - - 2.5 - 10 15 10 15 
ATP (mM) - - - - 10 - - - - 
UV - - - + + + + + + 
B) 
CK2 
CK2-Casein 
CK2 
A) Trial 3 
CK2-Casein 
Casein 
B) 
CK2-Casein 
A) Trial 2 
CK2 
CK2 
CK2-Casein 
Casein 
Figure A3.1: Photocrosslinking of CK2 and α-casein in the presence of Jurkat cell lysates. 
Photocrosslinking reactions were performed with CK2 kinase, casein substrate, ATP-ArN3 in the presence of Jurkat cell 
lysates and UV at 30 oC, followed by SDS-PAGE separation and visualization with a CK2 antibody (B), SyproRuby protein 
staining (A). ATP-ArN3 concentration and components of each reaction lane are as indicated.  Jurkat cell lysates (10 µg) 
were used in each reaction. The expected ~68 kDa crosslinked band is indicated as CK2-Casein, the 45 kDa band of CK2 
kinase as CK2, and 25 kDa band of α-casein as casein.  
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Figure A3.2: Photocrosslinking experiment with ATP-ArN3 and Nutlin treated cell lysate. 
Photocrosslinking reactions were performed by incubating the reaction components under UV as 
indicated for each reaction, at 30 °C for 2 hrs, followed by SDS-PAGE separation and visualization with a 
p53 antibody (top), and CK2 antibody (bottom). ATP-ArN3 (10 mM) and 30µg of total protein from 
Nutlin treated RKO cell lysates were used in each reaction. Lysates were heat denatured before the 
addition of ATP-ArN3 for 5 minutes at 95 °C. TFA was added to a final concentration of 50% after 
crosslinking to cleave the phosphoramidate bond in the crosslink. The high molecular weight crosslinked 
complex is indicated as p53 crosslinked bands, and 53 kDa band of p53 protein as p53. 
 
 
              1  2  3  4  5  6  7  8
  Lysates +  +  +  -  +  +  +  +
  Heat denatured lysate -  -  -  +  -  -  -  -
  ATP -  +  -  -  -  +  -  -
  ATP-ArN3 -  -  +  +  -  -  +  +
  UV -  -  -  +  +  +  +  +
  TFA -  -  -  -  -  -  -  +
  
p53 
p53 crosslinked  
bands 
p53 crosslinked  
bands 
p53 
Trial-2:  Westernblot with anti-p53 
 
Trial-3:  Westernblot with anti-p53 
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A) Westernblot with   
            anti-p53 
 
 
 
 
 
B) Westernblot with  
anti-DNA-PK 
 
         
C) Coommassie blue  
            Protein staining  
 
 
                        
    
 
 
 
 
 
 
Figure A3.3: Photocrosslinking Experiments to validate Phosphorylation of p53 by DNA-
PK kinase. The photocrosslinking reaction was performed by incubating the reaction 
components under UV as indicated for each reaction at 30 °C for 2 hrs, followed by SDS-PAGE 
separation and visualization with a p53 antibody (A), DNA-PK antibody (B), and Commassie 
blue staining (C). ATP-ArN3 (10 mM) and 30 µg total proteins from Nutlin treated RKO cell 
lysates were used in each reaction. Lysates were heat denatured before the addition of ATP-ArN3 
for 5 minutes at 95 °C. TFA added to a final concentration of 50% after crosslinking to cleave 
the phosphoramidate band of crosslink. The high molecular weight crosslinked complex is 
indicated as p53 crosslinked bands, 53 kDa band of p53 protein as p53, DNA-PK protein band as 
DNA-PK, and the DNA-PK complex as DNA-PK crosslinked bands.  
              1  2  3  4  5  6  7  8  
Lysates +  +  +  -  +  +  +  +  
Heat denatured lysate -  -  -  +  -  -  -  -  
ATP -  +  -  -  -  +  -  -  
ATP-ArN3 -  -  +  +  -  -  +  +  
UV -  -  -  +  +  +  +  +  
TFA -  -  -  -  -  -  -  +  
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Table A3.1: Proteins identified in the crosslinking experiment with Q Exactive Mass 
Spectrometry  
This table catalogs the number of unique peptides identified with respect to crosslinked and uncrosslinked 
lysates as well as with the use of rabbit antibody and mouse antibody for the IP of crosslinked complex.  
A) uncrosslinked lysates, IP with Rabbit Antibody; B) crosslinked lysates, IP with Rabbit Antibody; C) 
uncrosslinked lysates, IP with Mouse Antibody;  D) crosslinked lysates, IP with Mouse Antibody. The 
parameters were set to a 90% protein threshold, 99.9% peptide threshold, with the minimum number of 
peptides set to 1. Absence of a number or presence of zero under the different reaction conditions (A, B, 
C, and D) implies that there are no unique peptides identified for that protein.    
 
No. Identified Proteins  
Accession 
Number 
Mol. 
Wt 
No. of Uniques peptides 
identified  
A B C D 
1 
Cluster of 14-3-3 protein 
zeta/delta  
1433Z_HUMAN 
[2] 
28 kDa 1 
  
7 
2 40S ribosomal protein S13  RS13_HUMAN 17 kDa 
   
1 
3 60S ribosomal protein L11  RL11_HUMAN 20 kDa 
   
1 
4 
A-kinase anchor protein 
SPHKAP  
SPKAP_HUMAN 
186 
kDa    
1 
5 AFG3-like protein 2  AFG32_HUMAN 89 kDa 
   
3 
6 
Adenylyl cyclase-associated 
protein 1  
CAP1_HUMAN 52 kDa 
 
1 
 
2 
7 
Ankyrin repeat and KH domain-
containing protein 1 
ANKH1_HUMAN 
(+1) 
269 
kDa    
1 
8 Ataxin-2-like protein  ATX2L_HUMAN 
113 
kDa    
2 
9 
Baculoviral IAP repeat-
containing protein 6  
BIRC6_HUMAN 
530 
kDa    
1 
10 Bifunctional protein NCOAT  NCOAT_HUMAN 
103 
kDa    
1 
11 
Bifunctional purine biosynthesis 
protein PURH  
PUR9_HUMAN 65 kDa 
   
3 
12 
Brefeldin A-inhibited guanine 
nucleotide-exchange protein 1  
BIG1_HUMAN 
(+1) 
209 
kDa    
1 
13 
Bromodomain-containing protein 
4  
BRD4_HUMAN 
152 
kDa  
2 
  
14 C2 domain-containing protein 2  CU025_HUMAN 76 kDa 
 
3 1 18 
15 CAD protein  PYR1_HUMAN 
243 
kDa  
2 
 
16 
16 
CDK5 regulatory subunit-
associated protein 3  
CK5P3_HUMAN 57 kDa 
   
2 
17 CUB domain-containing protein 1  CDCP1_HUMAN 93 kDa 
   
1 
18 
Calcium-binding mitochondrial 
carrier protein Aralar1  
CMC1_HUMAN 75 kDa 
   
1 
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No. of Uniques peptides 
identified  
A B C D 
19 
Calcium-binding mitochondrial 
carrier protein Aralar2  
CMC2_HUMAN 74 kDa 
   
1 
20 
Chloride intracellular channel 
protein 1  
CLIC1_HUMAN 27 kDa 
   
3 
21 
Cluster of Chromodomain-
helicase-DNA-binding protein 4  
CHD4_HUMAN 
218 
kDa    
5 
22 
Clustered mitochondria protein 
homolog  
CLU_HUMAN 
147 
kDa    
1 
23 
Coiled-coil and C2 domain-
containing protein 1A  
C2D1A_HUMAN 
104 
kDa    
4 
24 
Coiled-coil domain-containing 
protein 47  
CCD47_HUMAN 56 kDa 
 
1 
  
25 
Constitutive coactivator of 
PPAR-gamma-like protein 1  
F120A_HUMAN 
122 
kDa    
2 
26 
Cytoplasmic FMR1-interacting 
protein 1  
CYFP1_HUMAN 
145 
kDa    
3 
27 Cytoskeleton-associated protein 4  CKAP4_HUMAN 66 kDa 
 
1 
 
1 
28 Cytoskeleton-associated protein 5  CKAP5_HUMAN 
226 
kDa    
4 
29 DNA damage-binding protein 1  DDB1_HUMAN 
127 
kDa  
1 0 5 
30 DNA repair protein XRCC4  XRCC4_HUMAN 38 kDa 5 12 
  
31 
DNA-dependent protein kinase 
catalytic subunit  
PRKDC_HUMAN 
469 
kDa  
6 
 
47 
32 
Developmentally-regulated GTP-
binding protein 1  
DRG1_HUMAN 41 kDa 
   
1 
33 
Dolichyl-
diphosphooligosaccharide--
protein glycosyltransferase 48 
kDa subunit  
OST48_HUMAN 51 kDa 
 
0 
 
2 
34 
Dolichyl-
diphosphooligosaccharide--
protein glycosyltransferase 
subunit 1  
RPN1_HUMAN 69 kDa 
 
3 
 
15 
35 
Dolichyl-
diphosphooligosaccharide--
protein glycosyltransferase 
subunit 2  
RPN2_HUMAN 69 kDa 
 
5 
 
10 
36 
Dolichyl-
diphosphooligosaccharide--
protein glycosyltransferase 
subunit STT3A  
STT3A_HUMAN 81 kDa 
   
3 
37 
Dolichyl-
diphosphooligosaccharide--
protein glycosyltransferase 
subunit STT3B  
STT3B_HUMAN 94 kDa 
   
1 
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Wt 
No. of Uniques peptides 
identified  
A B C D 
38 
Dual specificity mitogen-
activated protein kinase kinase 3  
MP2K3_HUMAN 39 kDa 
   
1 
39 Dynamin-1-like protein  DNM1L_HUMAN 82 kDa 
   
1 
40 
Dynamin-like 120 kDa protein, 
mitochondrial  
OPA1_HUMAN 
112 
kDa  
2 
 
7 
41 E3 UFM1-protein ligase 1  UFL1_HUMAN 90 kDa 
   
2 
42 
E3 ubiquitin-protein ligase 
BRE1B  
BRE1B_HUMAN 
114 
kDa    
2 
43 
E3 ubiquitin-protein ligase 
HUWE1  
HUWE1_HUMAN 
482 
kDa    
4 
44 
E3 ubiquitin-protein ligase 
TRIM21  
RO52_HUMAN 54 kDa 6 8 2 
 
45 
E3 ubiquitin-protein ligase 
TRIM32  
TRI32_HUMAN 72 kDa 
   
1 
46 E3 ubiquitin-protein ligase UBR4  UBR4_HUMAN 
574 
kDa    
15 
47 EH domain-containing protein 1  EHD1_HUMAN 61 kDa 
   
1 
48 
ER membrane protein complex 
subunit 1  
EMC1_HUMAN 
112 
kDa    
1 
49 
Echinoderm microtubule-
associated protein-like 4  
EMAL4_HUMAN 
109 
kDa    
1 
50 Elongator complex protein 1  ELP1_HUMAN 
150 
kDa    
2 
51 
Far upstream element-binding 
protein 1  
FUBP1_HUMAN 68 kDa 
   
2 
52 
Far upstream element-binding 
protein 2  
FUBP2_HUMAN 73 kDa 
 
1 
 
6 
53 
Far upstream element-binding 
protein 3  
FUBP3_HUMAN 62 kDa 
 
3 
 
3 
54 
Fragile X mental retardation 
syndrome-related protein 2  
FXR2_HUMAN 74 kDa 
   
1 
55 GTP-binding protein 1  GTPB1_HUMAN 72 kDa 
   
1 
56 GTP-binding protein SAR1a  
SAR1A_HUMAN 
(+1) 
22 kDa 
   
1 
57 
Gamma-interferon-inducible 
protein 16  
IF16_HUMAN 88 kDa 
 
4 
 
20 
58 Gem-associated protein 4  GEMI4_HUMAN 
120 
kDa    
1 
59 
Glutamate-rich WD repeat-
containing protein 1  
GRWD1_HUMAN 49 kDa 
 
1 
 
1 
60 
Guanine nucleotide-binding 
protein G(I)/G(S)/G(T) subunit 
beta-1  
GBB1_HUMAN 
(+3) 
37 kDa 
   
1 
61 
Guanine nucleotide-binding 
protein G(i) subunit alpha-1  
GNAI1_HUMAN 
(+9) 
40 kDa 
   
1 
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62 
Guanine nucleotide-binding 
protein-like 1  
GNL1_HUMAN 69 kDa 
   
2 
63 
H/ACA ribonucleoprotein 
complex non-core subunit NAF1  
NAF1_HUMAN 54 kDa 
 
1 
  
64 HEAT repeat-containing protein 3  HEAT3_HUMAN 75 kDa 
   
1 
65 Heat shock 70 kDa protein 4L  HS74L_HUMAN 95 kDa 
 
6 
 
13 
66 
Heterogeneous nuclear 
ribonucleoprotein A1  
ROA1_HUMAN 39 kDa 
  
0 4 
67 
Heterogeneous nuclear 
ribonucleoprotein D0  
HNRPD_HUMAN 38 kDa 
   
4 
68 
Heterogeneous nuclear 
ribonucleoprotein H  
HNRH1_HUMAN 49 kDa 
   
2 
69 
Heterogeneous nuclear 
ribonucleoprotein L  
HNRPL_HUMAN 64 kDa 
 
3 
 
2 
70 
Heterogeneous nuclear 
ribonucleoprotein Q  
HNRPQ_HUMAN 70 kDa 
   
5 
71 
Heterogeneous nuclear 
ribonucleoprotein R  
HNRPR_HUMAN 71 kDa 
 
1 
 
8 
72 
Heterogeneous nuclear 
ribonucleoprotein U  
HNRPU_HUMAN 91 kDa 
 
3 
 
20 
73 
Heterogeneous nuclear 
ribonucleoprotein U-like protein 
1  
HNRL1_HUMAN 96 kDa 0 
  
2 
74 
Heterogeneous nuclear 
ribonucleoprotein U-like protein 
2  
HNRL2_HUMAN 85 kDa 
 
0 
 
1 
75 
Heterogeneous nuclear 
ribonucleoproteins A2/B1  
ROA2_HUMAN 37 kDa 
  
0 7 
76 Histone-binding protein RBBP4  
RBBP4_HUMAN 
(+1) 
48 kDa 
 
1 
 
1 
77 Hsc70-interacting protein  
F10A1_HUMAN 
(+1) 
41 kDa 
   
1 
78 Hypoxia up-regulated protein 1  HYOU1_HUMAN 
111 
kDa    
1 
79 
Insulin-like growth factor 2 
mRNA-binding protein 2  
IF2B2_HUMAN 
(+1) 
66 kDa 
   
1 
80 
Interferon-induced, double-
stranded RNA-activated protein 
kinase  
E2AK2_HUMAN 62 kDa 
 
1 
 
3 
81 Kelch-like protein 22  KLH22_HUMAN 72 kDa 
 
1 
  
82 Kinesin-like protein KIF13B  KI13B_HUMAN 
203 
kDa    
1 
83 Kinesin-like protein KIF3A  KIF3A_HUMAN 80 kDa 
   
1 
84 Large proline-rich protein BAG6  BAG6_HUMAN 
119 
kDa    
1 
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85 
Leucine-rich repeat-containing 
protein 47  
LRC47_HUMAN 63 kDa 
   
1 
86 
Leucine-rich repeat-containing 
protein 59  
LRC59_HUMAN 35 kDa 
   
1 
87 
Lipopolysaccharide-responsive 
and beige-like anchor protein  
LRBA_HUMAN 
319 
kDa    
3 
88 
Long-chain fatty acid transport 
protein 4  
S27A4_HUMAN 72 kDa 
   
2 
89 
Lymphoid-restricted membrane 
protein  
LRMP_HUMAN 62 kDa 
   
1 
90 
Lysosome-associated membrane 
glycoprotein 2  
LAMP2_HUMAN 45 kDa 
   
1 
91 
MMS19 nucleotide excision 
repair protein homolog  
MMS19_HUMAN 
113 
kDa  
2 
 
3 
92 
Melanoma inhibitory activity 
protein 3  
MIA3_HUMAN 
214 
kDa    
2 
93 
Cluster of Metastasis-associated 
protein MTA2  
MTA2_HUMAN 
[2] 
75 kDa 
 
1 
 
6 
94 Methyltransferase-like protein 13  MET13_HUMAN 79 kDa 
   
1 
95 Microtubule-associated protein 4  MAP4_HUMAN 
121 
kDa    
2 
96 
Mitochondrial inner membrane 
protein  
IMMT_HUMAN 84 kDa 
   
2 
97 Myb-binding protein 1A  MBB1A_HUMAN 
149 
kDa  
1 
 
14 
98 Nck-associated protein 1  NCKP1_HUMAN 
129 
kDa    
3 
99 
Neuroblast differentiation-
associated protein AHNAK  
AHNK_HUMAN 
629 
kDa    
55 
100 Niban-like protein 1  NIBL1_HUMAN 84 kDa 
 
1 
 
8 
101 
Non-POU domain-containing 
octamer-binding protein  
NONO_HUMAN 54 kDa 
 
2 0 4 
102 
Nuclear cap-binding protein 
subunit 1  
NCBP1_HUMAN 92 kDa 
   
1 
103 
Nuclear mitotic apparatus protein 
1  
NUMA1_HUMAN 
238 
kDa    
3 
104 
Nuclear pore complex protein 
Nup155  
NU155_HUMAN 
155 
kDa    
1 
105 
Nuclear pore complex protein 
Nup205  
NU205_HUMAN 
228 
kDa    
1 
106 
Nuclear pore complex protein 
Nup93  
NUP93_HUMAN 93 kDa 
   
3 
107 
Nucleolar and coiled-body 
phosphoprotein 1  
NOLC1_HUMAN 74 kDa 
 
1 
 
1 
108 Nucleolar protein 56  NOP56_HUMAN 66 kDa 
   
1 
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109 Nucleolar protein 58  NOP58_HUMAN 60 kDa 
   
2 
110 Nucleolar protein 6  NOL6_HUMAN 
128 
kDa    
2 
111 
Nucleosome assembly protein 1-
like 1  
NP1L1_HUMAN 45 kDa 
 
1 
 
2 
112 
NudC domain-containing protein 
1  
NUDC1_HUMAN 67 kDa 
   
1 
113 
Oxysterol-binding protein-related 
protein 3  
OSBL3_HUMAN 
101 
kDa  
3 
  
114 
Oxysterol-binding protein-related 
protein 8 
OSBL8_HUMAN 
101 
kDa  
2 
 
5 
115 
Pentatricopeptide repeat domain-
containing protein 3, 
mitochondrial  
PTCD3_HUMAN 79 kDa 
 
1 
 
2 
116 
Phosphate carrier protein, 
mitochondrial  
MPCP_HUMAN 40 kDa 
   
1 
117 
Phospholipase A-2-activating 
protein  
PLAP_HUMAN 87 kDa 
   
1 
118 
Polypyrimidine tract-binding 
protein 1  
PTBP1_HUMAN 57 kDa 
 
8 
 
19 
119 
Pre-rRNA-processing protein 
TSR1 homolog  
TSR1_HUMAN 92 kDa 
 
1 
  
120 
Programmed cell death 6-
interacting protein  
PDC6I_HUMAN 96 kDa 
 
3 
 
14 
121 Programmed cell death protein 4  PDCD4_HUMAN 52 kDa 
   
1 
122 Protein FAM203A  
F203A_HUMAN 
(+1) 
42 kDa 
   
1 
123 Protein FAM83H  FA83H_HUMAN 
127 
kDa    
2 
124 Protein LYRIC  LYRIC_HUMAN 64 kDa 
 
1 
 
3 
125 Protein RRP5 homolog  RRP5_HUMAN 
209 
kDa    
1 
126 Protein Red  RED_HUMAN 66 kDa 
   
1 
127 Protein S100-A14  S10AE_HUMAN 12 kDa 
   
1 
128 Protein S100-A2  S10A2_HUMAN 11 kDa 
   
2 
129 Protein TBRG4  TBRG4_HUMAN 71 kDa 
 
1 
 
1 
130 Protein TFG  TFG_HUMAN 43 kDa 
 
1 
  
131 Protein VAC14 homolog  VAC14_HUMAN 88 kDa 
 
1 
 
2 
132 
Protein arginine N-
methyltransferase 5  
ANM5_HUMAN 73 kDa 
   
1 
133 Protein disulfide-isomerase A4  PDIA4_HUMAN 73 kDa 
   
4 
134 Protein disulfide-isomerase A6  PDIA6_HUMAN 48 kDa 
 
1 
 
10 
135 Protein scribble homolog  SCRIB_HUMAN 
175 
kDa    
1 
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136 Protein transport protein Sec16A  SC16A_HUMAN 
234 
kDa    
1 
137 
Cluster of Protein transport 
protein Sec23B  
SC23B_HUMAN 86 kDa 
   
3 
138 Protein transport protein Sec24C  SC24C_HUMAN 
118 
kDa    
1 
139 
Protein transport protein Sec61 
subunit alpha isoform 1 
S61A1_HUMAN 52 kDa 
   
3 
140 Protein unc-45 homolog A  UN45A_HUMAN 
103 
kDa  
0 
 
5 
141 
Protein-glutamine gamma-
glutamyltransferase E  
TGM3_HUMAN 77 kDa 
   
1 
142 
Protein-methionine sulfoxide 
oxidase MICAL1  
MICA1_HUMAN 
118 
kDa    
1 
143 RNA-binding protein 12  RBM12_HUMAN 97 kDa 
 
1 
 
6 
144 RNA-binding protein 14  RBM14_HUMAN 69 kDa 0 
  
3 
145 RNA-binding protein FUS  FUS_HUMAN 53 kDa 0 
  
3 
146 RRP12-like protein  RRP12_HUMAN 
144 
kDa    
2 
147 
Rab3 GTPase-activating protein 
non-catalytic subunit  
RBGPR_HUMAN 
156 
kDa    
2 
148 Ran GTPase-activating protein 1  RAGP1_HUMAN 64 kDa 
   
2 
149 Ran-binding protein 10  RBP10_HUMAN 67 kDa 
   
1 
150 
Ras GTPase-activating-like 
protein IQGAP1  
IQGA1_HUMAN 
189 
kDa  
2 
 
19 
151 Rho-associated protein kinase 2  ROCK2_HUMAN 
161 
kDa    
1 
152 
Ribonucleases P/MRP protein 
subunit POP1  
POP1_HUMAN 
115 
kDa    
1 
153 
Ribosomal L1 domain-containing 
protein 1  
RL1D1_HUMAN 55 kDa 
   
1 
154 
Ribosomal RNA processing 
protein 1 homolog B  
RRP1B_HUMAN 84 kDa 
   
2 
155 
Ribosomal biogenesis protein 
LAS1L  
LAS1L_HUMAN 83 kDa 
 
1 
  
156 Ribosome-binding protein 1  RRBP1_HUMAN 
152 
kDa    
1 
157 
SAM domain and HD domain-
containing protein 1  
SAMH1_HUMAN 72 kDa 
   
1 
158 SCY1-like protein 2  SCYL2_HUMAN 
104 
kDa  
1 
 
2 
159 SRSF protein kinase 1  SRPK1_HUMAN 74 kDa 
   
2 
160 Serine/threonine-protein kinase 4  STK4_HUMAN 56 kDa 
 
1 
  
161 
Serine/threonine-protein kinase 
MRCK beta  
MRCKB_HUMAN 
194 
kDa  
3 
 
1 
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162 
Serine/threonine-protein kinase 
TBK1  
TBK1_HUMAN 84 kDa 
   
1 
163 
Serine/threonine-protein 
phosphatase 2A 56 kDa 
regulatory subunit delta isoform  
2A5D_HUMAN 70 kDa 
 
0 
 
1 
164 
Serine/threonine-protein 
phosphatase 2A 65 kDa 
regulatory subunit A alpha 
isoform  
2AAA_HUMAN 65 kDa 
 
1 
 
6 
165 
Signal recognition particle 54 
kDa protein  
SRP54_HUMAN 56 kDa 
   
1 
166 
Signal recognition particle 68 
kDa protein  
SRP68_HUMAN 71 kDa 
   
2 
167 
Signal recognition particle 72 
kDa protein  
SRP72_HUMAN 75 kDa 
   
3 
168 
Sister chromatid cohesion protein 
PDS5 homolog B  
PDS5B_HUMAN 
165 
kDa    
1 
169 Skin-specific protein 32  XP32_HUMAN 26 kDa 
   
3 
170 
Spermatogenesis-associated 
protein 5-like protein 1  
SPA5L_HUMAN 81 kDa 
   
1 
171 
Staphylococcal nuclease domain-
containing protein 1  
SND1_HUMAN 
102 
kDa    
17 
172 
Stomatin-like protein 2, 
mitochondrial  
STML2_HUMAN 39 kDa 0 
  
1 
173 Stress-induced-phosphoprotein 1  STIP1_HUMAN 63 kDa 
 
2 
 
6 
174 
Structural maintenance of 
chromosomes flexible hinge 
domain-containing protein 1  
SMHD1_HUMAN 
226 
kDa    
1 
175 
Structural maintenance of 
chromosomes protein 3  
SMC3_HUMAN 
142 
kDa    
2 
176 
Submaxillary gland androgen-
regulated protein 3B  
SMR3B_HUMAN 8 kDa 
   
2 
177 
Succinate dehydrogenase 
[ubiquinone] flavoprotein 
subunit, mitochondrial  
DHSA_HUMAN 73 kDa 
 
1 
 
2 
178 Surfeit locus protein 4  SURF4_HUMAN 30 kDa 
 
0 
 
5 
179 
T-complex protein 1 subunit 
epsilon  
TCPE_HUMAN 60 kDa 1 5 
 
6 
180 
TATA-binding protein-associated 
factor 172  
BTAF1_HUMAN 
207 
kDa    
1 
181 
Thioredoxin domain-containing 
protein 5  
TXND5_HUMAN 48 kDa 
   
1 
182 Torsin-1A-interacting protein 1  TOIP1_HUMAN 66 kDa 
 
1 
 
1 
183 Torsin-1A-interacting protein 2  TOIP2_HUMAN 51 kDa 
 
1 
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184 
Trans-Golgi network integral 
membrane protein 2  
TGON2_HUMAN 51 kDa 
   
1 
185 
Translocating chain-associated 
membrane protein 1  
TRAM1_HUMAN 43 kDa 
   
1 
186 Transmembrane protein 33  TMM33_HUMAN 28 kDa 
   
2 
187 
Trifunctional purine biosynthetic 
protein adenosine-3  
PUR2_HUMAN 
108 
kDa  
3 
 
11 
188 
Tubulin--tyrosine ligase-like 
protein 12  
TTL12_HUMAN 74 kDa 
   
3 
189 Tuftelin-interacting protein 11  TFP11_HUMAN 97 kDa 
   
1 
190 
Tyrosine-protein phosphatase 
non-receptor type 1  
PTN1_HUMAN 50 kDa 
   
6 
191 
Tyrosine-protein phosphatase 
non-receptor type 11  
PTN11_HUMAN 68 kDa 
   
1 
192 
U2 snRNP-associated SURP 
motif-containing protein  
SR140_HUMAN 
118 
kDa  
1 
 
1 
193 
U4/U6.U5 small nuclear 
ribonucleoprotein 27 kDa protein  
SNR27_HUMAN 19 kDa 
   
1 
194 
U4/U6.U5 tri-snRNP-associated 
protein 2  
SNUT2_HUMAN 65 kDa 
   
1 
195 
U5 small nuclear 
ribonucleoprotein 200 kDa 
helicase  
U520_HUMAN 
245 
kDa 
0 3 
 
13 
196 
UV excision repair protein 
RAD23 homolog B  
RD23B_HUMAN 43 kDa 
 
1 
 
1 
197 Ubiquitin-protein ligase E3A  UBE3A_HUMAN 
101 
kDa  
1 
  
198 Ubiquitin-protein ligase E3C  UBE3C_HUMAN 
124 
kDa  
1 
 
3 
199 
Vacuolar protein sorting-
associated protein 13C  
VP13C_HUMAN 
422 
kDa    
1 
200 
Vacuolar protein sorting-
associated protein 16 homolog  
VPS16_HUMAN 95 kDa 
   
1 
201 
Vacuolar protein sorting-
associated protein 35  
VPS35_HUMAN 92 kDa 
   
3 
202 
Vasodilator-stimulated 
phosphoprotein  
VASP_HUMAN 40 kDa 
   
1 
203 
Very-long-chain (3R)-3-
hydroxyacyl-[acyl-carrier protein] 
dehydratase 3  
HACD3_HUMAN 43 kDa 
   
2 
204 WD repeat-containing protein 26  WDR26_HUMAN 72 kDa 
   
1 
205 
Wiskott-Aldrich syndrome 
protein family member 2  
WASF2_HUMAN 54 kDa 
   
1 
206 
X-ray repair cross-
complementing protein 5  
XRCC5_HUMAN 83 kDa 
 
1 
 
18 
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207 
X-ray repair cross-
complementing protein 6  
XRCC6_HUMAN 70 kDa 
 
2 
 
30 
208 
Zinc finger CCCH-type antiviral 
protein 1  
ZCCHV_HUMAN 
101 
kDa    
1 
209 
Zinc finger HIT domain-
containing protein 2  
ZNHI2_HUMAN 43 kDa 
   
1 
210 Zinc finger protein 207  ZN207_HUMAN 51 kDa 
 
1 
  
211 
Zymogen granule protein 16 
homolog B  
ZG16B_HUMAN 23 kDa 
 
1 
 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
2
5
 
 
 
                                             Table A3.2: Overview of MS data of p53 and kinases identified   
 
 
 
A to H are the eight SDS-PAGE gel slices of each lane of interest. A being 50 kDa Mol wt, with increasing molecular weight and H 
being the highest molecular weight. This table shows the no. of unique peptides identified with respect to crosslinked and 
uncrosslinked lysates as well as use of rabbit antibody and mouse antibody for the IP of crosslinked complex. The parameters set were 
protein threshold-90%, peptide threshold-99.9%, with minimum number of peptides set to 1. 
 Identified Proteins  Accession Number Mol.Wt 
No. of unique peptides identified  
 
Uncrosslinked Lysate 
Rabbit Antibody 
Crosslinked Lysate 
Rabbit Antibody 
Uncrosslinked Lysate 
Mouse Antibody 
Crosslinked Lysate 
Mouse Antibody 
A B C D E F G H A B C D E F G H A B C D E F G H A B C D E F G H 
1 
Cellular tumor 
antigen p53  P53_HUMAN 44 kDa  
4 1 
      
3 7 
 
2 1 1 
  
1 2 0 
     
1 1 
   
2 
 
2 
DNA-dependent 
protein kinase 
catalytic subunit  
PRKDC_HUMAN 469 kDa 
               
6 
               
47 
3 
Casein kinase II 
subunit alpha  
CSK21_HUMAN 45 kDa 1 
               
1 6 
      
1 
       
4 
Serine/threonine-
protein kinase 
MRCK beta  
MRCKB_HUMAN 194 kDa 
             
3 
                 
1 
5 
SRSF protein kinase 
1  
SRPK1_HUMAN 74 kDa 
                          
2 
     
6 
Interferon-induced, 
double-stranded 
RNA-activated 
protein kinase  
E2AK2_HUMAN 62 kDa 
          
1 
              
2 
     
1 
7 
Cyclin-dependent 
kinase 12  
CDK12_HUMAN 164 kDa 
                               
2 
126 
 
126 
 
 
Figure A3.4: Primary sequence of p53 proteins identified in crosslinked and uncrosslinked IP 
experiments. Amino acids observed in the MS/MS analysis are highlighted in yellow, while 
modified amino acids are in green (phosphorylation (S or T) or oxidation (M)). The parameters 
set were protein threshold-90%, peptide threshold-99.9%, with minimum number of peptides set 
to 1. 
Peptide Sequence: (R)LGFLHSGTAK(S)  
Peptide Sequence: (R)VEYLDDRNTFR(H)
 
 
P53_HUMAN (100%), 43,653.4 Da
Cellular tumor antigen p53 OS=Homo sapiens GN=TP53 PE=1 SV=4
7 exclusive unique peptides, 7 exclusive unique spectra, 14 total spectra, 85/393 amino acids (22% coverage)
M E E P Q S D P S V E P P L S Q E T F S D L W K L L P E N N V L S P L P S Q A M D D L M L S P D D I
E Q W F T E D P G P D E A P R M P E A A P P V A P A P A A P T P A A P A P A P S W P L S S S V P S Q
K T Y Q G S Y G F R L G F L H S G T A K S V T C T Y S P A L N K M F C Q L A K T C P V Q L W V D S T
P P P G T R V R A M A I Y K Q S Q H M T E V V R R C P H H E R C S D S D G L A P P Q H L I R V E G N
L R V E Y L D D R N T F R H S V V V P Y E P P E V G S D C T T I H Y N Y M C N S S C M G G M N R R P
I L T I I T L E D S S G N L L G R N S F E V R V C A C P G R D R R T E E E N L R K K G E P H H E L P
P G S T K R A L P N N T S S S P Q P K K K P L D G E Y F T L Q I R G R E R F E M F R E L N E A L E L
K D A Q A G K E P G G S R A H S S H L K S K K G Q S T S R H K K L M F K T E G P D S D
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Peptide Sequence: (K)SVTcTYSPALNK(M) 
Peptide Sequence: (R)cSDSDGLAPPQHLIR(V) 
 
Peptide Sequence: (R)RPILTIITLEDSSGNLLGR(N)  
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Peptide Sequence: (R)ALPNNTSSSPQPK(K) 
 
Peptide Sequence: (R)ELNEALELK(D)  
 
Peptide Sequence: (R)ELNEALELKDAQAGK(E)  
Figure A3.5: The annotated spectra of p53 peptides identified by MS/MS analysis shown in 
figure A3.1. A representation of the peptide fragments identified is shown with the peptide 
sequence on top of each spectrum.  
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Figure A3.6: Primary sequence of DNA-PK protein identified in the crosslinked IP experiments. 
Amino acids observed in the MS/MS analysis are highlighted in yellow, while modified amino 
acids are in green (phosphorylation (S or T) or oxidation (M)). The parameters set were protein 
threshold-90%, peptide threshold-99.9%, with minimum number of peptides set to 1. 
 
PRKDC_HUMAN (100%), 469,095.5 Da
DNA-dependent protein kinase catalytic subunit OS=Homo sapiens GN=PRKDC PE=1 SV=3
42 exclusive unique peptides, 44 exclusive unique spectra, 47 total spectra, 559/4128 amino acids (14% coverage)
M A G S G A G V R C S L L R L Q E T L S A A D R C G A A L A G H Q L I R G L G Q E C V L S S S P A V
L A L Q T S L V F S R D F G L L V F V R K S L N S I E F R E C R E E I L K F L C I F L E K M G Q K I
A P Y S V E I K N T C T S V Y T K D R A A K C K I P A L D L L I K L L Q T F R S S R L M D E F K I G
E L F S K F Y G E L A L K K K I P D T V L E K V Y E L L G L L G E V H P S E M I N N A E N L F R A F
L G E L K T Q M T S A V R E P K L P V L A G C L K G L S S L L C N F T K S M E E D P Q T S R E I F N
F V L K A I R P Q I D L K R Y A V P S A G L R L F A L H A S Q F S T C L L D N Y V S L F E V L L K W
C A H T N V E L K K A A L S A L E S F L K Q V S N M V A K N A E M H K N K L Q Y F M E Q F Y G I I R
N V D S N N K E L S I A I R G Y G L F A G P C K V I N A K D V D F M Y V E L I Q R C K Q M F L T Q T
D T G D D R V Y Q M P S F L Q S V A S V L L Y L D T V P E V Y T P V L E H L V V M Q I D S F P Q Y S
P K M Q L V C C R A I V K V F L A L A A K G P V L R N C I S T V V H Q G L I R I C S K P V V L P K G
P E S E S E D H R A S G E V R T G K W K V P T Y K D Y V D L F R H L L S S D Q M M D S I L A D E A F
F S V N S S S E S L N H L L Y D E F V K S V L K I V E K L D L T L E I Q T V G E Q E N G D E A P G V
W M I P T S D P A A N L H P A K P K D F S A F I N L V E F C R E I L P E K Q A E F F E P W V Y S F S
Y E L I L Q S T R L P L I S G F Y K L L S I T V R N A K K I K Y F E G V S P K S L K H S P E D P E K
Y S C F A L F V K F G K E V A V K M K Q Y K D E L L A S C L T F L L S L P H N I I E L D V R A Y V P
A L Q M A F K L G L S Y T P L A E V G L N A L E E W S I Y I D R H V M Q P Y Y K D I L P C L D G Y L
K T S A L S D E T K N N W E V S A L S R A A Q K G F N K V V L K H L K K T K N L S S N E A I S L E E
I R I R V V Q M L G S L G G Q I N K N L L T V T S S D E M M K S Y V A W D R E K R L S F A V P F R E
M K P V I F L D V F L P R V T E L A L T A S D R Q T K V A A C E L L H S M V M F M L G K A T Q M P E
G G Q G A P P M Y Q L Y K R T F P V L L R L A C D V D Q V T R Q L Y E P L V M Q L I H W F T N N K K
F E S Q D T V A L L E A I L D G I V D P V D S T L R D F C G R C I R E F L K W S I K Q I T P Q Q Q E
K S P V N T K S L F K R L Y S L A L H P N A F K R L G A S L A F N N I Y R E F R E E E S L V E Q F V
F E A L V I Y M E S L A L A H A D E K S L G T I Q Q C C D A I D H L C R I I E K K H V S L N K A K K
R R L P R G F P P S A S L C L L D L V K W L L A H C G R P Q T E C R H K S I E L F Y K F V P L L P G
N R S P N L W L K D V L K E E G V S F L I N T F E G G G C G Q P S G I L A Q P T L L Y L R G P F S L
Q A T L C W L D L L L A A L E C Y N T F I G E R T V G A L Q V L G T E A Q S S L L K A V A F F L E S
I A M H D I I A A E K C F G T G A A G N R T S P Q E G E R Y N Y S K C T V V V R I M E F T T T L L N
T S P E G W K L L K K D L C N T H L M R V L V Q T L C E P A S I G F N I G D V Q V M A H L P D V C V
N L M K A L K M S P Y K D I L E T H L R E K I T A Q S I E E L C A V N L Y G P D A Q V D R S R L A A
V V S A C K Q L H R A G L L H N I L P S Q S T D L H H S V G T E L L S L V Y K G I A P G D E R Q C L
P S L D L S C K Q L A S G L L E L A F A F G G L C E R L V S L L L N P A V L S T A S L G S S Q G S V
I H F S H G E Y F Y S L F S E T I N T E L L K N L D L A V L E L M Q S S V D N T K M V S A V L N G M
L D Q S F R E R A N Q K H Q G L K L A T T I L Q H W K K C D S W W A K D S P L E T K M A V L A L L A
K I L Q I D S S V S F N T S H G S F P E V F T T Y I S L L A D T K L D L H L K G Q A V T L L P F F T
S L T G G S L E E L R R V L E Q L I V A H F P M Q S R E F P P G T P R F N N Y V D C M K K F L D A L
E L S Q S P M L L E L M T E V L C R E Q Q H V M E E L F Q S S F R R I A R R G S C V T Q V G L L E S
V Y E M F R K D D P R L S F T R Q S F V D R S L L T L L W H C S L D A L R E F F S T I V V D A I D V
L K S R F T K L N E S T F D T Q I T K K M G Y Y K I L D V M Y S R L P K D D V H A K E S K I N Q V F
H G S C I T E G N E L T K T L I K L C Y D A F T E N M A G E N Q L L E R R R L Y H C A A Y N C A I S
V I C C V F N E L K F Y Q G F L F S E K P E K N L L I F E N L I D L K R R Y N F P V E V E V P M E R
K K K Y I E I R K E A R E A A N G D S D G P S Y M S S L S Y L A D S T L S E E M S Q F D F S T G V Q
S Y S Y S S Q D P R P A T G R F R R R E Q R D P T V H D D V L E L E M D E L N R H E C M A P L T A L
V K H M H R S L G P P Q G E E D S V P R D L P S W M K F L H G K L G N P I V P L N I R L F L A K L V
I N T E E V F R P Y A K H W L S P L L Q L A A S E N N G G E G I H Y M V V E I V A T I L S W T G L A
T P T G V P K D E V L A N R L L N F L M K H V F H P K R A V F R H N L E I I K T L V E C W K D C L S
I P Y R L I F E K F S G K D P N S K D N S V G I Q L L G I V M A N D L P P Y D P Q C G I Q S S E Y F
Q A L V N N M S F V R Y K E V Y A A A A E V L G L I L R Y V M E R K N I L E E S L C E L V A K Q L K
Q H Q N T M E D K F I V C L N K V T K S F P P L A D R F M N A V F F L L P K F H G V L K T L C L E V
V L C R V E G M T E L Y F Q L K S K D F V Q V M R H R D D E R Q K V C L D I I Y K M M P K L K P V E
L R E L L N P V V E F V S H P S T T C R E Q M Y N I L M W I H D N Y R D P E S E T D N D S Q E I F K
L A K D V L I Q G L I D E N P G L Q L I I R N F W S H E T R L P S N T L D R L L A L N S L Y S P K I
E V H F L S L A T N F L L E M T S M S P D Y P N P M F E H P L S E C E F Q E Y T I D S D W R F R S T
V L T P M F V E T Q A S Q G T L Q T R T Q E G S L S A R W P V A G Q I R A T Q Q Q H D F T L T Q T A
D G R S S F D W L T G S S T D P L V D H T S P S S D S L L F A H K R S E R L Q R A P L K S V G P D F
G K K R L G L P G D E V D N K V K G A A G R T D L L R L R R R F M R D Q E K L S L M Y A R K G V A E
Q K R E K E I K S E L K M K Q D A Q V V L Y R S Y R H G D L P D I Q I K H S S L I T P L Q A V A Q R
D P I I A K Q L F S S L F S G I L K E M D K F K T L S E K N N I T Q K L L Q D F N R F L N T T F S F
F P P F V S C I Q D I S C Q H A A L L S L D P A A V S A G C L A S L Q Q P V G I R L L E E A L L R L
L P A E L P A K R V R G K A R L P P D V L R W V E L A K L Y R S I G E Y D V L R G I F T S E I G T K
Q I T Q S A L L A E A R S D Y S E A A K Q Y D E A L N K Q D W V D G E P T E A E K D F W E L A S L D
C Y N H L A E W K S L E Y C S T A S I D S E N P P D L N K I W S E P F Y Q E T Y L P Y M I R S K L K
L L L Q G E A D Q S L L T F I D K A M H G E L Q K A I L E L H Y S Q E L S L L Y L L Q D D V D R A K
Y Y I Q N G I Q S F M Q N Y S S I D V L L H Q S R L T K L Q S V Q A L T E I Q E F I S F I S K Q G N
L S S Q V P L K R L L N T W T N R Y P D A K M D P M N I W D D I I T N R C F F L S K I E E K L T P L
P E D N S M N V D Q D G D P S D R M E V Q E Q E E D I S S L I R S C K F S M K M K M I D S A R K Q N
N F S L A M K L L K E L H K E S K T R D D W L V S W V Q S Y C R L S H C R S R S Q G C S E Q V L T V
L K T V S L L D E N N V S S Y L S K N I L A F R D Q N I L L G T T Y R I I A N A L S S E P A C L A E
I E E D K A R R I L E L S G S S S E D S E K V I A G L Y Q R A F Q H L S E A V Q A A E E E A Q P P S
W S C G P A A G V I D A Y M T L A D F C D Q Q L R K E E E N A S V I D S A E L Q A Y P A L V V E K M
L K A L K L N S N E A R L K F P R L L Q I I E R Y P E E T L S L M T K E I S S V P C W Q F I S W I S
H M V A L L D K D Q A V A V Q H S V E E I T D N Y P Q A I V Y P F I I S S E S Y S F K D T S T G H K
N K E F V A R I K S K L D Q G G V I Q D F I N A L D Q L S N P E L L F K D W S N D V R A E L A K T P
V N K K N I E K M Y E R M Y A A L G D P K A P G L G A F R R K F I Q T F G K E F D K H F G K G G S K
L L R M K L S D F N D I T N M L L L K M N K D S K P P G N L K E C S P W M S D F K V E F L R N E L E
I P G Q Y D G R G K P L P E Y H V R I A G F D E R V T V M A S L R R P K R I I I R G H D E R E H P F
L V K G G E D L R Q D Q R V E Q L F Q V M N G I L A Q D S A C S Q R A L Q L R T Y S V V P M T S R L
G L I E W L E N T V T L K D L L L N T M S Q E E K A A Y L S D P R A P P C E Y K D W L T K M S G K H
D V G A Y M L M Y K G A N R T E T V T S F R K R E S K V P A D L L K R A F V R M S T S P E A F L A L
R S H F A S S H A L I C I S H W I L G I G D R H L N N F M V A M E T G G V I G I D F G H A F G S A T
Q F L P V P E L M P F R L T R Q F I N L M L P M K E T G L M Y S I M V H A L R A F R S D P G L L T N
T M D V F V K E P S F D W K N F E Q K M L K K G G S W I Q E I N V A E K N W Y P R Q K I C Y A K R K
L A G A N P A V I T C D E L L L G H E K A P A F R D Y V A V A R G S K D H N I R A Q E P E S G L S E
E T Q V K C L M D Q A T D P N I L G R T W E G W E P W M
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Peptide Sequence: (R)DPTVHDDVLELEMDELNR(H) 
 
Peptide Sequence: (R)MEVQEQEEDISSLIR(S)
 
 
Peptide Sequence: (R)TVGALQVLGTEAQSSLLK(A)
 
Figure A3.7: The annotated spectra of DNA-PK peptides identified by MS/MS analysis, shown 
in figure A3.3. A representation of the peptide fragments identified is shown with the peptide 
sequence on top of each spectrum. MS spectra of only three of 47 unique peptides are shown as a 
representation here. 
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Figure A3.8: Primary sequence of MRCKB protein identified in the crosslinked IP experiments. 
Amino acids observed in the MS/MS analysis are highlighted in yellow, while modified amino 
acids are in green (phosphorylation (S or T) or oxidation (M)). The parameters were, protein 
threshold-90%, peptide threshold-99.9%, with minimum number of peptides set to 1. 
Peptide Sequence: (K)LALQEFSELNER(M) 
  
132 
 
132 
 
Peptide Sequence: (K)ELEAQLDDAVAEASK(E)  
Peptide Sequence: (K)AILTAAIVDADR(I)  
 
Figure A3.9: The annotated spectra of MRCKB peptides identified by MS/MS analysis, shown 
in figure A3.5. A representation of the peptide fragments identified is shown with the peptide 
sequence on top of each spectrum.  
    
Figure A3.10: Primary sequence of SRPK1 protein identified in the crosslinked IP experiments. 
Amino acids observed in the MS/MS analysis are highlighted in yellow, while modified amino 
acids are in green (phosphorylation (S or T) or oxidation (M)). The parameters set were protein 
threshold-90%, peptide threshold-99.9%, with minimum number of peptides set to 1. 
SRPK1_HUMAN (100%), 74,326.0 Da
SRSF protein kinase 1 OS=Homo sapiens GN=SRPK1 PE=1 SV=2
3 exclusive unique peptides, 3 exclusive unique spectra, 3 total spectra, 39/655 amino acids (6% coverage)
M E R K V L A L Q A R K K R T K A K K D K A Q R K S E T Q H R G S A P H S E S D L P E Q E E E I L G
S D D D E Q E D P N D Y C K G G Y H L V K I G D L F N G R Y H V I R K L G W G H F S T V W L S W D I
Q G K K F V A M K V V K S A E H Y T E T A L D E I R L L K S V R N S D P N D P N R E M V V Q L L D D
F K I S G V N G T H I C M V F E V L G H H L L K W I I K S N Y Q G L P L P C V K K I I Q Q V L Q G L
D Y L H T K C R I I H T D I K P E N I L L S V N E Q Y I R R L A A E A T E W Q R S G A P P P S G S A
V S T A P Q P K P A D K M S K N K K K K L K K K Q K R Q A E L L E K R M Q E I E E M E K E S G P G Q
K R P N K Q E E S E S P V E R P L K E N P P N K M T Q E K L E E S S T I G Q D Q T L M E R D T E G G
A A E I N C N G V I E V I N Y T Q N S N N E T L R H K E D L H N A N D C D V Q N L N Q E S S F L S S
Q N G D S S T S Q E T D S C T P I T S E V S D T M V C Q S S S T V G Q S F S E Q H I S Q L Q E S I R
A E I P C E D E Q E Q E H N G P L D N K G K S T A G N F L V N P L E P K N A E K L K V K I A D L G N
A C W V H K H F T E D I Q T R Q Y R S L E V L I G S G Y N T P A D I W S T A C M A F E L A T G D Y L
F E P H S G E E Y T R D E D H I A L I I E L L G K V P R K L I V A G K Y S K E F F T K K G D L K H I
T K L K P W G L F E V L V E K Y E W S Q E E A A G F T D F L L P M L E L I P E K R A T A A E C L R H
P W L N S
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Peptide sequence: (K)SAEHYTETALDEIR(L)  
 
Peptide sequence: (R)EMVVQLLDDFK(I)  
Peptide sequence: (K)STAGNFLVNPLEPK(N)  
Figure A3.11: The annotated spectra of SRPK1 peptides identified by MS/MS analysis, shown 
in figure A3.7. A representation of the peptide fragments identified is shown with the peptide 
sequence on top of each spectrum.  
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Figure A3.12: Primary sequences of E2AK2 protein identified in the crosslinked IP 
experiments. Amino acids observed in the MS/MS analysis were highlighted in yellow, while 
modified amino acids were in green (phosphorylation (S or T) or oxidation (M)). The parameters 
set were protein threshold-90%, peptide threshold-99.9%, with minimum number of peptides set 
to 1. 
Peptide Sequence: (K)VLALELFEQITK(G)  
Peptide Sequence: (K)VLALELFEQITK(G) 
  
E2AK2_HUMAN (100%), 62,097.1 Da
Interferon-induced, double-stranded RNA-activated protein kinase OS=Homo sapiens GN=EIF2AK2 PE=1 SV=2
2 exclusive unique peptides, 2 exclusive unique spectra, 3 total spectra, 23/551 amino acids (4% coverage)
M A G D L S A G F F M E E L N T Y R Q K Q G V V L K Y Q E L P N S G P P H D R R F T F Q V I I D G R
E F P E G E G R S K K E A K N A A A K L A V E I L N K E K K A V S P L L L T T T N S S E G L S M G N
Y I G L I N R I A Q K K R L T V N Y E Q C A S G V H G P E G F H Y K C K M G Q K E Y S I G T G S T K
Q E A K Q L A A K L A Y L Q I L S E E T S V K S D Y L S S G S F A T T C E S Q S N S L V T S T L A S
E S S S E G D F S A D T S E I N S N S D S L N S S S L L M N G L R N N Q R K A K R S L A P R F D L P
D M K E T K Y T V D K R F G M D F K E I E L I G S G G F G Q V F K A K H R I D G K T Y V I K R V K Y
N N E K A E R E V K A L A K L D H V N I V H Y N G C W D G F D Y D P E T S D D S L E S S D Y D P E N
S K N S S R S K T K C L F I Q M E F C D K G T L E Q W I E K R R G E K L D K V L A L E L F E Q I T K
G V D Y I H S K K L I H R D L K P S N I F L V D T K Q V K I G D F G L V T S L K N D G K R T R S K G
T L R Y M S P E Q I S S Q D Y G K E V D L Y A L G L I L A E L L H V C D T A F E T S K F F T D L R D
G I I S D I F D K K E K T L L Q K L L S K K P E D R P N T S E I L R T L T V W K K S P E K N E R H T
C
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Peptide Sequence: (K)IGDFGLVTSLK(N)  
 
Figure A3.13: The annotated spectra of E2AK2 peptides identified by MS/MS analysis, shown 
in figure A3.9. A representation of the peptide fragments identified is shown with the peptide 
sequence on top of each spectrum.  
 
 
 
Figure A3.14: Primary sequences of CDK12 protein identified in the crosslinked IP 
experiments. Amino acids observed in the MS/MS analysis are highlighted in yellow, while 
modified amino acids are in green (phosphorylation (S or T) or oxidation (M)). The parameters 
set were protein threshold-90%, peptide threshold-99.9%, with minimum number of peptides set 
to 1. 
CDK12_HUMAN (100%), 164,159.1 Da
Cyclin-dependent kinase 12 OS=Homo sapiens GN=CDK12 PE=1 SV=2
2 exclusive unique peptides, 2 exclusive unique spectra, 2 total spectra, 27/1490 amino acids (2% coverage)
M P N S E R H G G K K D G S G G A S G T L Q P S S G G G S S N S R E R H R L V S K H K R H K S K H S
K D M G L V T P E A A S L G T V I K P L V E Y D D I S S D S D T F S D D M A F K L D R R E N D E R R
G S D R S D R L H K H R H H Q H R R S R D L L K A K Q T E K E K S Q E V S S K S G S M K D R I S G S
S K R S N E E T D D Y G K A Q V A K S S S K E S R S S K L H K E K T R K E R E L K S G H K D R S K S
H R K R E T P K S Y K T V D S P K R R S R S P H R K W S D S S K Q D D S P S G A S Y G Q D Y D L S P
S R S H T S S N Y D S Y K K S P G S T S R R Q S V S P P Y K E P S A Y Q S S T R S P S P Y S R R Q R
S V S P Y S R R R S S S Y E R S G S Y S G R S P S P Y G R R R S S S P F L S K R S L S R S P L P S R
K S M K S R S R S P A Y S R H S S S H S K K K R S S S R S R H S S I S P V R L P L N S S L G A E L S
R K K K E R A A A A A A A K M D G K E S K G S P V F L P R K E N S S V E A K D S G L E S K K L P R S
V K L E K S A P D T E L V N V T H L N T E V K N S S D T G K V K L D E N S E K H L V K D L K A Q G T
R D S K P I A L K E E I V T P K E T E T S E K E T P P P L P T I A S P P P P L P T T T P P P Q T P P
L P P L P P I P A L P Q Q P P L P P S Q P A F S Q V P A S S T S T L P P S T H S K T S A V S S Q A N
S Q P P V Q V S V K T Q V S V T A A I P H L K T S T L P P L P L P P L L P G D D D M D S P K E T L P
S K P V K K E K E Q R T R H L L T D L P L P P E L P G G D L S P P D S P E P K A I T P P Q Q P Y K K
R P K I C C P R Y G E R R Q T E S D W G K R C V D K F D I I G I I G E G T Y G Q V Y K A K D K D T G
E L V A L K K V R L D N E K E G F P I T A I R E I K I L R Q L I H R S V V N M K E I V T D K Q D A L
D F K K D K G A F Y L V F E Y M D H D L M G L L E S G L V H F S E D H I K S F M K Q L M E G L E Y C
H K K N F L H R D I K C S N I L L N N S G Q I K L A D F G L A R L Y N S E E S R P Y T N K V I T L W
Y R P P E L L L G E E R Y T P A I D V W S C G C I L G E L F T K K P I F Q A N L E L A Q L E L I S R
L C G S P C P A V W P D V I K L P Y F N T M K P K K Q Y R R R L R E E F S F I P S A A L D L L D H M
L T L D P S K R C T A E Q T L Q S D F L K D V E L S K M A P P D L P H W Q D C H E L W S K K R R R Q
R Q S G V V V E E P P P S K T S R K E T T S G T S T E P V K N S S P A P P Q P A P G K V E S G A G D
A I G L A D I T Q Q L N Q S E L A V L L N L L Q S Q T D L S I P Q M A Q L L N I H S N P E M Q Q Q L
E A L N Q S I S A L T E A T S Q Q Q D S E T M A P E E S L K E A P S A P V I L P S A E Q T T L E A S
S T P A D M Q N I L A V L L S Q L M K T Q E P A G S L E E N N S D K N S G P Q G P R R T P T M P Q E
E A A A C P P H I L P P E K R P P E P P G P P P P P P P P P L V E G D L S S A P Q E L N P A V T A A
L L Q L L S Q P E A E P P G H L P H E H Q A L R P M E Y S T R P R P N R T Y G N T D G P E T G F S A
I D T D E R N S G P A L T E S L V Q T L V K N R T F S G S L S H L G E S S S Y Q G T G S V Q F P G D
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Peptide Sequence: (K)SAPDTELVNVTHLNTEVK(N) 
 
 
Peptide Sequence: (K)EGFPITAIR(E)  
 
Figure A3.15: The annotated spectra of CDK12 peptides identified by MS/MS analysis, shown 
in figure A3.11. A representation of the peptide fragments identified is shown with the peptide 
sequence on top of each spectrum.  
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ABSTRACT 
SYNTHESIS AND APPLICATION OF ATP ANALOGS FOR PHOSPHORYLATION-
DEPENDENT KINASE-SUBSTRATE CROSSLINKING 
 
by 
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Degree: Doctor of Philosophy  
Phosphorylation is an important post-translational modification that plays a key role in a 
variety of signaling cascades and cellular functions. Kinases phosphorylate protein substrates in 
a highly regulated manner and also demonstrate substrate promiscuity. Understanding kinase-
substrate specificity has been challenging and there is a need for new chemical tools.  To this 
end, we developed -phosphate modified ATP photocrosslinking analogs ATP-ArN3 and ATP-
BP that crosslink substrate and kinase in a phosphorylation-dependent manner. We have 
successfully demonstrated that ATP-ArN3 and ATP-BP can be used with natural kinase and 
substrates using cell lysates in vitro. We used our approach to identify novel kinases of p53. One 
powerful feature of this methodology is that we can obtain atomic level snapshots of the 
interactions between proteins when coupled with analytical techniques like mass spectrometry 
(MS). These tools will help us in validating our understanding of kinase-substrate interactions, 
their roles in signaling pathways, and in the cellular processes.   
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